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Abstract 
Screening of ethnomedicinal plants for antimalarial and chemopreventive activities 
among plants used in Cameroonian folklore medicine to treat fevers, malaria and tumour 
was conducted on Croton oligandrus (Euphorbiaceae), Justicia hypocrateriformis 
(Acanthanceae), Pseudospondias microcarpa (Anacardiaceae), Zanthoxylum lepreurii 
and Zanthoxylum zanthoxyloides (Rutaceae). The selection of plants was based on 
ethnomedicinal use and literature review. Bioassay-guided isolation of active components 
from the active plants was performed with the aim to scientifically validate their folklore 
usage.  The plant materials were dried, ground, and Soxhlet-extracted, successively, with 
n-hexane, dichloromethane (DCM) and methanol (MeOH). The antimalarial and 
chemopreventive potential of the plants were evaluated using haem polymerisation and 
the luciferase assays, respectively. The n-hexane and the DCM extracts of C. oligandrus, 
and the DCM and MeOH extracts of Z. zanthoxyloides were the most active in the 
luciferase assay causing 18, 21, 34 and 36-fold induction of the level of luciferase in 
AREc32 cells, respectively. Pseudospondias microcarpa was the most active antimalarial 
plant with IC50 values of 73.9 ± 25.8, 2.5 ± 1.5 and 4.0 ± 1.7 µM for the stem bark n-
hexane, DCM and MeOH extracts, respectively, and 13.0 ± 9.0 µM for the leaves MeOH 
extract. Fifty-one compounds including eleven novel ones were isolated from active 
fractions using column chromatography, thin layer chromatography and reversed-phase 
high-pressure liquid chromatography. Structural elucidation was carried out by 
spectroscopic means including 1D and 2D NMR and mass spectrometry. Crotonolins A-
D, skimmianine, hesperidin and myrtopsine were identified as potent chemopreventive 
compounds with fold induction greater than 2. None of the isolated compounds 
demonstrated any inhibition of haem polymerisation. This study generated the first 
phytochemical report on P. microcarpa, the second of C. oligandrus and the third of J. 
v 
 
hypocrateriformis. The biogenesis and chemotaxonomy of isolated compounds have also 
been discussed. 
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1.1 Cancer 
1.1.1 General overview 
Cancer is one of the leading causes of mortality and morbidity worldwide, ranking second 
after heart disease (Ferlay et al., 2013). The term cancer relates to 200 or more separate 
diseases characterized by uncontrolled growth and spread of abnormal cells in the body 
(Trichopoulos et al., 1996). In 2015, approximately 8.8 million deaths worldwide were 
caused by cancer (WHO, 2018a), and in the UK, an estimated 359,960 new cases were 
registered in 2015, and about 163,444 deaths were due to cancer (CR-UK, 2018). 
Globally, one in six deaths are due to cancer and this number is projected to almost double 
by the year 2030, if no measures are taken to cure or prevent the disease (WHO, 2018a). 
Factors such as smoking, obesity, inadequate diet, lack of physical activity and pollution, 
increase the risk of getting cancer (Grundy et al., 2017). Traditional cancer therapies 
include radiation, chemotherapy and surgery. However, these treatments have limited 
efficacy, huge side effects and the vital prognostic is unquestionable when the cancer has 
reached the stage of metastasis. As most cancer results from lifestyles and environmental 
factors, cancer prevention could be a better way to reduce the incidence of the disease. 
Besides, always ‘prevention is better that cure’. 
 
 
1.1.2 Mechanism of cancer development 
Cancer is a multiple step process and involves genetic and epigenetic changes.  Such 
changes in just one cell can lead to the development of cancer (Fink, 1979).  
Carcinogenesis consists of three main stages: initiation, promotion and progression 
(Figure 1.1) (Murakami et al., 1996). Initiation can be induced by exposure to a 
carcinogen giving rise to spontaneous changes such as DNA damage in one or more stable 
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cells, leading to mutations in the genetic code (Counts and Goodman, 1994). If the 
mutation occurs in a gene, which controls cell growth, that cell may become a pre-
cancerous cell (Cohen and Ellwein, 1995). If cell division occurs before repair of the 
damaged cell takes place, then the lesion will be present on the DNA of the daughter cell 
and will perpetuate into all the further progeny of that daughter cell. Further proliferations 
of the damaged cells due to exposure to promoting stimuli will give rise to a population 
of transformed cells and eventually will develop into a tumour (Cairns, 1981). Further 
stimulations of initiated cells in addition to mutations and chromosomal aberrations cause 
a fast increase in the tumour size and lead to increasing heterogeneity of the cell 
population (Devi, 2004). A tumour can be benign or malignant. Benign tumours are not 
usually life threatening and do not invade nearby cells or spread to others part of the body 
the way malignant tumours can. If untreated or unresponsive to treatment, malignant 
tumours can invade and destroy the surrounding tissues. As the tumour progresses under 
the effect of accumulation of multiple genetic alterations, some cells can be detached 
from the site of the primary growth, enter the circulating blood and lymph, and be 
transported to other organs/tissues. They can penetrate the vessels of the organ or tissues, 
continue to multiply in their new location and eventually develop into another clinically 
detectable tumour known as metastases (Yokota, 2000). 
 
Figure 1.1 Different stages of cancer development 
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1.1.3 Cancer occurrence and mortality rates 
In 2017, the most common causes of cancer death in the world were, lung (1.69 million 
deaths), liver (788,000 deaths), colorectal (774,000 deaths), stomach (754,000 deaths) 
and breast (571,000 deaths) (WHO, 2018a). It has been predicted that 42% of males and 
39% of females will suffer from cancer at some point in their life. Most common fatal 
cancers in females affect breast, colon, lung and cervix, while in males they affect lung, 
prostate, colon and stomach (WHO, 2014). Acute lymphoblastic leukaemia and brain 
tumours are the most common cancers causing death in children, except in Africa where 
non-Hodgkin lymphoma occurs more often (WHO, 2014). In the UK, breast, lung, colon 
and prostate are the most common cancer sites and accounted for more than half of all 
cancer deaths in 2014 (CR-UK, 2018). A total of 14 million cancer cases were registered 
in 2012, and this number is expected to rise by about 70% over the next two decades with 
almost half of all new cases being registered in developing countries (Ferlay et al., 2013). 
Currently, 70% of cancer deaths worldwide occur in low- and middle-income countries 
(WHO, 2018a). The chance of survival highly depends on the type of cancer and extent 
of disease at the beginning of treatment. The 5-year survival rates of many cancer patients 
are still low, 4% only for cancer affecting pancreas (Pezzuto et al., 2005). Making 
lifestyle changes such as  stopping smoking, adopting a healthy diet and undertaking 
physical activity can reduce cancer  incidence by 40% (Amin et al., 2009). 
 
 
1.1.4 Cancer chemotherapy 
Cancer chemotherapy is the use of cytotoxic drugs to destroy cancer cells. It can be used 
alone or in combination with surgery and/or radiotherapy. The toxic drugs interfere with 
DNA and cell division to preferentially kill cancer cells (Cheung-Ong et al., 2013). The 
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four main categories of cytotoxic drugs include alkylating agents, antimetabolites, 
hormonal agents and mitotic inhibitors. Alkylating agents derived from mustard gas, their 
anticancer properties are because of their ability to bind covalently with DNA via their 
alkyl groups (Lind, 2011). Therefore, DNA molecules are bound tightly together and 
cannot split during mitosis, thus preventing the proliferation of the cancer cell. Examples 
of these types of drugs include cisplatin and cyclophosphamide. Antimetabolites have 
similar structures with the metabolites with whom they interfere with in the organism. 
They act by blocking DNA dereplication thus preventing cell division. Some examples 
of antimetabolites are capecitabine and fludarabine. Hormonal agents are used to 
stimulate or inhibit the production and activity of some hormones involved in the 
development of certain cancers. Examples of such are leuprorelin and tamoxifen used in 
the treatment of prostate and breast cancers, respectively. Mitotic inhibitors are derived 
from plant natural products. They act by blocking cell division by preventing microtubule 
function (Rowinsky and Donehower, 1991). Examples of these drugs include etoposide 
and taxol (Figure 1.2). 
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1.1.5 Treatment of cancer by traditional medicine 
Traditional medicine is commonly used as both adjuvant and alternative to the use of 
synthetically manufactured chemotherapeutic drugs. Many surveys have identified plants 
used in different ethnic groups across the world for the treatment of cancer. An example 
of such survey could be the one carried out by Hartwell (1971), who combined data of 
3000 plants used traditionally for the treatment of cancer. Phytochemical studies of these 
plants led to the isolation of almost 1000 compounds with potent anticancer properties 
and the discovery of lead compounds for the development of new cancer drugs (Cragg 
and Newman, 2016). Table 1.1 lists some examples of isolated anticancer agents from 
plants. 
 
 
1.1.6 Cancer chemoprevention 
Cancer chemoprevention is defined as the use of vaccines or pharmaceutical agents to 
inhibit, retard, or reverse the carcinogenesis process (Mettlin, 1997). Since carcinogenesis 
is a multiple stage process and takes many years or decades to develop, there are several 
chances to intervene in this process (Tamimi et al., 2002). Moreover, exogenous causative 
factors including smoking, diet, physical exercise, environmental pollution, exposition to 
potential carcinogens and radiations, can be controllable and preventable (Grundy et al., 
2017). Inhibition of carcinogens, treatment of precancerous lesions, protection of persons 
at genetic risk and reduction of the incidence of cancer due to dietary epidemiology 
represent the four main lines address by cancer chemoprevention strategies (Surh, 1999). 
The ultimate goals of cancer chemoprevention research include identification of the most 
effective agents and/or to develop efficient approaches for clinical trial and ultimately, 
application to human population. Plant derived natural products offer a diverse source of 
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potential chemopreventive agents (Manna et al., 2000).  Indeed, several compounds 
isolated from plants i.e. avicins (Acacia victoriae), ursolic acid (Basil), resveratrol (red 
grapes), curcumin (Curcuma longa), all from dietary vegetables and fruits, have shown 
the ability to inhibit human cancer cells growth and therefore, may serve as 
chemopreventive agents (Shishodia et al., 2003; Aggarwal et al., 2004; Howes, 2015). 
 
Table 1.1 Examples of cytotoxic compounds isolated from plants 
Plant sources Isolated compounds Activity  References  
Acronychia bauer L. Acronycine Antitumour (Duke, 1992) 
Brucea species Miller  Bruceantin Antitumour/ 
Antileukaemia 
(Shah et al., 
2014) 
Bryophyllum pinnatum 
Salisb.  
Bryophyllin-A Antitumour (Duke, 1992) 
Camptotheca acuminata 
Decne 
Camptothecin Antileukaemia (Pezzuto, 
1997) 
Cassia obtusifolia L.  Emodin Against breast 
cancer 
(Huang, et al., 
2008) 
Catharanthus roseus (L.) 
G. Don 
Vincristine and 
vinblastine 
Antileukaemia  (Pezzuto, 
1997) 
Cephalotaxus harringtonii 
(Forbes) K. Koch 
Homoharringtonine Antileukaemia (Shah et al, 
2014) 
Rabdosia rubescens L. Rubescensine B Antihepatoma (Chang, 1998) 
Podophyllum peltatum L.   Etoposide and 
teniposide 
Antitumour (Pezzuto, 
1997) 
Stephania tetrandra Lour  Tetrandrine Against lung 
cancer 
(Duke, 1992) 
Zanthoxylum nitidum L.  Nitidine chloride Against lung 
cancer 
(Chang, 1998) 
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Chemopreventive agents (Figure 1.3) can be natural or synthetic substances. Examples 
include the synthetic drugs raloxifene and tamoxifen used to prevent breast cancer in 
women (Chlebowski, 2015) and phenethyl isothiocyanate, a naturally occurring 
compound in some cruciferous vegetables with potential chemopreventive effects on 
prostate cancer (Wang, 2010). Chemopreventive agents are classified into two groups, 
blocking agents and suppressing agents (Wattenberg, 1985). Suppressing agents act in 
either the promotion or the progression stages during carcinogenesis by inhibiting the 
proliferation of initiated cells. Blocking agents act on the initiation stage of the 
carcinogenesis either by blocking the formation of the carcinogen, or by inhibiting 
interaction of the ultimate carcinogen with crucial cellular macromolecules such as DNA, 
RNA and protein (Figure 1.4) (Surh, 1999; Kuo et al., 2012). 
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Figure 1.3 Some chemopreventive agents 
 
 
1.1.7 Chemoprevention by dietary phytochemicals 
Dietary phytochemicals are natural products commonly found in edible plants. They 
became an attraction for cancer chemoprevention research when researchers noticed that 
people adopting the Mediterranean diet (mean a diet of fish, vegetables, legumes, whole 
grains, potatoes, fruit and extra virgin olive oil) have the lower risk of developing cancer 
(Gotsis, 2015). Evidences later confirmed their anticancer and chemopreventive potential 
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(Shishodia et al., 2003; Aggarwal et al., 2004). Dietary phytochemicals mainly act as 
blocking agents by intervening in a range of cellular processes resulting in the inhibition 
of the early stages of the carcinogenesis (Sapienza and Issa, 2016). They prevent 
carcinogens from reaching targeted sites, support detoxification of highly reactive oxygen 
species, enhance innate immune surveillance and improve the elimination of initiated 
cells (Kotecha et al., 2016). The above-mentioned properties of dietary phytochemicals 
involve the activation of the nuclear factor erythroid-2 (NF-E2)-related factor 2 (Nrf2)-
Kelch-like ECH associated protein 1 (Keap1).This complex activation consequently 
results in the induction of cellular defence mechanisms, including phase II detoxifying 
enzymes, phase III transporters, antioxidative stress proteins, and other stress-defence 
molecules that protect normal cells from reactive oxygen species (ROS) and/or reactive 
nitrogen species (RNS) and reactive metabolites of carcinogenic species known to be the 
causative agents of more than 600-types of cancer (Lee et al., 2013; Landis-Piwowar et 
al., 2014). 
 
Figure 1.4 Multistage carcinogenesis and strategies for cancer chemoprevention 
(Adapted from Kuo et al., 2012) 
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1.1.8 Phase II detoxification enzymes 
One significant mechanism by which dietary phytochemicals protect cells from cancer is 
by the induction of the activity of drug metabolizing enzymes particularly of phase II 
detoxifying enzymes. Phase II detoxification enzymes provide the defence against foreign 
chemicals, to which humans are constantly exposed. Many xenobiotics are toxic and if 
they accumulate in the body, they may cause cell damages which will eventually kill the 
cell or develop into a cancer. Therefore, many enzymes with various specificities are 
required to reduce the toxicity of reactive intermediates, protect cells against oxidative or 
electrophilic challenges, and maintain chemical homeostasis in cells (Kwak et al., 2001). 
Examples of reactions and Phase II enzymes involved in detoxification include: reduction 
reaction catalysed by NAD(P)H dehydrogenase, quinone 1 (NQO1); conjugation 
reactions catalysed by UDP-glucuronosyltransferase (UGT) and glutathione transferase 
(GST); oxygenation reaction catalysed by heme oxygenase-1 (HO-1) (Zimniak, 2008). 
The genes encoding the detoxifying enzymes are typically regulated through a consensus 
cis-enhancer sequences known as the antioxidant responsive element (ARE) or 
electrophile response element (EpRE), which are in their promoter region. ARE-mediated 
gene expression plays a central role in the cellular defence against oxidants and 
electrophiles (Chen and Kong, 2004). It is activated through the binding of the 
transcription factor, Nrf2, in response to cellular attack by ROS or any other compound 
with the capacity to either undergo redox cycling or be metabolically transformed to a 
reactive or electrophilic species (Nguyen et al., 2009). NQO1, for example, is a key 
enzyme that protects against quinone-derived reactive intermediates and maintains 
cellular pool of antioxidants such as tocopherol (Nioi and Hayes, 2004). Generally, an 
increase in the activity of NQO1 enhances the ability of an organism to detoxify numerous 
potentially harmful xenobiotics (Dinkova-Kostova and Kostov, 2012; Landis-Piwowar et 
al., 2014). Therefore, substances that increases the activity of NQO1 can be potential 
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chemopreventive agents with the ability to inhibit chemically induced cancer formation 
(Perez et al., 2010). 
 
 
1.1.9 Nrf2 as a target for cancer chemoprevention 
Nrf2 is a protein that regulates the expression of many phase II detoxifying/antioxidant 
enzymes. Under normal condition, Nrf2 is sequestered in the cytoplasm by an actin-
binding protein, Kelch-like ECH associating protein 1 (Keap-1) and maintains at very 
low levels regulated by proteasomal degradation (Jaramillo and Zhang, 2013). Upon 
exposure of cells to inducers such as chemopreventive agents, the sensor cysteines of the 
Keap-1 that control the Keap-1-dependent Nrf2 degradation is inactivated by the inducers 
and this therefore, allows de novo synthesized Nrf2 to accumulate, to dissociate from the 
Keap-1 and to translocate to the nucleus where it binds to ARE (Carvalho et al., 2010), 
and transactivates phase 2 detoxifying and antioxidant genes and transporters, that defend 
cells from subsequent carcinogenic insults by reducing reactive compounds such as 
electrophiles and free radicals to less toxic intermediates whilst increasing the ability of 
the cell to repair any damage ensued (Jeong et al., 2006; Lau et al., 2008; Bryan et al., 
2013). Several studies have demonstrated that the major mechanism of protection against 
carcinogenesis is through Nrf2-mediated induction of drug metabolizing enzyme, 
particularly phase II detoxification and antioxidant enzymes (Lau et al., 2008). Various 
compounds, such as naphthoflavone and tert-butyl hydroquinone (tBHQ), are potent 
chemopreventive agents because of their ability to induce phase II enzymes in 
mammalian cells (Jeong et al., 2008). As blocking agents, dietary phytochemicals protect 
DNA from mutation by activating the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) 
mediation detoxification and antioxidant effect thus making the Nrf2 to be a good drug 
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target for cancer prevention by phytochemicals (Jaramillo and Zhang, 2013; Reuland et 
al., 2013; Landis-Piwowar et al., 2014).  
 
 
1.2 Malaria 
1.2.1 General overview 
Malaria is a disease endemic to tropical and subtropical regions of the world (Bloland, 
2001). The disease is caused by protozoan parasites Plasmodium, transmitted to humans 
through the bites of infected female Anopheles mosquitoes. The most life-threatening and 
drug-resistant cases are due to infection by the species P. falciparum (Daily, 2006). The 
development of resistance to drugs poses one of the greatest threats to malaria control and 
has been linked to recent increases in malaria morbidity and mortality. The World Health 
Organization’s 2016 ‘World Malaria Report’ estimates that in 2016, 216 million cases of 
malaria were reported causing 445,000 deaths compared to 212 million cases reported in 
2015 causing 446,000 deaths (WHO, 2017). Resistance to antimalarial drugs has 
threatened global malaria control since the emergence of resistance to chloroquine in the 
1970s. WHO advocates Artemisinin Combination Therapy (ACT) as first line treatment 
for acute uncomplicated malaria, where the potentially life threatening parasite P. 
falciparum is the predominant infecting species with the aim to improve efficacy and to 
retard the development of resistance (Reyburn, 2010). However, this treatment is also 
vulnerable and resistance to artemisinin has already been registered in Western Cambodia 
(Noedl et al., 2008). Because of the potential consequences if resistance to artemisinin 
were to become widespread, one of the great scientific and medical concerns today is to 
develop new drugs or vaccines to fight against malaria. 
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1.2.2 Malaria occurrence and mortality rate 
Malaria is one of the oldest diseases that affects human. The evidence of the occurrence 
of this disease, 5,000 years ago, was found in Chinese manuscript (Cox, 2010). The word 
malaria derived from the Italian word ‘mal aria’, which signifies bad air. The disease was 
first believed to have been caused by vapours given off by swamps by inhalation and was 
also called swamp fever. It was not until 1880 that the parasite responsible for the disease, 
known today as Plasmodium, was described by Alphonse Laveran (Cox, 2010). The 
vector responsible for the transmission of the disease, the mosquito Anopheles, was later 
identified by Ronald Ross in 1899 (Cox, 2010). Malaria is widespread in tropical and 
subtropical regions in sub-Saharan Africa, Central and South America, the Caribbean 
island of Hispaniola, the Middle East, the Indian subcontinent, South-East Asia, and 
Oceania (Figure 1.5). Despite its discovery several decades ago, and all the research 
implemented to prevent and eradicate the disease, malaria is still one of the leading causes 
of human mortality. Malaria is prevalent in 91 countries and occurs mainly in sub-Saharan 
Africa.  
  
Figure 1.5 Geographic distribution of malaria (Source: WHO. World Malaria Report. 
Geneva, 2016. Licence: CC BY-NC-SA 3.0 IGO.) 
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According to the WHO malaria report 2017, an estimated of 216 million cases of malaria 
were reported in 2016, an increase of 4 million cases compared to 2015. The disease made 
445,000 casualties in 2016, a similar number of deaths were observed the previous year 
(446,000). Sub-Saharan Africa is the most affected area with 90% of malaria cases and 
91% of malaria deaths. South-East Asia is the second affected region with 7% and 6% of 
reported malaria cases and deaths, respectively. Children under 5 years old are the most 
affected by the disease and 70% of all malaria deaths occur in this age group.  Malaria 
transmission and infection highly depend on the climate conditions and geographical 
position (Bloland and Organization, 2001).  Warm temperatures promote the breeding of 
the mosquito vector, and highland (altitude >2,000 m) and arid areas (<1000 mm 
rainfall/year) are less prone to the disease in areas where malaria does occur (Ermert et 
al., 2011).  
 
 
1.2.3 Life cycle of malaria Plasmodium 
The Plasmodium is a genus of parasites comprising about 200 species (Chavatte et al., 
2007). Five species including P. falciparum, P. vivax, P. malariae, P. ovale and P. 
knowlesi are responsible for malaria in humans. Malaria cases associated with the species 
P. malariae and P. ovale are less common. P. knowlesi mostly affects primates and do 
not seem to be a major threat to humans (Singh et al., 2004). Infections due to P. 
falciparum and P. vivax are the most life threatening.  P. vivax can persist for years in the 
dormant stage in the liver and can cause clinical relapses at regular intervals (Carvalho et 
al., 2010). Almost 99% of malaria cases in sub-Saharan Africa are due to P. falciparum, 
which is the most prevalent in that region. P. vivax is predominant in the others area 
affected by the disease outside Africa and were responsible for 4% of malaria deaths 
globally in 2016 (WHO, 2017). All the Plasmodium species causing malaria in humans 
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are transmitted by mosquito species of the genus Anopheles (Igweh and Okwa, 2012). 
The life cycle of the malaria parasite, discovered by Ronald Ross in 1899, is complex and 
takes place in both human and mosquito tissues (Cox, 2010). A simplified schematic 
representation of the malaria cycle is depicted in Figure 1.6. The cycle starts with the 
injection of sporozoites by the vector, the mosquito Anopheles, into the subcutaneous 
tissue or directly into blood vessels (Miller et al., 2002). The sporozoites are then 
transported to the liver via the bloodstream where they infect the liver cells (hepatocytes) 
(Kappe et al., 2010). Within the liver, sporozoites can invade any cells and then, undergo 
asexual replication to develop into schizonts which are formed by thousands of 
merozoites, which are later released into the bloodstream upon rupture of the schizont 
membrane and infect the red blood cells (RBC) (Cowman and Crabb, 2006; Kappe et al., 
2010). The liver stage normally lasts about 9-16 days. For infections due to P. vivax and 
P. ovale, sporozoites do not develop into schizonts immediately. They remain dormant in 
the liver as hypnozoite and that makes it difficult to diagnose and treat (Igweh and Okwa, 
2012). 
Within the RBC, a fraction of the merozoites initiate the intra-erythrocytic cycle that lasts 
about 36-48 h. They first develop into a ring-shaped form, then to a trophozoite form and 
later into schizont. Upon destruction of the RBC, the schizont released new merozoites 
into the bloodstream, which can infect new RBC and reinitiate the cycle. After several 
repeated cycles, when 10% of the bloodstream RBC are infected, clinical features 
associated with the disease can be observed in the patient (Wirth, 2002). The remaining 
merozoites differentiate into male and female gametocytes. The Mosquito Anopheles 
ingests those gametocytes during its blood meal. Within the mosquito, the gametocytes 
emerge from the red blood cells as gametes. The fusion of male and female gametes forms 
a zygote, which elongates into ookinete. The ookinete then later develops into an oocyst 
whose membrane’s rupture will release thousands of sporozoites that will travel to the 
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insect salivary glands. After this stage, the cycle is complete and the mosquito is ready to 
initiate a new infection on a healthy individual during another blood meal. 
 
Malaria symptoms appear approximately one week after infection. Common symptoms 
include periodic fever, shivering, cough, respiratory distress, pain in the joints, headache, 
watery diarrhoea, vomiting and convulsions (Miller et al., 2002). If malaria remains 
untreated, erythrocytes filled with mature stages of the parasite can adhere to the walls of 
capillary veins, causing vascular occlusion, severe anaemia, impaired consciousness, 
renal failure and cerebral death (cerebral malaria) (Miller et al., 2002; Tuteja, 2007). 
 
Figure 1.6 Life cycle of malaria cycle infection 
(https://hu.wikipedia.org/wiki/Fájl:Plasmodium_lifecycle_PHIL_3405_lores.jpg ) 
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1.2.4 Current antimalarial drugs and prevention 
Malaria is a preventable and treatable disease. Several drugs have been developed to 
prevent and treat the disease, and several vaccines are currently under development or in 
clinical trials. The WHO recommends the use of the artemisinin based combined therapy 
as first line treatment for uncomplicated malaria due to infection by P. falcifarum (Prasad 
et al., 2015). Quinine along with its derivative has been used for the treatment of severe 
cases of malaria. These therapies have considerably lowered the mortality and morbidity 
rates due to malaria during the last three decades (Bloland and Organization, 2001). 
 
 
1.2.4.1 Quinine and its derivatives 
Quinine was the first drug to be used to treat malaria. It was serendipitously discovered 
in the 1600s, when a native from south America suffering from high fever was 
miraculously cured after drinking from a pool of water contaminated with the Cinchona 
tree (Cragg and Newman, 2005a). Extract of the bark of Cinchona with wine or water 
was used to treat fever associated to malaria until the isolation of quinine as its crystalline 
sulphate in 1820 by Pierre J. Pelletier and Joseph Caventou.  The molecular formula of 
quinine was proposed by Paul Rabe in 1907, and later confirmed following its total 
synthesis by Robert B. Woodward and William Doering in 1944 (Achan et al., 2011). 
Quinine was the main antimalarial drug until the 1920s after which analogues notably 
chloroquine became more commonly used, due to them being more effective and having 
less side effects (Plowe, 2010). Quinine is still used today and remains the drug of last 
resort for the treatment of multidrug-resistant malaria (WHO, 2015). Other quinine 
derivatives in use today include chloroquine, primaquine, mefloquine and amodiaquine 
(Figure 1.7) (Bloland and Organization, 2001). 
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Figure 1.7 Some quinoline antimalarials 
 
 
1.2.4.2 Antifolates 
Folate compounds are derived from folic acid, which is formed from a pteridine ring, p-
aminobenzoic acid and glutamate. They act on the folate biosynthetic pathway of the 
Plasmodium, a pathway essential to malaria parasite survival, either as inhibitors of 
dihydropteroate synthase (antifolates class I) or as inhibitors of dihydrofolate reductase 
(antifolates class II), hence the name antifolates (Nzila, 2006). Class I antifolates in use 
include proguanil, chlorproguanil, pyrimethamine and trimethoprim. Class II antifolates 
also called sulpha-drugs in useuse include dapsone, sulfamethoxazole and sulfadoxine 
(Figure 1.8) (Bloland, 2001). Each class when used alone are effective  antimalarials, 
however, parasitological resistance can develop rapidly in that situation (Bloland and 
Organization, 2001). When used in combination, they produce a synergistic effect on the 
parasite and can be effective even in the presence of resistance to the individual 
components (Nzila, 2006). Antifolates are mainly used in sub-Saharan Africa regions 
where chloroquine resistant P. falcifarum is widespread. They have less or no action of 
P. vivax and P. ovale (Gregson, 2005). 
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Figure 1.8 Some antifolates used in malaria therapy 
 
 
1.2.4.3 Artemisinin and related drugs 
Artemisinin is a sesquiterpene lactone with antimalarial properties that was first isolated 
from the leaves of Artemisia annua (Tu, 2011). A. annua has been used for more than 
2000 years in Chinese traditional medicine for the treatment of fever and chills (Tu, 
2011). Artemisinin was discovered by Youyou Tu in 1972 as part of an antimalarial 
research project by the Chinese government. This discovery led her receive the Nobel 
Prize in Physiology or Medicine in 2015 (Xie, 2016). Artemisinin has later been used as 
a lead compound for the discovery of related antimalarials including artemether, 
dihydroartemisinin, artesunate and arteether (Figure 1.9) (Tu, 2017). WHO recommends 
the use of Artemisinin Combined Therapy (ACT) as first line treatment of uncomplicated 
malaria due to P. falciparum infection (WHO, 2018b). ACT is a combination of 
artemisinin or an artemisinin-derivative and a second drug with a different mechanism of 
action to enhance efficacy (Reyburn, 2010). Artemisinin and its derivatives must not be 
used as oral monotherapy, as this promotes the development of artemisinin resistance 
(WHO, 2018b).  
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Figure 1.9 Artemisinin and derivatives 
 
 
1.2.4.4 Other used antimalarial drugs 
Other antimalarials currently in use include antibiotics, such as tetracycline, and its 
derivatives, clindamycin and thiostrepton. They are used either as a  treatment or for 
prophylaxis in combination with quinine (Bloland and Organization, 2001). 
Lumefantrine, atovaquone and halofantrine are also antimalarials (Figure 1.10). They are 
used in area with P. falciparum multidrug resistance.  
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Figure 1.10 Other antimalarials: clindamycin, lumefantrine and atovaquone 
 
 
1.2.5 Malaria prevention 
The WHO has developed several policies to protect persons at risk of getting malaria in 
endemic regions and those travelling from non-malaria regions to malaria regions. These 
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include the control of the vector and chemoprophylaxis. In endemic regions, persons are 
protected from the mosquito Anopheles by the usage of long-lasting insecticidal nets 
(LLIN) and indoor residual spraying insecticides. LLIN are provided free of charge and 
all people at risk of malaria mainly children under 5 years old and pregnant women are 
encouraged to sleep under a well maintained LLIN every night. Preventive treatment with 
sulfadoxine-pyrimethamine are administrated on a trimestral basis to pregnant women 
and in addition to sulfadoxine-pyrimethamine, amodiaquine is administrated to children 
under 5 years old monthly. Similarly, for travellers from non-malaria to malaria regions, 
chemoprophylaxis using drugs that act on the blood stage of the Plasmodium and 
mosquito repellent lotions are used to prevent malaria. The WHO with partner 
organisations have also developed some vaccines against malaria (WHO, 2018b). The 
first of such, RTS,S/AS01 (RTS,S) developed with the partnership of GlaxoSmithKline 
will be available for use in  2018. RTS,S will be used to prevent children under 3 years 
old from getting malaria due to infection by P. falciparum. Another vaccine currently 
under development is Sanaria® PfSPZ Vaccine (Plasmodium falciparum sporozoite 
Vaccine), a clinical trial of which is currently being conducted in Equatorial Guinea 
(Olotu et al., 2018). 
 
 
1.2.6 Malaria drug resistance 
Even though the number of global malaria deaths has fallen by 48% since 2000, malaria 
is still a life threatening disease due to the development of resistance to existing drugs in 
most endemic areas affected and the difficulty to control the most effective malaria vector 
Anopheles gambiae (Prasad et al., 2015). The WHO defines antimalarial drug resistance 
as the ability of a parasite strain to survive and/or multiply despite the administration and 
absorption of a drug given in doses equal to or higher than the recommended but within 
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tolerance of the subject. The parasite must be sensitive to the used antimalarial and this 
later must be able to gain access to the parasite or the infected RBCs for the duration of 
the time necessary for its normal action (Bruce-Chwatt, 1986). Despite the long list of 
available antimalarials, parasites have developed resistance over time to almost all 
antimalarial drugs. Resistance to quinine was first reported in 1910 after its introduction 
in pure form in the 1840s, while resistance to artemisinin, introduced in malaria therapy 
in the 2000s, was recently registered in Cambodia and has since been spread in other areas 
of the world including south Asia, Serra Leone, Nigeria and Madagascar (Hien et al., 
2012). Antimalarial drug resistance has been the main problem in the management of the 
disease. 
 
 
1.2.6.1 Resistance to quinoline antimalarials  
Resistance of Plasmodium to quinine was first reported in 1910 and later confirmed in 
1938 (Clyde et al., 1972). Quinine resistant Plasmodium strains are rare in Africa but 
widespread in Southeast Asia and South America (Legrand et al., 2007). Resistance to 
quinine is usually low grade, with the drug retaining some activity but having its action 
delayed or diminished (Achan et al., 2011). Chloroquine became the cornerstone of 
malaria treatment in 1950s. However, just ten years after its introduction, high levels of 
resistance were recorded in Thailand and South America and have since been found in 
other countries including Malaysia, Vietnam, Cambodia and Burma and more recently in 
Sub-Saharan Africa. 
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1.2.6.2 Resistance to artemisinin and its derivatives 
Artemisinin was first used in the 1980s in China. Interest to artemisinin began to grow 
with the advent of resistance of Plasmodium to existing antimalarials. In the 1990s, 
artemisinin was introduced in malaria therapy in Thailand and Cambodia, and then in 
other malaria regions (Meshnick, 2002). The first resistance of P. falciparum parasites to 
artemisinins was detected in Thailand-Cambodia border in the early 2000 (Denis et al., 
2006). The resistance was confirmed in 2009 and has since been detected in Southeast 
Asia (Cambodia, Vietnam, Myanmar and Thailand) and in Africa (Nigeria, Madagascar 
and Sierra Leone) (Hien et al., 2012). Artemisinin and its derivatives are still effective; 
however, measures have been taken to reduce the chances of developing resistance in 
other malaria regions and to prevent the spread of resistance (Reyburn, 2010); the WHO 
bans monotherapy and recommends the use of artemisinin combined therapies (ACT) for 
the treatment of uncomplicated malaria. There are five available ACTs including 
artemether/lumefantrine, artesunate/amodiaquine, artesunate/mefloquine, 
dihydroartemisinin/piperaquine and artesunate/sulfadoxine-pyrimethamine (Prasad et al., 
2015). 
 
 
1.2.6.3 Resistance to antifolates  
Resistance to pyrimethamine and proguanil, the firsts DHFR inhibitors introduce in the 
malaria therapy, developed shortly after their introduction in the late 1940s and early 
1950s respectively in Southeast Asia (Gregson, 2005). Sulpha-drugs such as sulfadoxine 
and dapsone were introduced in the malaria therapy in the 1960s due to their long half-
life and least toxicity (Triglia and Cowman, 1999). However, their usage was almost 
immediately limited due to the parasite to develop rapid resistance. Antifolates were 
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reintroduced in form of a combination formulation of DHFR and sulfa-drug (e.g., 
sulfadoxine-pyrimethamine), when subsequent studies revealed their strong synergistic 
action and ability to block the plasmodium DNA replication (Abdul-Ghani et al., 2013), 
however resistance to sulfadoxine-pyrimethamine developed and spread rapidly in South 
East Asia from the mid-1960s (Nzila, 2006). Because of the affordability of this 
combination, the WHO still recommends it for the treatment of chloroquine-resistant P. 
falciparum in Africa where the resistance to the combination is still limited to Tanzania 
(White, 2004; Nzila, 2006). 
 
 
1.2.7 Mechanism of action of chloroquine: hemozoin as target for new 
antimalarials development 
Among existing antimalarial drugs, resistance to quinine has been shown to develop 
slowly compared to others antimalarials. Quinine, 200 years after its discovery remains 
one of the most used effective antimalarials. Quinine in combination with an antibiotic 
e.g., doxycycline, tetracycline or clindamycin is recommended as second line treatment 
for uncomplicated malaria (when the first-line drug fails or is not available) and remains 
the first line treatment in combination with clindamycin of malaria in the first trimester 
of pregnancy (WHO, 2015). Several studies have been carried out to investigate the 
mechanism of action of quinine and other quinoline antimalarials. Quinoline antimalarials 
such as quinine and chloroquine, act by interfering with the digestion of haemoglobin in 
the blood stage of the malaria life cycle (Foley and Tilley, 1997). During the intra-
erythrocytic stage, haemoglobin is digested by the parasite Plasmodium in its acidic 
vacuole. Toxic haem, which is dangerous for the parasite, is released and spontaneously 
converted to a less reactive dimer, hemozoin (Figure 1.11) (Slater, 1993; Egan et al., 
1994). Quinoline, inhibits the haem’s polymerisation to hemozoin and the consequence 
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is that the haem released during haemoglobin digestion is accumulated in the parisite’s 
vacuole killing the parasite with its own toxic waste (Slater and Cerami, 1992; Egan et 
al.,1994; Sullivan, 2002). Resistance to quinoline antimalarials is manifested by the 
capacity of the parasite to expel chloroquine at a rate that does not allow chloroquine to 
reach levels required for inhibition of haem polymerization (Egan et al., 2001). Hemozoin 
synthesis is an indispensable pathway for the survival of the parasite and therefore, a good 
target for the development of new antimalarial drugs. Several screening techniques based 
on the quinolines antimalarials drugs mechanism have been developed during the recent 
years to assess the formation of hemozoin in vitro and screen compounds as inhibitors of 
the formation of hemozoin (Tripathi et al, 2001; Ncokazi and Egan, 2005). 
 
 
Figure 1.11 Quinoline antimalarials mode of action (from Ivers and Ryan, 2012) 
 
 
1.2.8 Malaria and natural products 
The two essential drugs used for the treatment of malaria, quinine and artesunate, are 
derived from the medicinal plants Cinchona sp. and Artemisia annua respectively. Plants 
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have been the source of medicines for humans and animals for centuries. Over a thousand-
plant species are traditionally used for the treatment and prevention of malaria symptoms. 
Phytochemical studies of those plants led to the isolation of a range of compounds with 
potent antimalarial properties. Beaufay et al. (2018), Bero et al. (2010), and Kaur et al. 
(2009) have published comprehensive reviews (covering up to 2016) on natural occurring 
compounds from plants with promising antimalarial activities. More recently, the new 
tirucallane triterpene, seco-tiaminic acid B isolated from Entandrophragma congoënse, 
and the macrolide bastimolide B (Figure 1.12) isolated from the tropical marine 
cyanobacterium Okeania hirsute were found to possess antiplasmodial activity with IC50 
values of 2.3 μg/mL and 5.7 μM, respectively (Happi et al., 2018; Shao et al., 2018).  
OH OH
O O
HO
OH OH OH OH OH OH
H
H
H
O
HO
O
H
Bastimolide B
seco-tiaminic acid B  
Figure 1.12 Recent antiplasmodial compounds from natural source 
 
 
1.3 Natural products drug discovery 
The use of medicinal plants in the treatment of human ailments can be traced for millennia 
(Solecki, 1975). Plants were used about 2600 B.C. in various forms including infusion, 
pills, ointments and oils gargles for the treatment of diverse ailments and cosmetics 
(Cragg and Newman, 2005b). Even today, plants are the almost exclusive source of 
healthcare for 80% of the world’s population and particularly in developing countries 
(Ekor, 2014). On the international market, global trade of medicinal plants and related 
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products is estimated at about 40 billion GBP annually (Te, 2013). The knowledge 
associated with traditional medicine has promoted further investigations of medicinal 
plants as potential medicines (Dias et al., 2012). Phytochemical screenings show that 
antibacterial substances like alkaloids, flavonoids, glycosides, saponins and terpenoids 
are distributed in plant materials (Edeoga et al., 2005). Plant-derived compounds 
(phytochemicals) represent an interesting source of new bioactive agents (Ghosh et al., 
2007). Almost 21% of drugs in use today are derived from natural products and 51% of 
the 1562 new chemical entities introduced between 1981 and 2014 can be traced to a 
natural product origin (Newman and Cragg, 2016). The ethnopharmacological properties 
of plants have been used as a primary foundation for early drug discovery (McRae et al., 
2007). This has led to the discovery of the cancer drug Taxol isolated from the bark of 
Taxus brevifolia and the antimalarial drug quinine isolated from the bark of the Cinchona 
tree (Wani et al., 1971; Kremsner et al., 1994). Different approaches have so far been 
developed for drug discovery from natural products (the following will discuss the case 
of plants only) including random and non-random screenings such as taxonomic, 
chemotaxonomic, ethnobiological, metabolomic and information managed screening 
(Cordell et al., 1993; Schwikkard and Mulholland, 2014). 
 
 
1.3.1 Random screening 
Random screening is the arbitrary collection of a huge number of taxa for a large-scale 
screening (Balunas and Kinghorn, 2005). The plant kingdom comprises about 250,000 
plant species on which only around 10% have been screened for their potential bioactivity 
(Iqbal et al., 2017). This approach is the method of choice in the absence of known taxa 
with the activity of interest. The collection process involves no intellectualization. All 
taxa are collected and screened irrespective of their usage. Bioassay-guided isolation is 
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used to identify the compounds of interest using various chromatographic and analytical 
techniques. Paclitaxel, sold under the brand name Taxol and used for the treatment of 
various types of cancer, was first isolated from the bark of Taxus brevifolia tree, collected 
in Washington State as part of a random screening approach carried out by the USA 
National Cancer Institute in their search for new anticancer drug (Wani et al., 1971; Cragg 
et al., 1993). Discovery of lead compounds by this approach is completely serendipitous 
and its success depends on the specificity of the bioassay and the volume of extracts 
available. In addition, random screening is time consuming, cost effective and only 1-5% 
of the collected samples screened usually show preliminary bioactive activity (DiMasi et 
al., 1991). However, with the advent of robotic and high throughput screening techniques 
the efficiency of random screening has increased, and it is now possible to carry out rapid 
and sensitive screening of high numbers of samples at low cost (Pereira and Williams, 
2007).  
 
 
1.3.2 Ethnobotanical screening 
The ethnobotanical or ethnopharmacological screening is essentially based on the 
empirical usage of plants for therapeutic purposes. The decision to investigate a plant 
species is determined by the fact that the plant is already being used as medicine or as an 
insect repellent or for some cultural purpose (Gullo, 1994). The screening of the plant 
extracts and any isolated compounds is usually guided by what the plant is traditionally 
used for and any positive results would serve to validate the use of the plant traditionally 
as well as provide useful leads for further drug development. Several manuscripts 
describing the usage of plants for medicinal purposes, their dosage and mode of 
administration in various countries, notably in China, India, Mediterranean and South 
American countries are available. Ethnobotanical screening has been useful for the 
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discovery of lead compounds of valuable interest that have undergone chemical 
modifications to enhance their activity or reduce their toxicity. Fabricant and Farnsworth 
(2001) have demonstrated that 80% of the 94 medicinal plants from which 122 
compounds have been isolated and used as drugs, have had an ethnomedical use identical 
or related to the current use of the active principle of the plant. In 1785, Withering, an 
English scientist, published a book on the use of the foxglove, Digitalis purpurea, for the 
treatment of heart disorders; the study of foxglove later led to the isolation of the 
cardiotonic agent, digitoxin (Fabricant and Farnsworth, 2001). There are many other 
signiﬁcant drugs developed from traditional medicinal plants, e.g., quinine and 
artemisisin. 
The main advantage of the ethnobotanical screening is that the active compounds isolated 
from a plant are likely to show the activity of interest than those derived from plant 
species with no history of human use. This approach is also valuable for the discovery of 
complex skeletons unconceivable during synthesis that can then been used as lead 
compounds for drug discovery. The main inconvenient with this approach is the 
inadequate design of ethnobotanical data collection, and the misinterpretation of the role 
medicinal plants play in the medical systems of local and indigenous communities (Etkin, 
1993; De Albuquerque and Hanazaki, 2009). In addition, the plant identified may not 
contain any pharmacologically active compounds with the therapeutic effect observed 
being due the results of different factors (Moerman, 2007) including interactions with 
other components of the formulation as it is common for a secondary species of plant or 
additives such as wine to be added to complete the traditional formulation. Another 
limitation is the occurrence in the plant of compounds of interest at low concentration or 
as mixture of analogues making their separation difficult (Gullo, 1994). 
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1.3.3 Taxonomic and chemotaxonomic screening 
Chemotaxonomic screening resides on the ability of plants from the same genus to 
biologically synthesize the same class of metabolites (Gullo, 1994). This approach then 
involves the study of species within a plant family or genera which are known to produce 
biologically active compounds such as alkaloids or flavonoids (Cordell et al., 1993). An 
example of drug, discovered using such approach, is digitoxin isolated from Digitalis 
lanata, a species from the same genus as Digitalis purpurea known to produce the cardiac 
glycoside digoxin (Farnsworth et al., 1985). This approach is useful for taxonomic study 
to characterize and classify plants in a family by generating a profile of their secondary 
metabolites. Compounds obtained are similar in structure and can be used for structure 
activity relationship studies (Gullo, 1994). The limitation of this approach is the variation 
of plant metabolites within the period of the year, site of collection and the absence of 
metabolites of interest due to mutations or genetic factors affecting the gene clusters 
responsible for their accumulation in the plant (Makins et al., 1983). 
 
 
1.3.4 Virtual screening 
Virtual Screening, which is also known as the ‘information-managed approach’ uses all 
available biological information and chemical data available in journals and databases to 
direct the search for new drugs (Cordell et al, 1993; Sarker and Nahar, 2018). This 
approach is useful in identifying structures that are more likely to bind to the target of 
interest (Rollinger et al., 2008). In addition to the panoply of articles published daily, 
there are several databases containing extensive libraries of compound properties as well 
as software programs available to simulate or predict the binding capability of a 
compound to the receptor or target of interest. NAPRALERT (Natural Product ALERT) 
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is the first of such databases, created and developed by Farnsworth and coworkers (Loub 
et al., 1985) which contains over 140,000 compounds isolated from natural sources. Other 
examples are the Combined Dictionary of Natural Products, Chemlab, ChEMBL and the 
Collaborative Drug Discovery (CDD) database. Such virtual screening approach is useful 
to identify active pharmacophores which may be optimised by chemical modification. 
The main benefit of this approach is to prevent the re-study of known compounds that 
have already been investigated. By dereplication strategies, databases are linked to 
hyphenated chromatographic methods e.g. CE-MS, GC-MS, HPLC-DAD-ESI-MS/MS, 
which allows the rapid identification of new chemical entities from complex matrices 
such as plant extracts. (Dinan, 2006; Sarker and Nahar, 2012). This virtual screening 
approach is very productive as evidenced by its use in the pharmaceutical industry (Cheng 
et al., 2012). However, it is expensive, time consuming and such databases must be highly 
collaborative and updated on a regular basis. 
 
 
1.4 Cameroonian medicinal plants and their potential 
Cameroon’s population rely on medicinal plants for their primary healthcare. Indeed, due 
to the high cost of modern drugs, only 3 out of 20 patients can afford prescription drugs 
(Nkongmeneck et al., 2007; Kuete and Efferth, 2010). Cameroonian medicinal plants 
have exhibited a range of valuable activities including antimicrobial, antimalarial, 
antiproliferative, anti-inflammatory, antidiabetic, analgesic and antituberculotic (Kuete 
and Efferth, 2010). They have also shown to be rich in distinctive bioactive compounds 
(Kuete and Efferth, 2010; Ntie-Kang et al., 2013) such as michellamine B, an alkaloid 
isolated from the leaves of a Cameroonian native plant Ancistrocladus korupensis that 
has been found to be capable of the complete inhibition of cytopathic effects of HIV-1 
and HIV-2 on human lymphoblastoid target cell in vitro (Boyd et al., 1994). Cameroonian 
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flora is rich with an estimated 7,850 known species of which only 37% have been studied 
(Onana, 2015). Additionally, current studies of Cameroonian medicinal plants continue 
to show that they are a potential rich source of biologically active compounds for the 
development of new medicines (Noté et al., 2016; Fankam et al., 2017; Happi et al., 
2018). 
 
 
1.5 Selected Cameroonian medicinal plants for this study 
Plant materials were selected for this study based on ethnopharmacological information 
and an extensive literature survey. Plants used traditionally as remedies by local 
communities in Cameroon in their primary healthcare system for the treatment of malaria 
or anaemia related diseases were identified. Plants with minimal or no scientific data to 
validate their use were then selected and collected for further investigation. The following 
five plants belonging to four families were harvested: Croton oligandrus Pierre ex Hutch, 
Pseudospondias microcarpa (A. Rich.) Engl., Ruspolia hypocrateriformis (Vahl) Milne-
Redh, Zanthoxylum lepreurii Guill.  and Perr. and Zanthoxylum zanthoxyloides (Lam.) 
Zepern. and Timler. 
 
 
1.5.1 Croton oligandrus Pierre ex Hutch 
Scientific name Croton oligandrus Pierre ex Hutch 
Synonyms  Croton oligandrum 
Family  Euphorbiaceae 
Subfamily  Crotonoideae 
English name Croton Tribe Crotoneae 
Vernacular name Ebin (Cameroon)  
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Botanical description 
Croton oligandrus Pierre ex Hutch (Figure 1.13) belongs to the Euphorbiaceae family. 
The Euphorbiaceae, also known as the spurge family, is the largest family of flowering 
plants of about 322 genera and 8910 (Webster, 1993). Croton is a genus with nearly 1300 
species distributed in tropical and subtropical regions of the World (Berry et al., 2005). 
C. oligandrus, formally known as Croton oligandrum, is a tree of about 9-15 m high 
commonly found in western and central African secondary forests, especially in 
Cameroon and Gabon. Its leaves are sub-silvered underneath, oblong-elliptic or elliptic-
lanceolate, sub-caudate and rounded at the base. The seeds are oblong, convex on the 
back, 12 mm long, 7 mm broad, slightly shining and a little wrinkled. The wood is white, 
and the bark has an ash-grey colour with a remarkable aromatic odour. 
(a)          (b) 
Figure 1.13 a) Ptericarp (scientific tropical archive, http://actd.iict.pt), and b) seeds of C. 
oligandrus 
 
Ethnobotanical uses 
Croton oligandrus is usually harvested in the wild for use as traditional medicine or as 
timber. In Cameroon, the bark decoction is taken orally to treat pneumonia and 
splenomegaly as well as for ritual practice (Jiofack et al., 2009; Mpondo et al., 2017). 
The same bark decoction is used in Gabon for the treatment of anaemia and colic (Betti, 
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2013). The powder is sniffed to treat nasal tumours and it is externally applied to treat 
scabies (Schmelzer, 2008).  
 
Previous phytochemical investigations 
Linalool (1) has been identified as the main constituent of Croton oil (Agnaniet et al., 
2005). Abega et al. (2014) isolated the diterpenes 7-acetoxytrachiloban-18-oic acid (2), 
crotonadiol (3), crotonoligaketone (4), crotonzambefuran (5) and imbricatadiol (6), and 
the triterpenes 3-O-acetylaleuritolic acid (7), lupeol (8), β-sitosterol (9), and stigmasterol 
(10) from the stem bark of C. oligandrus (Figure 1.14). 
 
Previous pharmacological investigations 
There is only one report which investigated the pharmacology of C. oligandrus. The stem 
bark’s essential oil was screened for its antiradical and antioxidant activities, with no 
activity being found in both cases (Agnaniet et al., 2005). 
 
Figure 1.14 Isolated compounds from the bark of C. oligandrus 
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1.5.2 Ruspolia hypocrateriformis (Vahl) Milne-Redh  
Scientific name Ruspolia hypocrateriformis (Vahl) Milne-Redh 
Synonyms  Eranthemum affine Spreng. 
Eranthemum hypocrateriforme (Vahl) R.Br. ex Roem.and 
Schult. 
Justicia hypocrateriformis Vahl 
Pseuderanthemum hypocrateriforme (Vahl) Radlk. 
Siphoneranthemum hypocrateriforme (Vahl) Kuntze 
Family  Acanthaceae 
Subfamily  Acanthoideae Tribe Justicieae 
English name Ruddy Rose, Pricklybush, Cameroun tea, blood tonic plant 
Vernacular name kifu ke menseh (Cameroon) 
 
Botanical description 
The Acanthaceae, acanthus family, is made up of 221 genera and 4000 species (Scotland 
and Vollesen, 2000). The family, distributed in tropical and subtropical regions of the 
World with a few species found in temperate regions, includes herbs, shrubs or rarely 
trees (Burch and Demmy, 1986). The Ruspolia comprises five species native to Africa 
with one species endemic to Madagascar (Milne-Redhead, 1936). Ruspolia 
hypocrateriformis (Vahl) Milne-Redh (synonym: Justicia hypocrateriformis Vahl) 
(Figure 1.15), is a shrub with scattered growth measuring above 1 m in height. The leaves 
are ovate or elliptic and glabrous when mature. The flowers are borne in showy terminal 
inflorescences with coral-red tubular flowers 3.75 cm long. (Burch and Demmy, 1986). 
Its natural habitat includes savanna, and secondary and deciduous forest areas from 
Senegal to west Cameroon, and it is dispersed to Uganda, Kenya and southern Africa 
(Milne-Redhead, 1936). In Cameroon, it is seen growing around homes and gardens. 
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Figure 1.15 Young flourishing plant of R. hypocrateriformis (Orji et al., 2016) 
 
Ethnobotanical uses 
Ruspolia hypocrateriformis is a shrub used as ornamental and medicinal plant in 
Cameroon. The leaves are soaked or boiled in water, and the obtained juice is drunk to 
treat diarrhoea and anaemia (Adjanohoun et al., 1996; Noumi, 2015).  
 
Previous phytochemical investigations 
Phytochemical screening has revealed the presence of alkaloids, anthraquinones, 
flavonoids and saponins from the leaves of the species harvested in Cameroon (Agbor et 
al., 2014).  Alkaloids and anthraquinones were absent from the Nigerian species (Orji et 
al., 2017). Pyrrolidine alkaloids including hypercratine (11), norruspoline (12), 
norruspolinone (13) and ruspolinone (14) have been isolated from the roots (Figure 1.16) 
(Roessler et al., 1978; Neukomm et al., 1983). 
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Figure 1.16 Isolated compounds from the roots of R. hypocrateriformis 
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Previous pharmacological investigations 
Previous pharmacological investigations revealed that R. hypocrateriformis aqueous 
extract possesses antidiarrhoeal activity supported by its antioxidant potential (Agbor et 
al., 2014) while a supplement of the hydro-ethanol extract daily may help in the 
management of lead poisoning (Orji et al., 2016). 
 
 
1.5.3 Pseudospondias microcarpa (A. Rich.) Engl. 
Scientific name Pseudospondias microcarpa (A. Rich.) Engl. 
Synonyms  Sorindeia obliquifoliolata Engl.  
Spondias angolensis O. Hoffm.  
Spondias microcarpa A. Rich. 
Family  Anarcadiaceae 
Subfamily  Spondiadoideae Tribe Spondiadeae 
English name African grape 
Vernacular name Gueme, Atom koe mpom (Cameroon) 
 
Botanical description 
The genus Pseudospondias belongs to the family Anacardiaceae. There are only two 
recognised species including P. microcarpa Engl. and P. longifolia Engl. distributed 
throughout sub-Sahara tropical Africa (Aubreville, 1950). P. microcarpa (A. Rich.) Engl. 
basionym Spondias microcarpa A. Rich. (Figure 1.17), is a spreading tree of up to 20 m 
high. The trunk is often irregular, twisted, the branches growing near the base and often 
covered with other plants. The leaves are oblong-ovate to elliptic, odd pinnate on stalks 
to 30 cm, with 2-8 pairs leaflets plus 1, each leaflet stalked, rather stiff, oval 5-20 cm, 
base very unequal, tip long pointed, darker above than below, the basal ones smaller. The 
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fruit are soft drupes measuring about 2.5 cm, red or blue-black when ripe are resinous, 
the stone inside is 4-sided and contains the seeds (Burkill, 1985). 
 
Figure 1.17 Fruits and ptericarps of P. microcarpa (img. By J. Stevens, 
http://www.zambiaflora.com/speciesdata) 
 
Ethnobotanical uses 
Pseudospondias microcarpa produces edible fruits. The wood is soft and used as 
firewood, to produce charcoal and canoes (Ruffo et al., 2002). Many medicinal properties 
have been attributed to P. microcarpa across Africa. In Congo, the bark powder is used 
to treat scabies (Nglobua et al., 2013). The plant is also used for the treatment of malaria, 
dyspepsia, diarrhoea and opportunistic infections (Mbatchi et al., 2006; Bruno, 2013). 
The leaves decoction is drunk in Tanzania to relieve chronic cough and malaria (Kisangau 
et al., 2007). The wood is used as chewing stick in Benin while the bark decoction 
alleviates teeth problems (Adjanohoun et al., 1996; Akpona et al., 2009). In Sierra Leone, 
the bark and young leaves decoction is drunk to stimulate appetite (Macfoy, 2013). The 
plant is used in Ghana as a sedative and for treatment of diseases affecting the central 
nervous system (Burkill, 1985). The reddish resin contained in the bark is used in Liberia 
to treat jaundice and other diseases affecting the eyes (Burkill, 1985). The stem bark 
macerate is mixed with Coster afer and palm wine in Cameroon for the treatment of 
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helminthiasis and constipation (Noumi and Yomi, 2001). Other medicinal uses of the bark 
and leaves include the treatment of malaria, diabetes, anaemia, rheumatism, gonococci 
and elephantiasis (Burkill, 1985). 
 
Previous phytochemical investigations 
The presence of alkaloids, anthraquinones, cardiac glycosides, coumarins, flavonoids, 
polyphenols, quinones, saponins, tannins, and triterpenes were reported from the stem 
bark aqueous and MeOH-DCM extracts (Yondo et al., 2009). Alkaloids, tannins, 
terpenoids, steroids and heteroside cardiotonics have been reported from the leaves 
(Akpona et al., 2009). 
   
Previous pharmacological investigations  
The ethanolic extracts of the roots and stem bark of the plant harvested in Tanzania 
exhibited good antiplasmodial activity, with IC50 of 1.13 μg/mL and 4.33 μg/mL, 
respectively (Malebo et al., 2010). From the species harvested in Cameroon, the leaves 
and stem bark hydro-ethanolic extracts and the roots ethyl acetate extract showed 
moderate antimicrobial and antioxidant properties (Yondo et al., 2009). A moderate 
antiplasmodial activity against Plasmodium K1 strain and cytotoxic activity against 
HepG2 cell lines were also observed (Sidjui et al., 2016). P. microcarpa hydro-ethanolic 
extract possesses antidepressant-like effect, analgesic and anticonvulsant activities 
(Adongo et al., 2015). The extract has also showed anxiolytic-like activity similar to that 
of diazepam (Adongo et al., 2016).  
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1.5.4 Zanthoxylum lepreurii Guill. and Perr. 
Scientific name Zanthoxylum lepreurii Guill.  and Perr. 
Synonyms  Fagara angolensis Engl., Fagara attiensis Hutch. and Dalziel  
Fagara beniensis Engl., Fagara membranifolia Mildbr. 
Fagara kibomboensis De Wild., Fagara nitens (Hiern) Engl.  
Fagara leprieurii (Guill.  and Perr.) Engl., Fagara olung Engl.  
Fagara polyacantha Engl., Fagara stuhlmannii (Engl.) Engl.  
Zanthoxylum crenatum A. Cheval., Zanthoxylum nitens Hiern  
Zanthoxylum stuhlmannii Engl., Fagara kelekete De Wild.  
Family  Rutaceae 
Subfamily  Toddalioideae Tribe Zanthoxyleae 
English name Satinwood, sand knobwood 
Vernacular name Melan, bongo (Cameroon) 
 
 
Figure 1.18 Dried Fruits of Z. leprieurii 
 
Botanical description 
The genus Zanthoxylum L. belongs to the Rutaceae family and comprises about 200 
species of pantropical trees. In Africa, the genus is represented by 35 species of economic 
importance for their usage as spice, edible fruit, medicinal plants and wood for 
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construction (Matu, 2011). The major characteristic of Zanthoxylum trees is that their 
trunks, branches, branchlets, leaf stalks and inflorescence axes are covered by prickles or 
spines (Adesina, 2005). Zanthoxylum leprieurii Guill. and Perr. is a medium tree of up to 
15-25 m high found in rain forests and savanna woodland with brown branches armed 
with straight or sometimes curved spines (Tabuti, 2016). The leaves are alternate and 
impair-pinnate with 8-16 leaflets; leaflets are opposite or almost opposite, elliptical to 
oblong-elliptical, apex acuminate or caudate with oblique base. The flowers are 
unisexual, small and nearly sessile. Fruits (Figure 1.18) and seeds are almost globose 
measuring 4-5 mm and 3-3.5 mm in diameter, respectively. While the fruit are reddish 
and glandular pitted, the seeds are black and shiny. Z. leprieurii has a wide distribution 
and occurs from Senegal east to Ethiopia and south to Mozambique and eastern South 
Africa (Tabuti, 2016). 
 
Ethnobotanical uses 
The wood of Z. leprieurii is used in house and boat-building, carpentry, decorative and 
musical instrument construction and in the paper and pulp industry (Adesina, 2005). 
Different parts of the plant are traditionally used in Africa for medicinal purposes. The 
leaves are used for the treatment of stomatitis, gingivitis and bilharzia, while the roots are 
used as anti-ulcerative, antiseptic, urinary antiseptic, antisickling and antibacterial (Ngane 
et al., 2000). The stem bark is used as antimicrobial, digestive aid, antidiarrhoeic, 
anticancerous, anti-odontalgic and parasiticide (Ngoumfo et al., 2010). In Ghana, a 
decoction of the stem bark and root bark is used as a diuretic. The stem bark and leaves 
are used topically to treat wounds, syphilitic sores and leprous ulcers. The bark, when 
boiled in hot water produces vapour, which is inhaled to treat toothache and rheumatic 
pain. Decoction and poultice of stem bark is used for the treatment of skin and urinary 
tract infections, dysentery and intestinal worm infestation (Adesanya and Sofowora, 
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1983; Agyare et al., 2009). In Senegal, the powdered bark together with the latex of 
Baissea axillaris (Benth.) Hua is applied to tumours (Tabuti, 2016). In Cameroon, fruit 
are sold on local markets for their usage as spice (Ngoumfo et al., 2010). The leaves, 
stems and roots are used in the treatment of gonococci, urinary infections, dysentery, 
kidney pain and sterility (Noumi and Yomi, 2001). The fruit infusion is used for the 
treatment of sickle cell anaemia (Tabuti, 2016). 
 
Previous phytochemical investigations 
The phytochemistry of the Zanthoxylum genus has been thoroughly investigated in 
relation to its use for the treatment of sickle cell anaemia. Preliminary phytochemical 
screening of the stem bark aqueous-methanol extract of Z. leprieurii revealed the presence 
of alkaloids, flavonoids, carbohydrates and saponins (Tatsadjieu et al., 2003). Alkaloids 
such as aporphine, acridone, benzophenanthridine and quinoline derivatives were found 
to be the main constituents of the stem bark, pericarps, roots and fruit. Flavonoids, lignans 
and isobutylamides have also been reported. Table 1.2 summarises the isolated 
compounds (Figure 1.19) from Z. leprieurii. α-pinene (62), (E)-β-ocimene (63), limonene 
(64) and myrcene (65) (Figure 1.19) were found to be the major constituents of the fruit 
essential oil of Z. leprieurii (Fogang et al., 2012).  
 
Previous pharmacological investigations 
Zanthoxylum leprieurii fruit essential oil showed antimicrobial and antibacterial activity, 
inhibiting the growth of several microorganisms and bacteria strains (Tatsadjieu et al., 
2003). The oil also possesses antioxidant, anti-inflammatory, antidermatophitic and 
moderate cytotoxic properties (Misra et al., 2013; Tchabong et al., 2017). The aqueous-methanol 
stem bark extract was found to have wound healing properties as well as antimicrobial, 
cytotoxic and antioxidant activities (Kuete et al., 2011; Agyare et al., 2014). The aqueous 
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ethanolic extracts of the leaves, roots and stem bark have demonstrated moderate 
antifungal activity while the chloroform extract of the fruit showed moderate toxicity with 
the brine-shrimp assay (Ngane et al, 2000; Ngoumfo et al, 2010). Acridone alkaloids, 1-
hydroxy-3-methoxy-N-methylacridone (16), arborinine (13), 1,3-dihydroxy-2-methoxy-
N-methylacridone (19) and tegerrardin A (26) isolated from the fruit of Z. leprieurii were 
found to be moderately active against lung carcinoma cells (A549), colorectal 
adenocarcinoma cells (DLD-1) and normal cells (WS1) with IC50 values ranging from 27 
to 77 µM (Ngoumfo et al., 2010; Kuete et al., 2011). Nitidine (45) demonstrated strong 
antileukemic activities against L1210 and P388 and showed growth inhibition of Lewis 
lung carcinoma (Wall et al., 1987). 2-Hydroxy-1,3-dimethoxy-N-methyl-9-acridone (25) 
and 3-hydroxy-1,5,6-trimethoxyacridone (22) showed good activity against pan-sensitive 
and resistant strains of Mycobacterium tuberculosis (Bunalema et al., 2017). Arborinine 
(23) and xanthoxoline (27) demonstrated good in vitro antiplasmodial activity against 
Plasmodium falciparum 3D7 strains with IC50 values of 4.5±1.0 and 4.6± 0.6 μg/mL, 
respectively (Tchinda et al., 2009). The same study reported arborinine (23) and 
tegerrardin A (26) as good chelating agents with 90% and 61% radical scavenging 
activity, respectively (Tchinda et al., 2009). 
 
Table 1.2 Secondary metabolites isolated from Z. leprieurii 
Isolated compounds Plant parts References 
Acridone alkaloids   
1-Hydroxy-3,4-dimethoxy-N-
methylacridone (15) 
Fruits, roots (Fish and Waterman, 1972a; 
Tchinda et al., 2009) 
1-Hydroxy-3-methoxy-N-
methylacridone (16) 
Fruits, roots 
and stem 
bark 
(Adesina, 2005; Ngoumfo et 
al., 2010; Bunalema et al., 
2017) 
   
   
44 
 
Table 1.2 continued    
1-Hydroxy-N-methylacridone (17) Fruits, roots 
and stem 
bark 
(Adesina, 2005) 
1,2-Dihydroxy- 
3-methoxy-N-methylacridone (18)  
Fruits and 
roots  
(Ngoumfo et al., 2010) 
1,3-Dihydroxy-2-methoxy-N-
methylacridone (19)  
Fruits and 
roots 
(Ngoumfo et al., 2010) 
1,3-Dihydroxy-4-methoxy-N-
methylacridone (20)  
Roots (Fish and Waterman, 1972b) 
2-Hydroxy-1,3-dimethoxy-N-methyl-
acridone (21)  
Stem bark (Bunalema et al., 2017) 
3-Hydroxy-1,5,6-trimethoxy-acridone 
(22)  
Fruits and 
stem bark 
(Wouatsa et al., 2013a; 
Bunalema et al., 2017) 
Arborinine (23) Fruits and 
roots  
(Tchinda et al., 2009; 
Ngoumfo et al., 2010) 
Helebelicine A (24)  Fruits (Ngoumfo et al., 2010) 
Helebelicine B (25)  Fruits (Ngoumfo et al., 2010) 
Tegerrardin A (26)  Fruits and 
roots 
(Tchinda et al., 2009; 
Ngoumfo et al., 2010) 
Xanthoxoline (27) Fruits, roots 
and stem 
bark 
(Adesina, 2005; Tchinda et 
al., 2009; Ngoumfo et al., 
2010) 
Alkamides   
(2E,4E)-N-Isobutyleicosa-deca-2,4-
dienamide (28)  
Roots (Adesina, 2005) 
(2E,4E,8E,10E,12E)-N-Isobutyl-
2,4,8,10,12-tetradecapentaenamide (29)  
Roots (Adesina, 2005) 
N-Isopentyl-cinnamamide (30)  Roots (Adesina, 2005) 
N-Docosanoyltyramine (31) Fruits and 
roots 
(Ngoumfo et al., 2010) 
Violyedoenamide (32) Fruits and 
roots 
(Ngoumfo et al., 2010) 
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Table 1.2 continued   
Aporphine alkaloids   
Magnoflorine (33)  Roots and 
stem bark 
Adesina, 2005 
N-Methylcorydine (34)  Roots Adesina, 2005 
Tembetarine (35)  Roots and 
stem bark 
(Fish and Waterman, 1972b) 
Benzophenanthridine alkaloids   
10-O-Demethyl-12-O-
methylarnottianamide (36)  
Roots (Ngoumfo et al., 2010) 
10-O-Demethyl-12-O-
methylisoarnottianamide (37)  
Roots (Ngoumfo et al., 2010) 
Angoline (38)  Fruits and 
roots  
(Ngoumfo et al., 2010) 
Arnottianamide (39)  Roots (Adesina, 2005) 
Chelerythrine (40)  Roots and 
stem bark  
(Adesina, 2005) 
Decarine (41)  Fruits and 
roots  
(Ngoumfo et al., 2010) 
Dihydroavicine (42)  Roots (Adesina, 2005) 
Dihydronitidine (43)  Fruits and 
roots 
(Ngoumfo et al., 2010) 
Fagaronine (44)  Roots  (Adesina, 2005) 
Nitidine (45)  Roots and 
stem bark 
(Adesina, 2005; Ngoumfo et 
al., 2010) 
Norchelerythrine (46)  Roots (Adesina, 2005) 
Coumarins   
6,7-Dimethylcoumarin (47)  Fruits and 
roots  
(Ngoumfo et al., 2010) 
6,7,8-Trimethoxycoumarin (48)  Bark (Eshiet and Taylor, 1968) 
7, 8-Dimethoxycoumarin (49)  Fruits (Misra et al., 2013) 
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Table 1.2 continued   
Scoparone (50)  Roots and 
stem bark 
(Adesina, 2005; Tchinda et 
al., 2009) 
Xanthotoxin (51)  Roots and 
stem bark 
Adesina, 2005 
Lignans   
Asarinin (52)  Roots (Adesina, 2005) 
Lirioresinol-B-dimethyl ether (53)  Roots (Adesina, 2005) 
Sesamin (54)  Fruits, roots 
and stem 
bark 
(Adesina, 2005; Ngoumfo et 
al., 2010) 
Quinoline alkaloids   
Skimmianine (55)  Roots  Adesina, 2005 
Triterpenes   
β-Sitosterol (9) Fruits (Ngoumfo et al., 2010) 
β-Sitosterol palmitate (56)  Bark (Eshiet and Taylor, 1968) 
Lupeol (8) Fruits and 
roots 
(Ngoumfo et al., 2010) 
Other compounds   
Candicine (57)  Stem bark 
and roots 
(Fish and Waterman, 1972a) 
Glucose (58)  Fruits and 
roots  
(Ngoumfo et al., 2010) 
Hesperidin (59)  Fruits and 
roots  
(Ngoumfo et al., 2010) 
Sacchore (60)  Fruits and 
roots  
(Ngoumfo et al., 2010) 
Sinapic acid (61)  Fruits (Misra et al., 2013) 
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Figure 1.19 Isolated compounds from Z. leprieurii 
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Figure 1.19 continued 
 
 
1.5.5 Zanthoxylum zanthoxyloides (Lam.) Zepern. and Timler 
Scientific name Zanthoxylum zanthoxyloides (Lam.) Zepern. and Timler 
Synonyms  Fagara senegalensis (DC.) A. Chev. 
Fagara zanthoxyloides Lam. 
Zanthoxylum senegalense DC 
Zanthoxylum polyganum Schum. 
Family  Rutaceae 
Subfamily  Toddalioideae Tribe Zanthoxyleae 
English name Candlewood  
Vernacular name Nwah che (Cameroon) 
 
Botanical description  
Zanthoxylum zanthoxyloides is a small tree of up to 6-12 m tall widespread in Africa 
savanna and dry forest vegetations (Matu, 2011). The trunk is spiny with straight, often 
short bole and rounded and a quite dense crown. The bark is grey to beige, rough, with 
fine vertical fissures, often with woody prickle-bearing protuberances; the slashes are 
yellow, odorous, orange-mottled beneath while the stems are glabrous, grey, with solitary 
prickles. The leaves are alternate, glabrous, impari-pinnate with 5-7(-11) opposite or 
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alternate leaflets, up to 12(-20) cm long; leaflets are obovate to elliptical, 5-10 cm x 2-4 
cm, with cuneate to rounded base, obtuse or rounded apex, sometimes apiculate or 
notched, with many glandular dots, smelling of pepper and lemon when crushed, rigidly 
papery, pinnately veined with 10-14 pairs of lateral veins, barely prominent, fusing near 
the margin. The flowers are unisexual, regular, white or greenish, sessile; corolla barely 
open; Male flowers pentamerous. Petals imbricate. Rudiment of pistil subulate, upon a 
thickened central disk. The fruits (Figure 1.20) are rather crowded, in paniculate clusters 
shorter than the leaves, 1-carpellary, 1-seeded. Seeds are shining, blue-black; fruits 
contain an ovoid follicle, 5-6 mm in diameter, brown, with glandular dots, dehiscent, 1-
seeded (Burkill, 1985). 
   
Figure 1.20 Dried Fruits of Z. zanthoxyloides 
 
Ethnobotanical uses 
Zanthoxylum zanthoxyloides as the other African Zanthoxylum species has a broad 
spectrum of ethnopharmacological usage across Africa. In Ouganda, the root-bark extract 
is used in treating elephantiasis, toothache, impotence, gonorrhoea, malaria, 
dysmenorrhoea and abdominal pain (Adjanohoun et al., 1993). In Senegal, the plant is 
used in the treatment of enteritis, dysentery, diarrhoea, guinea worm, urethritis and as an 
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anti-odontalgic. In Cameroon, the leaves, stems and roots of these plants are used in the 
treatment of gonococci, urinary infections and dysentery (Noumi and Yomi, 2001). The 
seeds are used as spices. Leaves and bark are used for the treatment of cough, fever, colds, 
toothache and snake bites. The leaves are also used as scaring, antiseptic, astringent and 
laxative, while the stem bark is used as antirheumatic, anti-odontalgic, diuretic, urinary 
antiseptic, digestive aid and parasticide. The roots are used as antiseptic, antisickler, 
digestive aid and parasticide (Ngane et al., 2000; Kassim et al., 2004). In Ivory Coast, 
sap from the pulped bark is applied as eye drops to treat eye infections. In Ghana, roots 
and stem bark powder is taken to treat whooping cough (Arbonnier, 2004). In Nigeria, 
stem bark and roots decoction are drunk to treat cancer. Roots and stem bark of Z. 
zanthoxyloides are also used as chewing sticks for teeth cleaning (Arbonnier, 2004).  
 
Previous phytochemical investigations 
Zanthoxylum zanthoxyloides is a rich source of bioactive metabolites including alkaloids, 
aliphatic and aromatic amides, lignans, coumarins, sterols and carbohydrate residues 
(Figure 1.21). A list of isolated compounds from different parts of the plant as well as 
their activities is presented in Table 1.3.  The main constituents of the fruit essential oils 
were found to be α-pinene (62), (E)-β-ocimene (63), citronellal (143), citronellol (144), 
citronellyl acetate (145), geraniol (146), limonene (64) and myrcene (65) (Figure 1.21) 
(Tatsadjieu et al., 2003; Fogang et al., 2012). 
 
Previous pharmacological investigations 
Zanthoxylum zanthoxyloides has demonstrated a panel of biological activities. The plant 
powder and extract have good insecticidal and antifeedant activities against a range of 
crop pests (Ojo et al., 2016). The fruit essential oil possesses antimicrobial, antibacterial, 
insecticidal and antioxidant properties (Tatsadjieu et al., 2003; Fogang et al., 2012). 
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Roots and stem bark methanolic extracts were found to be least toxic with LD50 5.0 g/Kg 
and 1.5 mg/kg body weight, respectively in Wistar rats and the ethanolic extracts have 
moderate antifungal activity (Ngane et al., 2000; Misra et al., 2013). The crude alkaloid 
extracts obtained from the trunk bark demonstrated good antimalarial activity with IC50 
ranging from 1.91 to 4.32 μg/mL (Gansane et al., 2010). The DCM extract of the stem 
and roots bark and the methanol extract of the stem bark have also been found to possess 
good antiplasmodial activity with IC50 ranging from 1 and 10 µg/mL. Extract of the root 
bark has also demonstrated significant anti-inflammatory, anti-sickling and analgesic 
activities and moderate antibacterial, antiprotozoal and antiviral activities against a range 
of pathogenic bacteria, Herpes simplex virus and Leishmania major (Kassim et al., 2005; 
Ahua et al., 2007; Barnabas et al., 2011). Extract of the root bark is also reported to have 
gastroprotective activity (Boye et al., 2012). Ethanolic extract of the leaves has shown 
antifungal, anthelmintic, antidiabetic, hypolipidaemic and antioxidant activities (Aloke et 
al., 2012; Adekunle et al., 2014). A moderate cytotoxic activity of the fruits ethanolic 
extract has also been reported (Choumessi et al., 2012).  
 
The acridones 3,4,5,7-tetrahydroxy-1-methoxy-N-methylacridone (67) has been found to 
possess a moderate antibacterial activity against Micrococcus luteus and Pseudomonas 
aeruginosa and 3-hydroxy-1,5,6-trimethoxy-acridone (22) showed moderate cytotoxic 
effect against liver cancer cell line WRL-68 (Wouatsa et al., 2013a). Furoquinoline 
alkaloid atanine (128) possessed antiprostaglandin synthetase activity (Prempeh and 
Mensah-Attipoe, 2009). Fagaronine (44), 2-hydroxymethylbenzoic acid (109), 
burkinabins A, B and C (111-113) have demonstrated strong antileukaemic acid justifying 
of the usage of Z. zanthoxyloides plant in the traditional treatment of sickle cell anaemia 
(Adesina, 2005; Ouattara et al., 2009). Chelerythrine (40), berberine (90) and 6-
canthinone (136) possessed antimicrobial activity (Adesina, 2005).  
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Table 1.3 Secondary metabolites isolated from Z. zanthoxyloides 
Isolated/identified compounds Plant parts References 
Acridone alkaloids   
1-Hydroxy-3-methoxy-N-methylacridone 
(16) 
Fruits (Wouatsa et al., 2013a) 
1,6-Dihydroxy-3-methoxy-acridone (66)  Fruits (Wouatsa et al., 2013a) 
3-Hydroxy-1,5,6-trimethoxy-acridone (22) Fruits (Wouatsa et al., 2013a) 
3,4,5,7-Tetrahydroxy-1-methoxy-10-
methyl-9-acridone (67)  
Fruits (Wouatsa et al., 2013a) 
4-Hydroxyzanthacridone (68)  Fruits (Wouatsa et al., 2013a) 
4-Hydroxyzanthacridon-(2,4’)-oxide (69)  Fruits (Wouatsa et al., 2013a) 
4-Methoxyzanthacridone (70)  Fruits (Wouatsa et al., 2013a) 
Helebelicine A (24) Fruits (Wouatsa et al., 2013a) 
Alkamides   
(2E,4E)-N-Isobutyldeca-2,4-dienamide 
(71)  
Roots (Chaaib et al., 2003) 
(2E,4E)-N-Isobutylhexadeca-2,4-
dienamide (72)  
Fruits, roots 
and bark 
(Adesina, 2005) 
(2E,4E)-N-isobutylocta-2,4-dienamide (73)  Roots (Chaaib et al., 2003) 
(2E,4E)-N-Isobutyltetradeca-2,4-
dienamide (74)  
Fruits (Adesina, 2005) 
(2E,4E,8E,10E,12E)-N-Isobutyl-
2,4,8,10,12-tetradecapentaenamide (29)  
Roots (Adesina, 2005) 
Cis-fagaramide (75)  Roots and 
stem bark 
(Chaaib et al., 2003; 
Adesina, 2005) 
N-Isopentylcinnamamide (30)  Roots (Adesina, 2005 
Pellitorine (76)  Roots (Adesina, 2005) 
Piperlonguminine (77)  Roots (Adesina, 2005) 
Rubebmamin (78)  Roots and 
stem bark 
(Adesina, 2005; 
Oriowo, 1982) 
Trans-fagaramide (79)  Roots (Chaaib et al., 2003; 
Queiroz et al., 2006) 
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Table 1.3 continued   
Aporphine alkaloids   
Berberine (80)  Roots (Adesina, 2005) 
Magnoflorine (33)  Roots (Adesina, 2005) 
N-Methylcorydine (34)  Roots (Adesina, 2005) 
N, N-Dimetylindicarpine (81)  Roots (Queiroz et al., 2006) 
Tembetarine (35)  Roots (Adesina, 2005) 
Benzophenanthridine alkaloids   
6-(2-Oxobutyl)-dihydrochelerythrine (82)  Roots (Chaaib et al., 2003) 
6-Acetonyldihydrochelerythrine (83)  Roots (Chaaib et al., 2003) 
6-Ethoxychelerythrine (84) Roots bark Torto et al., 1966 
6-Hydroxydihydrochelerythrine (85)  Roots (Wangensteen et al., 
2017) 
Bis-Dihydrochelerythrinyl ether (86)  Roots (Adesina, 2005) 
Arnottianamide (38)  Roots (Adesina, 2005) 
Buesgenine (87)  Roots (Wangensteen et al., 
2017) 
Chelerythrine (40)  Roots (Torto et al., 1966) 
Dihydroavicine (42)  Roots (Adesina, 2005) 
Dihydrochelerythrine (88)  Stem bark (Torto et al., 1973) 
Fagaridine (89)  Stem bark (Torto et al., 1973) 
Fagaronine (34)  Roots and 
stem bark 
(Queiroz et al., 2006) 
Norchelerythrine (36)  Roots (Queiroz et al., 2006) 
Oxychelerythrine (90)  Roots (Adesina, 2005) 
Coumarins   
4-Methoxycoumarin (91) Fruits (Tine et al., 2017) 
6-Methylcoumarin (92)  Fruits (Tine et al., 2017) 
6,7-Dimethylesculetin (47)  Fruits (Tine et al., 2017) 
6,7,8-Trimethoxycoumarin (48)  Roots (Wangensteen et al., 
2017) 
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Table 1.3 continued   
7-Methylcoumarin (93)  Fruits (Tine et al., 2017 
Bergapten (94) Fruits and stem bark (Adesina, 2005) 
Daphnetin-7-methylether (95)  Fruits and stem bark (Tine et al., 2017) 
Herniarin (96)  Fruits and stem bark (Tine et al., 2017) 
Isobergapten (97)  Fruits (Tine et al., 2017) 
Isopimpinellin (98)  Fruits and leaves (Tine et al., 2017) 
Imperatorin (99)  Stem bark (Adesina, 2005) 
Marmesin (100)  Fruits (Adesina, 2005) 
Pimpinellin (101) Stem bark (Adesina, 2005) 
Psoralen (102)  Fruits (Adesina, 2005) 
Scoparone (50)  Fruits, roots and bark (Adesina, 2005; Misra et 
al., 2013 
Scopoletin (103) Stem bark (Adesina, 2005) 
Umbelliferone (104)  Stem bark (Adesina, 2005) 
Xanthotoxin (51)  Fruits and stem bark (Adesina, 2005) 
Lignans   
Asarinin (52) Roots (Adesina, 2005) 
Sesamin (54) Roots (Chaaib et al., 2003) 
Xanthoxylol (105)  Roots (Elujoba and Nagels, 1985) 
Triterpenes    
β-Amyrin (106)  Roots (Adesina, 2005) 
β-Sitosterol (9) Fruits and roots (Chaaib et al., 2003; Misra 
et al., 2013) 
Campesterol (107)  Roots (Adesina, 2005) 
Lupeol (8) Fruits and roots (Chaaib et al., 2003; Misra 
et al., 2013) 
Squalene (108)  Roots (Adesina, 2005) 
Stigmasterol (10)  Fruits and roots (Chaaib et al., 2003; 
Adesina, 2005; Misra et al., 
2013) 
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Table 1.3 continued   
Phenolic and flavonoids   
2-Hydroxymethylbenzoic acid 
(109)  
Roots (Adesina, 2005) 
2,5-Dihydroxybenzoic acid 
(110)  
Leaves 
(Isaac et al., 2009 
Burkinabin A (111)  Roots (Ouattara et al., 2004; 
Queiroz et al., 2006) 
Burkinabin B (112)  Roots (Ouattara et al., 2004) 
Burkinabin C (113)   Roots (Ouattara et al., 2004; 
Queiroz et al., 2006) 
Caffeic acid (114)  Leaves and stem bark (Asante et al., 2009) 
Chlorogenic acid (115)  Stem bark, roots (Wangensteen et al., 2017) 
Diosmin (116)  Roots (Adesina, 2005) 
Gallic acid (117)  Leaves (Asante et al., 2009) 
Hesperidin (59) Roots (Queiroz et al., 2006) 
Kaempferol (118)   Stem bark (Ogunbolude et al., 2014) 
Neochlorogenic acid (119)  Roots (Wangensteen et al., 2017) 
para-Coumaric acid (120)  Leaves (Asante et al., 2009) 
para-Hydroxybenzoic acid 
(121)  
Roots (Elujoba and Nagels, 1985) 
Quercetin (122)  Stem bark (Ogunbolude et al., 2014) 
Rosmaniric acid (123) Leaves (Asante et al., 2009) 
Rutin (124)  Stem bark (Ogunbolude et al., 2014) 
Syringic acid (125)  Leaves  (Elujoba and Nagels, 1985; 
Asante et al., 2009) 
Vanillic acid (126)  Leaves, roots (Asante et al., 2009; 
Elujoba and Nagels, 1985) 
Quinoline alkaloids   
Acronycine (127)   Fruits and roots (Adesina, 2005) 
Atanine (128)  Ptericarps, Stem bark 
and roots 
(Torto et al., 1973; 
Adesina, 2005) 
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Table 1.3 continued   
Dictamnine (129)  Roots (Wangensteen et al., 2017) 
Fagarine (130)  Roots (Adesina, 2005) 
Skimmianine (55) Roots (Adesina, 2005) 
Other compounds   
(-)-p-Synephrine (131)  Roots (Wangensteen et al., 2017) 
4-Methylthiocanthin-6-one 
(132) 
Fruits and roots (Adesina, 2005) 
4'-(3''-Methylbut-2''-enyloxy)-
3-phenylpropanol (133)  
Roots (Chaaib et al., 2003) 
4'-(4’’-Hydroxy-3’’-methyl-
butyloxy)-2-phenylethyl (134)  
Roots (Chaaib et al., 2003) 
5-Methoxycanthin-6-one (135) Fruits and roots (Adesina, 2005) 
6-Canthinone (136)  Roots (Adesina, 2005) 
7,8-Di-O-(3-methoxy-4-
hydroxybenzoyl)-2,5-
dihydroxycyclooctane-1,6-
endoperoxyde (137) 
Roots bark (Chaaib et al., 2003) 
p-Mentha-1,8-dien-9-ol (138)  Fruits (Misra et al., 2013) 
Cuspidiol (139)  Roots (Chaaib et al., 2003) 
Dihydrocuspidiol (140)  Roots (Chaaib et al., 2003) 
Germacrone (141)  Roots (Adesina, 2005) 
Zantholic acid (142)  Fruits (Wouatsa et al., 2013b) 
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Figure 1.21 Identified and isolated compounds from Z. zanthoxyloides 
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Figure 1.21 Continued 
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1.6 Aim and objectives  
Despite important medical and technological advances made in the development of new 
drugs, as well as considerable efforts in the treatment and the campaign against cancer 
and malaria, they remain two of the most commoncauses of death worldwide. About 200 
million cases of malaria are reported every year giving rise to an estimated 445,000-
500,000 deaths yearly (WHO, 2017). The burden of the disease is boosted by the 
resistance of the parasites to existing antimalarial drugs and by the resistance of the 
mosquito vector to insecticides in endemic areas particularly in sub-Saharan Africa, 
where 91% of deaths from malaria are reported. As for cancer, it is the second leading 
cause of death worldwide claiming about 8.8 million deaths in 2015 (WHO, 2018a). 
Globally, one in six deaths are due to cancer and this number is projected to almost double 
by the year 2030. Therefore, more research on alternative prevention and treatment are 
needed. 
Traditional medicine is important and indispensable in the development and discovery of 
new drug leads. Indeed, screenings of medicinal plants based on their 
ethnopharmacological applications, especially in the treatment of tumours and malaria, 
have led to some remarkable discoveries in the past.  
Thus, the aim of the present investigation was to identify phytochemicals with 
antimalarial and/or chemopreventive properties from five medicinal plants based on their 
folklore use in the Cameroonian community for the treatment of different types of fever, 
malaria and tumours.  
This aim comprised following objectives: 
• To obtain crude extracts from the selected plants and to evaluate their potent 
chemopreventive and antimalarial activities.  
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• To carry out bioassay directed isolation of active compounds. 
• To characterise these bioactive compounds by spectroscopic means. 
• To evaluate the biological activities of the isolated compounds. 
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Chapter 2 Materials and Methods 
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2.1 Plant materials 
Plants were collected from the Centre (Mount Eloundem, Mfoundi) and the West 
(Dschang Local Market) regions of the Republic of Cameroon, which is a tropical country 
located in sub-Saharan Africa at longitude 7.3697° N, and latitude 12.3547° E (Figure 
2.1), with the assistance Mr Victor Nana, a botanist of the Cameroon National Herbarium 
(CNH), Yaoundé, Cameroon. Mr Nana also identified all the species collected by 
comparison with respective voucher specimens available at the CNH.  Plant materials 
were collected during the months of June and November in 2015. Table 2.1 gives details 
on the different plants’ parts collected, the voucher numbers, period and place of 
collection. 
 
Figure 2.1 Map showing Cameroon geographical position and the different regions 
where the plants were collected 
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Table 2.1 List of medicinal plants studied 
Plant name Family  Voucher 
Number 
Part 
collected  
Period/ 
Region 
Croton oligandrus 
Pierre ex Hutch 
Euphorbiaceae 6687/SFR Stem bark 
and leaves 
June 2015/ 
Centre 
Justicia 
hypocrateriformis 
(Vahl) Milne-Redh 
Acanthaceae 37822/SFR Leaves June 2015/ 
Centre 
Pseudospondias 
microcarpa (A. Rich.) 
Engl. 
Anacardiaceae 41437/SFR Fruits, 
leaves and 
stem bark 
June 2015/ 
Centre 
Zanthoxylum lepreurii 
Guill. and Perr. 
Rutaceae 106669/SFR Fruits November 
2015/ West 
Zanthoxylum 
zanthoxyloides (Lam.) 
Zepern. and Timler 
Rutaceae 21793/SFR Fruits November 
2015/ West 
 
 
2.2 Chemicals and reagents 
2.2.1 Chemicals 
All the solvents were purchased from Fisher Scientific Ltd. (Loughborough, UK). 
Deionized water used in the present work was obtained from a MiliQ water system 
(Merck, Germany). Deuterated NMR solvents including chloroform (CDCl3), methanol 
(CD3OD), acetone (acetone-d6), pyridine (Pyr-d5), DMSO (DMSO-d6) and water (D2O) 
were purchased from Cambridge Isotope Laboratories Inc. (Tewksbury, USA). Precoated 
aluminium plates of Silica gel 60 PF254 (0.2 mm thickness, 20 x 20 cm) for Thin Layer 
Chromatography (TLC) were sourced from Merck Ltd., Germany. Silica gel (70-230 
mesh) and Silica Kieselgel 60H, purchased from Sigma-Aldrich Company Ltd. (Dorset, 
UK), were used for open column chromatography (CC) and vacuum liquid 
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chromatography (VLC), respectively. Sodium dodecyl sulphate (SDS), bovine hemin, 
sodium acetate buffer 3M, NaOH and 37% HCl solution were also purchased from 
Sigma-Aldrich Company Ltd. 
 
 
2.2.2 Cell lines, cell culture media and reagents 
Names and tissues of origin of each cell line used in this study are listed in Table 2.2. 
AREc32 cells were a generous gift of Prof Roland Wolf (University of Dundee, UK), 
while the other cell lines were obtained from Dr Andrews Evans cells bank (LJMU, 
Liverpool, UK). 
Table 2.2 Cell lines used in bioassays  
Name Origin 
AREc32 Human mammary MCF7-derived reporter cells 
A549 Adenocarcinoma human alveolar basal epithelial cells 
MCF7 Human breast adenocarcinoma cells 
PC3 Human prostate cancer cell line 
PNT2 Human normal prostate epithelium cells 
 
Foetal bovine serum (FBS), penicillin/streptomycin, L-glutamine, Dulbecco’s Modified 
Eagles Medium (DMEM), trypsin-EDTA and phosphate buffer saline (PBS), were 
purchased from Biosera (Neuville, France). Doxorubicin, gentamicin and trypan blue 
solution were obtained from Sigma Aldrich Company Ltd. (Dorset, UK). Luciferase assay 
kit reagent was from Promega Corp. (Loughborough, UK). 
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2.3 Phytochemical work 
2.3.1 Plant preparation and Soxhlet extraction 
The plant materials were individually cut into small pieces; air dried at room temperature 
and powdered using a maize grinder into a coarse powder. The powdered plant materials 
were extracted using Soxhlet extraction.  
Individual plant material was placed in a thimble made of thick filter paper and placed in 
the extraction chamber, extraction solvent (0.9 L) was poured in and the condenser was 
placed on the extraction chamber (Figure 2.2). The solvent was brought to boil using an 
ElectrothermalTM electromantle (Fisher Scientific, Loughborough-UK). When solvent 
boiled, the extraction chamber was gradually filled with solvent and performed extraction 
until it reached the maximum level, when the solvent with the dissolved extracted 
components went back to the flask. This was one cycle of extraction. This cycle was 
repeated 10 times for each solvent used. In this way, the dissolved components remained 
in the flask, while clean solvent was evaporated and the plant material in the thimble was 
repeatedly extracted (Rostagno and Prado, 2013). The plant material was extracted, 
successively, with n-hexane, dichloromethane (DCM) and methanol (MeOH). The 
resulting extracts were concentrated to dryness under reduced pressure on a Cole-Palmer 
rotary evaporator (Stone, UK). Extracts were stored at 4oC and dissolved in appropriate 
solvent prior to usage.  
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Figure 2.2 Soxhlet apparatus 
 
 
2.3.2 Chromatographic techniques  
2.3.2.1 Vacuum liquid chromatography  
Vacuum liquid chromatography (VLC) was used for the rapid fractionation of active non-
polar and medium polarity extracts. The technique was used as described by Pelletier et 
al. (1986). The system consisted of a sintered glass Buchner filter funnel with an 
attachment to a side arm flask connected to a vacuum pump (Figure 2.3).  Approximately 
the two third of the VLC funnel was dry-packed with Kieselgel 60H, the stationary phase, 
under vacuum and the appropriate solvent was allowed to flow through the system (Reid 
and Sarker, 2012). A portion of the n-hexane or DCM extract were dissolved in a little 
amount of appropriate solvent, mixed with normal silica gel (70-230 mesh), taken to 
dryness either by air drying or under reduced pressure using rotary evaporator and the 
mixture was loaded on the top of the funnel as a uniform thin layer. Vacuum was applied, 
and the column was eluted with a stepwise gradient of mobile phase consisting of an 
increasing amount of ethyl acetate in n-hexane (Hex/EA 0%, 10%, 20%, 40%, 60% and 
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80%, H1-H6) or MeOH in DCM (DCM/MeOH 0%, 2%, 6%, 10%, 15% and 25%, D1-
D6) for the n-hexane or DCM extract respectively to obtained six different fractions. 
Collected VLC fractions were concentrated to dryness under reduced pressure and 
analysed by TLC to get an idea of their composition. Fractions with similar TLC profiles 
were mixed together. 
 
Figure 2.3 VLC system 
 
 
2.3.2.2 Solid-phase extraction  
Solid-phase extraction (SPE) was used for the fractionation of active methanolic extract 
and to clean-up DCM extract prior to preparative HPLC. The SPE is quite similar to VLC 
with the only difference being that a commercially available pre-packed SPE cartridge is 
used instead of a funnel prepacked with silica gel (Reid and Sarker, 2012) (Figure 2.4). 
A Strata C-18-E cartridge 20 g (Phenomenex, California-USA) was used for this study. 
A portion of the dried MeOH extract (2 g) was suspended in 10 mL of a 10% MeOH in 
water mixture and loaded into the cartridge, previously washed with MeOH (50 mL), 
followed by equilibration with water (100 mL). The cartridge was eluted with MeOH–
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water mixture of decreasing polarity to obtain four fractions (F1-F4): 20, 50, 80 % MeOH 
in water and 100% MeOH (200 mL each). All four fractions were evaporated to dryness 
using a combination of a rotary evaporator and a freeze-dryer. A portion of each resulting 
fraction was dissolved in MeOH to obtain a solution of 1 mg/mL and analysed by HPLC-
UV/DAD. For the clean-up of DCM extract, 2 g of the sample were dissolved in 10 mL 
30% MeOH in water solution and the cartridge was eluted with 80% MeOH in water 
solution.  
 
Figure 2.4 Solid Phase Extraction system 
 
 
2.3.2.3 Thin layer chromatography  
Thin layer chromatography (TLC) is a separation technique mainly used for the detection 
and monitoring of compounds through a separation process based on the criteria of 
adsorption, binding to silica and polarity (Gibbons, 2012). The technique was used in this 
study to screen the plant extracts for the presence of secondary metabolites, to determine 
the starting eluting solvent composition for column chromatography, to monitor fractions 
collection during chromatography, to check the purity of isolated compounds from CC 
and as isolation technique for the purification of compounds (preparative TLC). Precoated 
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silica gel 60 PF254 aluminium plates were used for this purpose. Samples were applied 
manually at the base, about 1 cm from the bottom edge of the TLC plate, using a glass 
capillary and developed in a chromatographic chamber using an appropriate solvent 
system. Multiple developments were sometime needed to improve resolution. After 
drying, the developed plates were visualised by irradiation with short-wave (254 nm) and 
long-wave (366 nm) using a Camag UV lamp (CAMAG, Hungerford-UK) and by 
spraying with a 1% anisaldehyde solution in aqueous H2SO4 followed by heating to 105 
°C in Sciquip oven 30S (Sciquip, Shrewsbury-UK) for 5 min (Figure 2.5).  
In the case of preparative TLC, only a small part (1/10 part) of TLC plate was spread with 
the anisaldehyde reagent after having covered the remaining part with aluminium foil. 
Bands of interest were identified and scratched with the help of spatula. The compounds 
of interest were extracted from the collected silica gel by cold maceration with a mixture 
of 10% MeOH in DCM. 
(a)   (b) 
Figure 2.5 TLC plates of a) xylopic acid developed in Hex:EtOAC (8:2) and sprayed 
with 1% anisaldehyde and b) skimmianine developed in DCM:MeOH (9.2:0.8) 
visualised at 254 nm 
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2.3.2.4 Column chromatography  
Column chromatography (CC) was used to isolate compounds from active n-hexane 
fraction. Silica gel (70-230 mesh) was used for this purpose. The sample and the column 
(Figure 2.6) were prepared in the same way as described for VLC, but in the case of CC 
the elution was carried out purely under the gravitational force, and no negative or 
positive pressure was applied. Wet packing technique was also used instead of dry 
packing as for the case of VLC. n-Hexane was used as packing solvent. Excess solvent 
was run through the column to allow the silica gel to settle well before introducing the 
sample on the top of the column. The column was eluted with a stepwise gradient of 
mobile phase of increasing polarity. The initial solvent composition was determined by 
TLC analysis. Depending on the column size, 10-50 mL of eluents were collected per 
fraction, and their contents were analysed by TLC.  
 
Figure 2.6 CC system operated by manual fraction collection 
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2.3.2.5 High-performance liquid chromatography  
High-performance liquid chromatography (HPLC) is a separation technique both used as 
analytical and preparative for the detection, separation, quantification and isolation of 
compound mixtures, including natural products.  
 
2.3.2.5.1 Analytical high-performance liquid chromatography 
Analytical HPLC was used to screen the plant extracts for the presence of secondary 
metabolites, to develop methods for isolation using preparative HPLC and to verify the 
purity of isolated compounds. The experiment was performed on an UPLC Dionex 3000 
(Thermoscientific, UK) or Agilent 1260 infinity series (Agilent, UK) both equipped with 
a binary pump, an autosampler, a column chamber, a degasser and a UV/DAD detector 
from the same corresponding model and company. Samples were prepared in MeOH (1 
mg/mL) and analysed on a Phenomenex Gemini-NX 5 U C18 column (150 × 4.6 mm, 
Phenomenex, USA) or a Hypersil 5 U C18 column (150 × 4.6 mm, Phenomenex, USA) 
with a gradient of 30-100% MeOH (containing 0.1% TFA), 70-0% H2O (containing 0.1% 
TFA) over 30 min or of 30-100% ACN, 70-0% H2O (containing 0.1% TFA). The column 
temperature was set at 25 °C. A volume of 10 µL of the prepared sample was injected and 
the chromatogram was monitored at 1 mL/min using variable UV/vis wavelengths 
comprising between 205 and 366 nm. Methods described above were always used to 
verify the purity of the collected fractions obtained from preparative HPLC analyses and 
as starting methods for the development of further methods (Table 2.3) to be used on 
preparative HPLC for isolation and purification of compounds. 
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2.3.2.5.2 Preparative high-performance liquid chromatography 
Preparative HPLC was used for the isolation and purification of compounds from the 
DCM and MeOH fractions using developed methods from analytical HPLC. Table 2.3 
below shows the different methods developed on the analytical HPLC and used on the 
prep-HPLC for the isolation of compounds. The experiment was carried out on an Agilent 
1260 infinity series equipped with a binary pump, a degasser, a column chamber and a 
UV/DAD detector. An ACE Gemini-NX 5 U C18 column (150 × 21.2 mm, Hichrom Ltd, 
UK) maintained at 25 ⁰C and monitor at a flow rate of 10 mL/min was used for isolation. 
Manual peak collection was carried on using UV/DAD detector and repeated 
chromatography were needed to isolate a good amount of compound. The samples were 
all prepared in MeOH. MeOH and H2O used for HPLC analysed contained 0.1% TFA. 
Table 2.3 List of the different HPLC methods developed 
 Time slot (min) %MeOH %ACN %H2O 
Method A 0 - 30 30 - 100 - 70 - 0 
 30 - 35 100 - 0 
Method B 0 - 15 - 30 - 65 70 - 35 
Method C 0 - 20 30 - 75 - 70 - 25 
Method D 0 - 10 45 - 50 - 55 - 50 
 10 - 30 50 - 60 - 50 - 40 
Method E 0 - 30 30 - 65 - 70 - 35 
 
 
 
2.3.3 Isolation of compounds  
2.3.3.1 Isolation of compounds from Croton oligandrus 
The air-dried and powdered stem bark (330.8 g) of C. oligandrus were extracted with n-
hexane, DCM and MeOH to obtain 3.7, 2.1 and 7.4 g of beige oily, beige and brown 
extracts, respectively.  
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A portion of the n-hexane (3.3 g) and DCM (1.8 g) extracts were adsorbed on to normal 
silica gel (70-230 mesh) and fractionated using VLC to obtain six fractions each (H1- H6) 
and (D1-D6) for n-hexane and DCM extracts, respectively, following the VLC procedure 
as described earlier. 
Fraction H3 (420.9 mg) of n-hexane extract was further purified using a CC over silica 
gel using a gradient of Hex-EtOAc 0-30% to give a mixture (18.2 mg) of 149 and 150, 
and 147 (4.4 mg). Compounds 7 (16.1 mg) and 8 (19.0 mg) were obtained from H5, H6 
and D4 by recrystallisation using Hex-EtOAc 15-30%. The mixture of 149 and 150 (3.2 
mg) were also obtained from D2 and D3 of the DCM crude extract by recrystallisation 
with Hex-EtOAc 15%.  D4, D5 and D6 showed similar TLC and HPLC profiles and were 
then mixed together for purification. The mixture of the two fractions (783.0 mg) was 
finally purified by preparative RP-HPLC using the method A (Table 2.3). Figure 2.7 
showed the obtained chromatogram as well as the peaks corresponding to the different 
compounds (148, 151-162) identified and characterised from the combined fractions.  
 
Figure 2.7 Chromatogram of C. oligandrus fractions D4+D6-method A, inj. vol. 130 
µL, sample conc. 182.7 mg/mL, monitored at 215nm 
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Table 2.4 Isolation of compounds from C. oligandrus 
Cpds 
 
Extract 
containing 
the cpds 
VLC 
fraction 
containing 
the cpds 
Mode of 
isolation 
Rf or tR 
in min 
Visual aspect Amount 
in mg 
7 n-hexane H5, D4 - 0.47* White powder 16.1 
8 n-hexane H6, D4 - 0.40* White powder 19.0 
147 n-hexane H3 CC 0.56* White powder 4.4 
148 DCM D4, D5 and 
D6 
HPLC 12.51 White powder 8.3 
149+150 DCM, n-
hexane 
H3, D2 and 
D3 
CC 0.63* White powder 21.4 
151 DCM D4, D5 and 
D6 
HPLC 23.54 White powder 6.3 
152 DCM D4, D5 and 
D6 
HPLC 23.03 White powder 3.3 
153 DCM D4, D5 and 
D6 
HPLC 20.57 White powder 15.6 
154 DCM D4, D5 and 
D6 
HPLC 18.89 White powder 13.9 
155 DCM D4, D5 and 
D6 
HPLC 15.76 White powder 2.9 
156+157 DCM D4, D5 and 
D6 
HPLC 17.54 White powder 7.8 
158+159 DCM D4, D5 and 
D6 
HPLC 19.55 White powder 6.5 
160 DCM D4, D5 and 
D6 
HPLC 16.19 White powder 7.3 
161 DCM D4, D5 and 
D6 
HPLC 29.29 Yellow 
powder 
4.1 
162 DCM D4, D5 and 
D6 
HPLC 30.31 White powder 5.7 
*TLC plate developed in Hex:EtOAc 40% 
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The MeOH extract was not processed further as it was found to be non-active. In addition, 
the same extraction procedure was carried out with 280.0 g of the dried leaves to obtain 
6.9, 2.9 and 9.9 g of n-hexane, DCM and MeOH extracts, respectively. Only the n-hexane 
extract was found to be active. However, it was not processed further as preliminary 1H 
NMR revealed a mixture of 7, 8 and fatty acids.  
 
 
2.3.3.2 Isolation of compounds from Justicia hypocrateriformis 
The air-dried and powdered leaves (450.5 g) of J. hypocrateriformis were extracted with 
n-hexane, DCM and MeOH to obtain 13.6, 10.2 and 41.8 g of dark green, brown green 
and dark brown extracts, respectively. Preliminary screening revealed MeOH as the only 
active extract. 
The MeOH extract (4 g) was dissolved in MeOH and cleaned using SPE eluted with 
MeOH/H2O 50% to remove chlorophyll. After drying, 2 g of the obtained extract was 
subjected to standard SPE procedure described above. F1 (668.8 mg) was adsorbed on to 
normal silica gel and subjected to CC using of a gradient of EtOAc:MeOH 0-30%. Forty-
one fractions of 50 mL were collected and grouped based on their TLC profiles to eight 
main subfractions (F1A-F1H). A white crystalline precipitate identified as sucrose (60) 
was obtained from F1H (CC fractions 30-41, collected with 24-30% MeOH in EtOAc). 
Compound 170-171 were obtained by PTLC of CC fractions 17-20 (EtOAc:MeOH 13%). 
The Plate was developed in DCM:MeOH 10%. 
Fractions F2 (428.6 mg) and F3 (361.8 mg) were subjected to preparative RP-HPLC using 
method C and D (Table 2.3) respectively. Chromatograms of the fractions are shown on 
Figure 2.8. Seven compounds (163-169) were identified and characterised from the 
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collected peaks. Overall, ten compounds were isolated and characterised from the leaves 
of J. hypocrateriformis (Table 2.5). 
 
Figure 2.8 Chromatogram of J. hypocrateriformis fractions, a) F2, method C, injection 
vol. 500 µL, sample conc. 25 mg/mL, monitored at 320 and 366 nm b) F3, method D, 
injection vol. 100 µL, sample conc. 50 mg/mL, monitored at 205 nm 
 
Table 2.5 Isolation of compounds from J. hypocrateriformis 
Cpds 
 
SPE fractions 
containing the 
compounds 
Mode of 
isolation 
Rf or tR 
in min  
Visual aspect Amount 
in mg 
163 F2, F3 HPLC 15.53 Yellow powder 8.4 
164 F3 HPLC 19.34 Yellow powder 2.9 
165 F2, F3 HPLC 24.71 Yellow powder 2.2 
166 F3 HPLC 17.50 Yellow powder 3.3 
167 F2 HPLC 16.75 Yellow powder 2.6 
168 F2 HPLC 27.01 Yellow powder 4.4 
169 F2 HPLC 17.75 Brown powder 1.6 
170+171 F1 PTLC* of CC 
pooled fractions 
17-20 
0.37 Brown powder 3.4 
* PTLC developed in DCM:MeOH 10%. 
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2.3.3.3 Isolation of compounds from Pseudospondias microcarpa 
Stem bark (276.0 g), fruits (262.0 g) and leaves (437.0 g) of P. microcarpa were 
individually extracted to yield 2.2, 4.1 and 13.4 g of n-hexane; 1.0, 0.9 and 2.7 g of DCM; 
and 5.9, 7.1 and 12.5 g of MeOH extract, respectively. Only the stem bark DCM and 
MeOH extracts, and the leaves MeOH extract were subjected to chromatographic 
separation.  
The bark DCM extract was cleaned up, while the MeOH extract was subjected to standard 
SPE prior to isolation of their phytochemicals by preparative RP-HPLC. F2 and F3 
obtained from the SPE of the MeOH extract were found to have similar chromatograms 
after analytical HPLC and combined to a single fraction. The DCM extract (597.6 mg) 
and the MeOH fractions F2+F3 (194.3 mg) were chromatographed using methods A and 
E (Table 2.3), respectively. Both extracts afforded compounds 103, 148 and 175 (Table 
2.7) from the peaks collected. 
The leaves MeOH extract was cleaned up and subjected to standard SPE method as 
described for J. hypocarteriformis. F2 (198.8 mg) and F3 (328.6 mg) were found to have 
similar analytical HPLC profiles and were mixed together for separation of their 
constituents. Separation was performed using HPLC method C (Table 2.3). Four 
compounds (164, 166, 172 and 173) were identified and characterised from the obtained 
chromatogram (Figure 2.10). F1 and F4 were not processed further. Table 2.6 lists all the 
compounds isolated and characterised from P. microcarpa. 
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Figure 2.9 Chromatogram of P. microcarpa leaves fractions F2 + F3, method C, injection 
vol. 120 µL, sample conc. 75 mg/mL, monitored at 230 nm 
 
Table 2.6 Isolation of compounds from P. microcarpa 
Cpds 
 
Part of plant 
containing 
the cpds 
Extract 
containing 
the cpds 
SPE/VLC 
containing 
the cpds  
Mode of 
isolation 
(method) 
tR in 
min  
Visual 
aspect 
Amount 
in mg 
103 Stem bark DCM - HPLC (A) 4.55 Brown 
powder 
3.1 
MeOH F2 and F3 HPLC (E) 13.28 
148 Stem bark DCM  - HPLC (A) 4.28  Beige 
powder 
3.6 
MeOH F2 and F3 HPLC (E) 13.00 
164 Leaves  MeOH F2 and F3 HPLC (C) 18.67 Brown 
powder 
1.9 
166 Leaves  MeOH F2 and F3 HPLC (C) 19.23 Brown 
powder 
2.1 
172 Leaves  MeOH F2 and F3 HPLC (C) 11.20 Yellow 
powder 
6.1 
173 Leaves  MeOH F2 and F3 HPLC (C) 14.69 Brown 
powder 
2.4 
174 Stem bark DCM - HPLC (A) 4.78 Brown 
powder 
4.3 
MeOH F2 and F3 HPLC (E) 13.33 
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2.3.3.4 Isolation of compounds from Zanthoxylum leprieurii 
The air-dried and powdered fruits (546.8 g) of Z. leprieurii were extracted with n-hexane, 
DCM and MeOH to obtain 32.7, 21.1 and 54.3 g of brown oily, light maroon and dark 
maroon extracts, respectively.  
The brown oily n-hexane extract (20 g) was subjected to CC over silica gel 60 (230-400 
mesh, 6.5 cm x 50 cm) using a gradient system of Hex:EtOAc (0-50%) and DCM-MeOH 
(10-30%) as eluents. Fifty-three sub-fractions (ca. 125 mL each) were collected and 
pooled on the basis of their analytical TLC profile to six main fractions A-F. Fraction B 
(3.8 g, pooled sub-fractions 9-20) was further chromatographed using silica gel 60 (230-
400 mesh) CC with increasing amounts of EtOAc in n-hexane as eluent to afford 175 
(120.5 mg) and 176 (230.2 mg). Fraction C (1.9 g, pooled sub-fractions 22-32) was 
subjected to repeated CC as previously described to yield 178 (7.4 mg), 179 (80.7 mg), 
along with a mixture of sterols. A white granular precipitate giving single pink spot on 
TLC and identified as 177 (43.1 mg) was obtained from fraction F (2.1 g, pooled sub-
fractions 48-53). 
Fractions D4 (2.46 g), D5 (533.5 mg) and D6 (892.3 mg) obtained by VLC of the DCM 
extract (7.11 g) were mixed together based on their TLC profiles. The mixture obtained 
(2 g) was cleaned up using SPE, dried, resuspended in MeOH and subjected to preparative 
RP-HPLC using HPLC method C (Table 2.3) for compounds isolation. From the peaks 
collected, compounds 114, 180-182 were identified and characterised. 
The MeOH extract was found to be inactive and was not purified. Table 2.7 lists all the 
compounds isolated from Z. leprieurii and their methods of isolation.  
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Table 2.7 isolation of compounds from Z. leprieurii 
Cpds 
 
Extract 
containing 
the cpds 
VLC 
fractions 
containing 
the cpds  
Mode of isolation Rf or 
tR in 
min  
Visual 
aspect 
Amount 
in mg 
114 DCM D4, D5 and 
D6 
HPLC 
 
10.62 Brown 
powder 
4.4 
175 n-hexane - CC of CC pooled 
fractions 9-20 
(Hex:EtOAc 10-
20%) eluted with 
EtOAc in n-
hexane (5-15%)  
0.47*  White 
powder 
120.5 
176 n-hexane - 0.38* White 
powder 
230.2 
177 n-hexane - Precipitates in CC 
pooled fractions 
48-53 
(DCM:MeOH 
15%)  
0.12* White 
powder 
43.1 
178 n-hexane - CC of CC pooled 
fractions 22-32 
(Hex:EtOAc 20-
30%) eluted with 
EtOAc in n-
hexane  
(1-20%) 
0.18* White 
powder 
7.4 
179 n-hexane - 0.22* White 
powder 
80.7 
180 DCM D4, D5 and 
D6 
HPLC 9.41 
 
Brown 
powder 
3.6 
181 DCM D4, D5 and 
D6 
HPLC 
 
7.70 
 
Brown 
powder 
1.3 
182 DCM D4, D5 and 
D6 
HPLC 
 
9.42 Yellow 
powder 
3.3 
 *TLC developed in Hex:EtOAC 25% and sprayed with 1% anisaldehyde solution 
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2.3.3.5 Isolation of compounds from Zanthoxylum zanthoxyloides 
The air-dried ground fruits (350.0 g) of Z. zanthoxyloides were extracted to give 34.6 g, 
3.9 g and 19.6 g of n-hexane, DCM and MeOH extract, respectively.  
The DCM extract (3.0 g) was subjected to VLC to obtained six fractions D1-D6 as 
describe above. Fractions D4 (336.0 mg), D5 (223.2 mg) and D6 (129.9 mg) were mixed 
based on their TLC profiles, cleaned up and subjected to RP-HPLC for separation. 
Compounds 54, 55, 79, 128, 184 and 187 were identified and characterised from the 
fractions collected from the obtained chromatogram (Figure 2.10). 
 
Figure 2.10 Chromatogram of Z. zanthoxyloides DCM fractions D4-D6, method A, 
injection vol. 300 µL, sample conc. 50 mg/mL, monitored at 220 nm 
 
The MeOH extract was subjected to standard SPE and four fractions F1-F4 were obtained. 
The procedure was repeated twice to obtain a good amount of each fraction. F2 (704.8 
mg) was subjected to preparative HPLC analysis (Figure 2.11a) using HPLC method B 
(Table 2.3) to yield 183 (3.5 mg) and 184 (3.6 mg) having the retention times (tR) 4.35 
and 5.95 min, respectively. Fraction F2-B (5.7 mg) collected at tR = 5.28 min was further 
purified through preparative TLC to afford 189 (3.2 mg, EtOAc:MeOH 7:3, Rf 0.41). 
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Fraction F2-D (3.6 mg) collected at tR = 6.55 min was also purified by preparative TLC 
to obtain 190 (1.9 mg, EtOAc:MeOH 7:3, Rf 0.46). Preparative TLC of fraction F2-E (3.8 
mg) collected at tR = 7.22 min provided 188 (1.8 mg, EtOAc:MeOH 7:3, Rf 0.41). 
Purification of fraction F2-F (10.2 mg) collected at tR = 7.61 min using TLC with a 
mixture of EtOAc:MeOH (7:3) as eluent afforded more of 188 (2.5 mg, Rf 0.41) and 186 
(3.6 mg, Rf 0.28). 
F3 (845.8 mg) was also analysed by preparative HPLC using method A (Figure 2.11b). 
Compounds 54, 55, 59, 128, 183, 185, 187 and 191 were identified and characterised 
from the collected fractions. 
Fractions F1 and F4 were not processed further. F1 was found to be rich in sugar while 
F4 were found to contain the same compounds as the DCM extract. Table 2.8 groups all 
the characterised compounds from Z. zanthoxyloides.  
 
Figure 2.11 Chromatogram of Z. zanthoxyloides a) F2, method B, inj vol. 280 µL, sample 
conc. 182.5 mg/mL, monitored at 254 nm b) F3, method A, inj vol. 120 µL, sample conc. 
100 mg/mL, monitored at 230 nm 
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Table 2.8 Isolation of compounds from Z. zanthoxyloides 
Cpds 
 
Extract (s) 
containing 
the cpds 
VLC/SPE 
fraction (s) 
containing 
the cpds  
Mode of isolation 
(method) 
Rf or 
tR in 
min  
Visual 
aspect 
Amount 
in mg 
54 DCM, 
MeOH  
D4-D6, F3 HPLC (A) 27.35 Brown 
powder 
20.7 
55 DCM, 
MeOH 
D4-D6, F3 HPLC (A) 19.90 White 
needles  
36.1 
59 MeOH  F3 HPLC (A) 13.14 Yellow 
powder 
1.9 
79 DCM D4-D6 HPLC (A) 20.43 Brown 
powder 
5.4 
128 DCM, 
MeOH  
D4-D6, F3 HPLC (A) 24.01 Yellow 
powder  
3.9 
183 MeOH  F2, F3 HPLC (A and B) 4.88 Yellow 
powder  
11.5 
184 DCM, 
MeOH  
D4-D6, F2 HPLC (B) 12.42 Beige 
powder 
3.6 
185 MeOH  F3  HPLC (A) 10.00 Brown 
powder 
1.2 
186 MeOH  F2 1. HPLC (B) 
2. PTLC of HPLC 
fraction (tR 7.61) 
in EtOAc:MeOH 
7:3 
0.28 Yellow 
powder  
3.6 
187 DCM, 
MeOH  
D4-D6, F3 HPLC (A) 25.85 Yellow 
powder 
11.2 
188 MeOH  F2 1. HPLC (B) 
2. PTLC of HPLC 
fraction (tR 7.61) 
in EtOAc:MeOH 
7:3 
0.41 White 
liquid 
4.3 
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Table 2.8 continued 
189 MeOH  F2 HPLC (B) 0.41 White liquid 3.2 
190 MeOH  F2 1. HPLC (B) 
2. PTLC of HPLC fraction (tR 
7.61) in EtOAc:MeOH 7:3 
0.46 White liquid 1.9 
191 MeOH  F3 HPLC (A) 23.77 Yellow 
powder 
1.7 
 
 
2.3.4 Identification and characterisation of isolated compounds 
Structure elucidation of all the isolated compounds was carried out by spectroscopic 
analyses including 1D (1H and 13C NMR) and 2D NMR (1H-1H COSY, DEPT 145, 1H-
13C HSQC-DEPT, 1H-13C HMBC, 1H-1H NOESY and 1H-1H TOCSY) and mass 
spectrometry. Some compounds were also characterised by UV, FT-IR spectroscopy and 
polarimetry. Spectroscopic techniques are useful means for assessing the purity and the 
determination of the structures of natural substances (Boiteau et al., 1964). 
 
2.3.4.1 Nuclear magnetic resonance  
Nuclear magnetic resonance (NMR) is a useful spectroscopic technique to obtain 
structural information about a given molecule. NMR spectra are plots of signals arising 
from absorption of radio frequency due to excitement of a nucleus or simultaneous 
excitement of two nuclei (Breitmaier and Sinnema, 1993; Crews et al., 1998). Only 1H 
and 13C nuclei were excited during experiments. Experiments consist of 1D and 2D 
experiments. 1D experiments used in this study include proton (1H) and carbon (13C) 
NMR while 2D NMR experiments are 1H-1H COSY (Correlation SpectroscopY), DEPT 
135º (Distortionless Enhancement by Polarization Transfer), 1H-1H NOESY (Nuclear 
Overhauser Effect SpectroscopY) and 1H-1H TOCSY (TOtal Correlation SpectroscopY), 
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HMBC (1H-13C Heteronuclear Multiple Bond Correlation Spectroscopy) and HSQC (1H-
13C Heteronuclear Single Quantum correlation). NOESY was used to determine the 
relative stereochemistry of the molecule while TOCSY was used to identify protons 
belonging the same spin system for the structure elucidation of glycosylated molecules 
(Agrawal, 1992; Reggelin et al., 1992). Experiments were performed on either a Bruker 
AMX 600 or a Bruker AMX 300 instrument (Bruker, Germany). Chemical shifts (δ) are 
given in part by millions (ppm) and the coupling constants J in Hertz (Hz). 
 
 
2.3.4.2 Ultraviolet-visible and Fourier transform infrared spectroscopies 
Ultraviolet-visible (UV) and Fourier Transform Infrared (FT-IR) spectroscopies were 
recorded on Analytik Jena Specord 210 (Jena, Germany) and Agilent Cary 630 FT-IR 
(Agilent, UK) spectrophotometers respectively. Both methods are useful for the detection 
of functional groups in a molecule. Wavelengths scan for the UV was between 200-500 
nm. Quartz cells were used for samples and blanks. The results were reported in nm as 
the wavelength of the maxima. 
 
 
2.3.4.3 Optical rotation 
Optical rotation was determined using Bellingham- Stanley ADP660 polarimeter with the 
sodium D line (589.3 nm) as the source of light. The measurements were made at 25 °C 
in a 10 cm cell. The results were calculated with the following formula: [α]25D= 
1000×α/l.c (in which α= observed rotation, l = cell length in dm and c = concentration in 
g/100 mL). 
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2.3.4.4 Mass spectrometry  
Mass spectrometry (MS) is a technique useful in determination of the molecular weight 
of compounds, the possible molecular formula and fragmentation pattern (Hoffmann et 
al., 1996). High resolution mass spectra (HR MS) were recorded at the National Mass 
Spectrometry Facility (NMSF) (Swansea, UK) on a Xevo G2-S ASAP or LTQ Orbitrap 
XL1 spectrometers. Low and high resolution MS analyses were also performed at LJMU. 
HR MS was run on an Agilent 6200 Series Accurate-Mass Time-of-Flight (TOF) LC/MS 
using electro spray ionisation (ESI) in positive ion mode connected to an Agilent auto-
sampler injection system. The analyte was prepared in MeOH and the mass spectrum was 
recorded relating to their mass to charge (m/z) at a capillary potential of 3,500 V. Low 
resolution analyses were performed on a Waters LCT Premier™ ESI-TOF Mass 
Spectrometer.  
 
 
2.4 Bioactivity studies 
2.4.1 Samples preparation for screening 
Stock solutions of assayed samples were prepared in DMSO 100 mg/mL for crude 
extracts and fractions, and 100 mM for pure isolated compounds and stored at 4 oC. Prior 
to use, the stock solution was further diluted in the medium to final working 
concentrations ranging from 0-1000 µg/mL for extract and, 0-250 µM for pure 
compounds on the day of assay. 
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2.4.2 Cell culture 
Dulbecco's Modified Eagles Medium (DMEM), Foetal bovine serum (FBS), 
penicillin/Streptomycin, and L-glutamine were warmed at 37 °C before making up a 
complete media. Penicillin/streptomycin (100 units/mL, 4 mL), L-glutamine (4 mL) and 
50 mL of FBS were added into 500 mL of DMEM in a sterilised environment. The media 
was mixed and stored in a fridge at 4°C. Growth media was pre-warmed at 37°C for 20 
min before each use. In the case of AREc2 cell line, 4 mL of 100 mg/mL of geneticin was 
also added to the growth medium. All cell lines were cultured at 37 °C in 95 % air and 5 
% CO2 in 25 or 75 cm
2 tissue culture flask (Corning, Staffordshire, UK) containing 
appropriate medium for the cell line.  
When cells were 80-100 % confluent, they were passaged or used for the desired 
experiment. Firstly, the media was removed from the flasks and cells were washed with 
PBS twice to remove the residual medium and dead cells, as they are non-adherent to the 
flask surface. Small amount of pre-warmed trypsin-EDTA (0.2-0.5 mL) was added and 
incubated for 1-2 min at room temperature, then excess of trypsin was removed and the 
cells were incubated for an additional 2-4 min at 37 °C. The flasks were tapped gently to 
dislodge the cells and were visualised under a microscope. 
After the cells were completely disassociated from the flask, the complete growth media 
was added into the flask. The medium was pipetted up and down several times to break 
up any cell clumps. The cell suspension was split into two fresh flasks and were labelled 
with new passage number and kept in an incubator at 37°C.  
For the assays, after reaching 80-90% confluence, the cells were seeded into 96 well 
plates or 6 well plates at density 1.2 × 104 in a corresponding working volume of 180 
μL/well and allowed to grow for 24 h before each experiment commenced. 
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2.4.3 Cell viability assays 
Trypan blue assay using a haemocytometer was used during cell counting to determine 
cell numbers for setting up assays. Equal amount of trypan blue and cell solution were 
mixed by pipetting up and down for few times, and 10 μL of the obtained solution was 
transferred in each quadrant of the haemocytometer. Viable cells are typically round and 
refractile and exclude the stain, whilst non-viable cells are stained dark blue. 
3-(4,5-dimethylthlthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay based on 
the method described by Mosmann (1983) was used to assess the cytotoxicity of extracts 
and pure isolated compounds on the different cell lines used in this study. The MTT is 
converted by the NADPH present in viable cells to a purple formazan crystal (Figure 
2.12) which has an absorbance maximum near 570 nm. When cells died, they lose the 
ability to convert the MTT into formazan and therefore, colour formation serves as a 
useful convenient manner of viable cells only.  
 
Figure 2.12 MTT transformation to formazan 
 
Cells were seeded into 96 well plates at density 1.2 × 104 cells/well. After 24 h incubation, 
the medium was removed and replaced with fresh medium containing assayed sample 
(extract or pure compound) at the desired concentration. The final concentration of 
DMSO in each well was no more than 0.1%. A set of untreated control cells was included 
in each experiment, as well as a set of cells treated with 0.1% DMSO. Following 
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incubation with the extracts for 24 h (48 h for pure compounds except with AREc32 cell 
line), 20 μL of MTT solution (prepared in PBS at the concentration of 5 mg/mL) was 
added to each well. After 2 h of incubation at 37 °C, the medium was discarded and 
replaced with 100 μL of DMSO. The OD570 was determined with a microplate reader 
(CLARIO Star Microplate reader, BMG Labtech, UK). The percentage of cell viability 
was determined as percentage of control cells [(absorbance of treated cells/absorbance of 
untreated cells) × 100]. 
 
 
2.4.4 Luciferase reporter gene assay 
The ability of the extracts, fractions and isolated compounds to activate the expression of 
ARE driven genes which are commonly activated by Nrf2 were evaluated by cell-based 
luciferase assay with a cell line which contains an ARE-driven luciferase reporter gene 
(AREc32, modified MCF-7 cell line). Luciferases are a class of oxidative enzymes found 
in several species that enable the host to bioluminesce in the presence of luciferin (Figure 
2.13). The emission can be read using a luminometer and is directly correlated to the level 
of ARE activation (Wang et al., 2006).  
 
Figure 2.13 Formation of oxyluciferin 
 
The Steady-Glo Luciferase assay kit from Promega was used for this purpose according 
to the manufacturer instructions. Briefly, AREc32 cells were seeded into 96 well plates 
at density 1.2 × 104 cells/well and treated for 24 h with the concentration of extract or 
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pure compound causing no more than a 10% reduction of cell viability as determined by 
the MTT assay. Wells were then washed twice with 100 µL of PBS and 20 µL of 
luciferase reporter lysis buffer (Promega, USA) was added to each well followed by a 
freeze thaw cycle (24 h) to achieve complete cell lysis. The 20 µL cell lysate was then 
aspirated and dispensed into a white opaque 96 well plates. 80 µL of Luciferase reporter 
substrate was added to each well and the luminescence immediately measured using a 
plate reader (ClarioStar microplate reader, BMG Labtech, UK). Levels of luciferase 
activity were expressed relative to the basal level of luciferase activity in control (no 
treatment) and presented as a fold increase (relative to control). 
 
 
2.4.5 Haem polymerisation assay 
The potential antimalarial activity of plant extracts was evaluated by the method 
described by Hussain et al. (2011). Briefly, varying concentrations (0-2 mg/mL in 10% 
DMSO) of the extracts were incubated with 300 µM of hematin (freshly dissolved in 0.1 
M NaOH), 10 mM oleic acid and 10 µM HCl. The reaction volume was adjusted to 1000 
µL using 500 mM sodium acetate buffer, pH 5. Chloroquine diphosphate was used as a 
positive control. The samples were incubated overnight at 37 ºC with regular shaking. 
After incubation, samples were centrifuged (14,000 x g, 10 min, at 21 °C) and the 
hemozoin pellet repeatedly washed with sonication (30 min, at 21 °C; FS100 bath 
sonicator; Decon Ultrasonics Ltd.) in 2.5% (w/v) SDS in phosphate buffered saline 
followed by a final wash in 0.1 M sodium bicarbonate, pH 9.0, until the supernatant was 
clear.  After the final wash, the supernatant was removed, and the pellets were re-
suspended in 1 mL of 0.1 M NaOH before determining the hemozoin content by 
measuring the absorbance at 405 nm using a 1 cm quartz cuvette. The results were 
recorded as % inhibition (I%) of haem polymerization/crystallization compared to 
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positive control (chloroquine) using the following formula: I% = [(AB–AA)/AB] x 100, 
where AB: absorbance of blank; AA: absorbance of test samples. All the solutions were 
pre-warmed at 60°C before initial mixing. 
 
 
2.5 Statistical analysis 
All bioassay experiments were carried out in triplicate with a minimum of three replicates 
per assayed concentration. Data were expressed as means ± SEM (standard error of 
mean). The graphs were plotted using Excel Microsoft office 2016. SEM is shown on the 
graph as an error bar. IC50, LC10 and LC50 where calculated using Graph Prism 7.0 
software. P value were calculated using unpaired student t-test and considered significant 
when P ≤ 0.01. 
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Chapter 3 Results and Discussion 
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3.1 Yield of extraction 
Different parts of the following medicinal plants viz. Croton oligandrus Pierre ex Hutch, 
Ruspolia hypocrateriformis (Vahl) Milne-Redh, Pseudospondias microcarpa (A. Rich.) 
Engl., Zanthoxylum lepreurii Guill. and Perr. and Zanthoxylum zanthoxyloides (Lam.) 
Zepern.  and Timler (Figure 3.1) were collected, dried at room temperature, ground and 
successively extracted with a Soxhlet apparatus using n-hexane, DCM and MeOH. 
Eighteen extracts were obtained (Table 3.1). As the three solvents used have different 
polarity index, the constituents of the plant were gradually extracted according to their 
affinity with each solvent. The highest yield percentage of extraction was that of Z. 
zanthoxyloides with 23.9 % recovery percentage while P. microcarpa bark yielded the 
lowest extraction percentage of 3.3 %. 
 a)    b)  c) 
d)  e)  f) 
Figure 3.1 Pictures showing the different plant parts collected 
a) Croton oligandrus Pierre ex Hutch stem bark; b) Ruspolia hypocrateriformis Vahl 
Milne-Redh leaves; c) Pseudospondias microcarpa (A. Rich.) Engl. stem bark; d) 
Pseudospondias microcarpa (A. Rich.) Engl. leaves; e) Zanthoxylum lepreurii Guill.  and 
Perr. fruits; f) Zanthoxylum zanthoxyloides (Lam.) Zepern. and Timler fruits. 
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Table 3.1 Yield of extraction of the different plants collected 
Plants  Powder 
weight (g) 
Extract weight (g)  Yield (%) 
  Hexane  DCM  MeOH   
C. oligandrus bark  330.8 3.7  2.1 7.4  4.0 
R. hypocrateriformis leaves  450.0 13.6 10.2 41.8 14.6 
P. microcarpa bark  276.6 2.2  1.1 5.9  3.3 
P. microcarpa leaves  437.3 13.4  2.7 12.5  6.5 
Z. leprieurii fruits 546.8 32.7  21.1 54.3 19.8 
Z. zanthoxyloides fruits  350.0 59.58 5.9 18.25 23.9 
 
 
 
3.2 Preliminary screening  
3.2.1 Luciferase activity 
The extracts obtained from the collected plant materials were screened for their potential 
cancer chemopreventive properties using the AREc32 cell line. AREc32 cells are stably 
transformed variant of the MCF-7 cells containing a luciferase reporter gene under the 
control of antioxidant promoters, and therefore, is an excellent cell model for the 
identification of potent activator of the Nrf2 signalling pathway (Wang et al., 2006). 
 
 
3.2.1.1 AREc32 cells viability 
The cell viability of the AREc32 cells in the presence of each extract was first assessed 
by the MTT assay with the aim of determing the threshold dose nontoxic for the cells and 
the suitable dosage for the luciferase assay. The cells were incubated in the presence of 
the extracts and the effect of those extracts on cell viability measured after 24 h and 
compared to that of control (untreated cells). Results are shown on Figure 3.2. The DCM 
Extract of P. microcarpa bark was found to be the most toxic to the AREc32 cells killing 
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nearly 50% of cells at 62.5 µg/mL while the MeOH Extract of Z. zanthoxyloides fruits 
was found to be the least toxic with only 70% of cells death occurring at 1 mg/mL. JHL 
and PML were found to have a cytotoxic effect on AREc32 cells at very low 
concentrations. The concentration causing no more than 10% cells death (LC10), was 
chosen as the assayed concentration for the luciferase assay (Table 3.2) as no significant 
cell death was observed below that concentration. 
 
   
                            
Figure 3.2 Effect of tested extracts on the viability of AREc32 cells. 
Cells were treated for 24 h with 0.1% DMSO (control), or with various concentrations (0 
– 1 mg/mL) of extracts. Cell viability was determined by MTT assay. Each measured 
parameter is plotted as mean ± SEM of three independent experiments (5 replicates/ 
experiment). COB: C. oligandrus bark; RHL: R. hypocrateriformis leaves; PMB: P. 
microcarpa bark; PML: P. microcarpa leaves; ZLF: Z. leprieurii fruits; ZZF: Z. 
zanthoxyloides fruits, HEX: n-Hexane extract; DCM: DCM extract; MeOH: MeOH 
extract. 
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Table 3.2 Concentrations of extracts causing no more than 10% toxicity 
Extract Least toxic concentration (LC10 in µg/mL) 
 COB JHL PMB PML ZLF ZZF 
HEX 60 4 60 60 4 5 
DCM 60 3 30 30 5 50 
MeOH 10 5 30 30 5 500 
Cells were treated for 24 h with various concentrations (0 – 1 mg/mL) of extracts. Cell 
viability was determined by MTT assay. LC10 was determined using GraphPad Prism 
software of three independent experiments (5 replicates/ experiment). COB: C. 
oligandrus bark; RHL: R. hypocrateriformis leaves; PMB: P. microcarpa bark; PML: P. 
microcarpa leaves; ZLF: Z. leprieurii fruits; ZZF: Z. zanthoxyloides fruits, HEX: n-
Hexane extract; DCM: DCM extract; MeOH: MeOH extract. 
 
 
3.2.1.2 Luciferase assay 
Luciferase assay was carried out as describe in the experimental section (Chapter 2, 
2.4.4). The results are shown on Figure 3.3. Among the tested extracts, COBHEX, 
COBDCM, ZZFDCM and ZZFMeOH extracts were found to induce luciferase activity. 
ZZFMeOH was the most active with a 36-fold induction follow by its DCM extract with 
33-fold induction. The activities of Z. zanthoxyloides DCM and MeOH extracts were 
similar to that of tBHQ (50 µM) used as positive control. tBHQ is a well characterized 
chemopreventive compound which exert its activity by inducing Nrf2-regulated genes 
(Wang et al., 2006). The fact that only DCM and MeOH extracts induced high levels of 
the luciferase activity (greater than 30-fold) might be linked to presence of polar 
compounds in the plant. 
 
Several Zanthoxylum species are traditionally used in Asia and Central America to treat 
and prevent cancer (Epifano et al., 2011). Phytochemical studies of Z. zanthoxyloides 
have led to the isolation of alkaloids with good cytotoxicity against a panel of cancer cell 
lines (Wouatsa et al., 2013). It is interesting to note that Z. leprieuri extracts did not show 
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any significant increase of the luciferase activity compared to the closely related species 
Z. zanthoxyloides. A comparative study carried out by Wouatsa et al. (2013a) has revealed 
that the two plants only have few phytochemicals in common. 
In contrast to Z. zanthoxyloides, for which polar extracts were active, only nonpolar and 
medium polar extracts of C. oligandrum showed good luciferase induction. COBHEX 
and COBDCM extracts were found to induce the luciferase activity by 18 and 21-fold, 
respectively. Croton is a rich source of diterpenes (Xu et al., 2018), and some isolated 
diterpenes from plants have been reported to have cancer chemopreventive activity 
(Dhanasekaran et al., 2009; Endringer et al., 2014). 
 
Figure 3.3 Luciferase activity of the screened extracts 
AREc32 cells were seeded in 96-well plates at 1.2 x 104 cells/well. After 24 h, tBHQ (50 
μM) and the extracts were added to the medium. The cells were then incubated for another 
24 h and assayed for luciferase activity as detailed in Chapter 2, 2.4.4. The value of 
luciferase activity of untreated cells (CT) was set at 1. Values shown are mean ± SEM of 
three experiments. *p < 0.1; **p < 0.01, ***p < 0.001 significantly increased versus 
control. DMSO 0.1%: (cells treated with 0.1% DMSO medium). 
 
The most active crude extracts were fractionated using VLC for n-hexane and DCM 
extracts, and SPE for MeOH extract. For each n-hexane or DCM extract, six fractions 
were obtained and four fractions only for MeOH extract. The effect of the fractions on 
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the viability of AREc32 cells was assessed by the MTT assay to determine their least 
toxic concentration (Concentrations causing no more than 10% cells death), and the 
obtained concentration (Table 3.3) was used as dosage to evaluate the luciferase activity 
of the fractions. 
 
Table 3.3 Concentrations of fractions causing no more than 10% toxicity  
Extract Least toxic concentration (LC10 in µg/mL) 
 
F1 F2 F3 F4 F5 F6 
COBHEX 5 5 10 1 0.5 1 
COBDCM 5 10 0.5 5 0.5 5 
ZZFDCM 0.5 1 1 5 5 0.1 
ZZFMeOH 5 1 0.5 5 - - 
Cells were treated for 24 h with various concentrations (0 – 1 mg/mL) of extracts. Cell 
viability was determined by MTT assay. LC10 was determined using GraphPad Prism 
software of three independent experiments (5 replicates/ experiment). F1-F6 are fractions 
obtained from VLC and SPE of active crude extracts COB: C. oligandrus bark; ZZF: Z. 
zanthoxyloides fruits, HEX: n-Hexane extract; DCM: DCM extract; MeOH: MeOH 
extract. 
 
The level of induction of the luciferase activity by each fraction tested is depicted in 
Figure 3.4. Overall, fractionation considerably reduced the activity, as most of the 
fractions did not show significant fold induction of the luciferase activity as the mother 
crude extract. The only plausible explanation could be that the activities observed from 
the corresponding crude extract were due to synergistic action of the different compounds 
present in the plant. In addition, the fractionation techniques used, VLC and SPE 
separated the constituents of the plant based on their affinity with the eluent used. Thus, 
each fraction is a mixture of several compounds with similar polarity in different 
proportions conferring a unique phytochemical profile. Moreover, plant extracts contain 
complex mixtures of compounds in which most of the time a single constituent is not 
responsible for the overall activity (Williamson, 2001).  
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Among the tested fractions, COBHEX F1 and ZZFMeOH F3 showed induction of 3.24- 
and 2.4-fold, respectively. The activity of ZZFMeOH F3 was comparable to that of tBHQ 
6 μM (2.5- fold induction) while COBHEX F1 was more active than tBHQ 6 μM. The 
remaining fractions showed fold induction below 2. According to McMahon and 
coworkers (2014), chemicals causing fold increase of luciferase activity greater than 2 
are considered as active.  
 
Figure 3.4 Luciferase activity of the fractions 
AREc32 cells were seeded in 96-well plates at 1.2 x 104 cells/well. After 24 h, tBHQ (6 
and 12 μM) and the fractions were added to the medium. The cells were then incubated 
for another 24 h and assayed for luciferase activity as detailed in Chapter 2, 2.4.4.  The 
value of luciferase activity of untreated cells (CT) was set at 1. Values shown are mean ± 
SEM of three experiments. *p < 0.01; **p < 0.001, ***p < 0.0001 significantly increased 
versus control. DMSO, cells treated with 0.1% DMSO medium. 
 
 
3.2.2 Haem polymerisation assay 
Hemozoin, also called malaria pigment, is essential for the survival of the malaria parasite 
in red blood cells (Coronado et al., 2011). The pigment is a polymer of haem units, which 
is biocrystallised during haem detoxification in the erythrocytic life of the parasite. 
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Inhibition of the haem polymerisation is therefore targeted for the search of antimalarial 
substances. Several screening techniques have been developed for the purpose. In the 
present study, we have performed the assay using the method published by Hussain et al. 
(2011) as described in the experimental section. Chloroquine diphosphate was used as 
positive control. Results are shown in Table 3.4. 
 
Table 3.4 Haem polymerisation inhibitory concentration (IC50 in µg/mL) 
Extract  IC50 (µg/mL) ± SEM 
 HEX DCM  MeOH 
COB 180.0 ± 6.0 164.8 ± 53.0 ˃ 1 
JHL 206.7 ± 52.0 ˃ 1 170.3 ± 77.9 
PMB 73.9 ± 25.8 2.5 ± 1.5 4.0 ± 1.7 
PML ˃ 1 ˃ 1 13.0 ± 9.0 
ZLF ˃ 1 45.8 ± 25.0 ˃ 1 
ZZF ˃ 1 ˃ 1 ˃ 1 
Chloroquine 0.43 ± 0.08  
IC50 was determined using GraphPad Prism of three independent experiments (3 
replicates/experiment). COB: C. oligandrus bark; RHL: R. hypocrateriformis leaves; 
PMB: P. microcarpa bark; PML: P. microcarpa leaves; ZLF: Z. leprieurii fruits; ZZF: Z. 
zanthoxyloides fruits, HEX: n-Hexane extract; DCM: DCM extract; MeOH: MeOH 
extract. 
 
Among the five plants screened, P. microcarpa extracts were found to be the most active. 
Inhibition of the haem polymerisation was observed for the DCM and MeOH extracts of 
the stem bark with IC50 values 2.5 ± 1.5 and 4.0 ± 1.7 µg/mL, respectively.  MeOH extract 
produced 50% inhibition at 13.0 µg/mL. The PMB hexane extract was less active (IC50 
73.9 ± 25.8 µg/mL), while PML hexane and MeOH were found to have no effect at the 
highest   concentration tested. The IC50 obtained for PMB DCM and MeOH extracts were 
comparable to the result obtained when the stem bark ethanol extract (IC50 1.13± 0.16 
µg/mL) was screened in vitro against multi-drug resistant Plasmodium falciparum K1 
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strain (Malebo et al., 2009). The IC50 of the MeOH extract was close to the result 
published by Mbatchi et al. (2006) (IC50 26 ± 10 µg/mL) when the ethanol extract was 
tested in vitro against human erythrocytes infected by FcM29 originated from Cameroon. 
Z. zanthoxyloides fruits extracts were found to be not active at the highest concentration 
tested. However, previous screenings have demonstrated a moderate antimalarial activity 
for the root and trunk bark extracts (Kassim et al., 2005; Gansane et al., 2010). 
This is the first report on the evaluation of the antimalarial activity C. oligandrus and J. 
hypocrateriformis. Overall, extracts with IC50 < 200 µg/mL, i.e. COBHEX, COBDCM, 
JHLMeOH, PMBHEX, PMBDCM, PMBMeOH, PMLMeOH and ZLFDCM were 
selected for further studies. 
 
 
3.3 Characterisation and structure elucidation of isolated compounds 
3.3.1 Phytochemistry of Croton oligandrus 
The n-hexane and DCM extracts of C. oligandrus exhibited good antimalarial and 
chemopreventive properties. CC and RP-HPLC analyses of the n-hexane and DCM 
extracts led to the isolation and characterization of eighteen compounds, which were 
identified as 3-β-O-acetyl aleuritolic acid (7), lupeol (8), vanillin (147), trans-ferulic acid 
(148), a mixture of ferulate derivatives: cluytyl ferulate (149) and hexacosanoyl ferulate 
(150), crotocorylifuran (151), crotonzambefuran A (152), megalocarpoidolide D (153), 
12-epi-megalocarpoloide D (154), crotonolin E (155), the epimeric mixtures of crotonolin 
A (156) and crotonolin B (157), and  crotonolin C (158) and crotonolin D (159), 
crotonolin F (160), 7-α-hydroxydehydroabietic acid (161) and 7-oxo-dehydroabietic acid 
(162) (Figure 3.5). This is the first report on the occurrence of the compounds 147-162 in 
C. oligandrus. Compounds 154-160 are new clerodane diterpenes from any natural 
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source. Diterpenes are the most abundant secondary metabolites found in the genus 
Croton, representing about 85% of all the isolated metabolites with clerodane being the 
most abundant subclass (Xu et al., 2018). 
 
Figure 3.5 Structures of isolated compounds from the bark of C. oligandrus 
 
 
3.3.1.1 Structure elucidation of 3-β-O-acetyl aleuritolic acid (7) 
Compound 7 was obtained as a white powder, which precipitated in a mixture of Hex-
EtOAc (7:1). Its molecular formula C32H50O4 was deduced from the ESI-MS spectrum in 
positive ion mode (Figure 3.6) by the sodiated molecular ion peak at m/z 521 [M+Na]+. 
Its 1H NMR spectrum (Figure 3.7, Table 3.5), showed seven methyl singlets at δH 0.88, 
0.90, 0.96, 0.97, 0.97, 0.98, 0.99, 1.95 and 2.06; a doublet of doublets at δH 5.52 (J = 3.4, 
7.9 Hz) indicating the presence of an olefinic proton (Misra and Khastgir, 1970) and 
103 
 
another doublet of doublets at δ 4.48 (J = 5.3, 10.9 Hz), attributable to an oxymethine 
proton. All these preliminary observations suggested the presence of a triterpenoid 
skeleton in the molecule. This was further confirmed by the presence of thirty-two carbon 
signals in the 13C NMR spectrum of 7 (Figure 3.8, Table 3.5) corresponding to eight 
methyls, ten methylenes, five methines including an oxymethine at δC 80.9 (C-3) and an 
olefinic methine at δC 116.7 (C-15), nine quaternary carbons including an olefinic carbon 
at δC 160.6 (C-14) and two carbonyls signals at δC 184.0 and 170.9 indicating the presence 
of a carboxylic acid and an acetoxy function, respectively. The signals at δC 160.5 and 
116.8 could be assigned to the double-bonded carbons (C=C), which are typical of that 
of C14-C15 double bond signals of a taraxerane skeleton (Rasool et al., 1989). The 
position of the double bond could be confirmed by the different 1H-13C long-range 
correlations (Figure 3.8) observed in the HMBC spectrum. The methyl signal at δH 2.06 
was attributed to the methyl of the acetoxy group based on its correlation to the carbonyl 
at δC 170.9 observed in the HMBC. The acetoxy group could be placed on C-3 of the 
triterpene skeleton as there was a 3J correlation from the 3-oxymethine (δH 4.48) to the 
acetoxy carbonyl (δC 170.9), observed in the HMBC spectrum. The assignment of all 1H 
and 13C NMR signals (Table 3.5) of 7 was achieved by a combination of COSY, HSQC 
and HMBC spectral analyses, and in comparison, with the published data for 3-β-O-acetyl 
aleuritolic acid (Mahato and Kundu, 1994; Prabowo et al., 2013). Thus, compound 7 was 
identified conclusively as 3-β-O-acetyl aleuritolic acid. Acetyl aleuritolic acid (7) was 
first isolated from the bark of Aleurites montana (Euphorbiaceae) and is widespread in 
all genera of the Euphorbiaceae including the genus Croton (Misra and Khastgir, 1970; 
Salatino et al., 2007).  
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Figure 3.6 ESI-MS spectrum of 7 
 
 
 
 
Figure 3.7 1H NMR (600 MHz, CDCl3) of 7 
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Figure 3.8 13C NMR (150 MHz, CDCl3) and key HMBC correlations of 7 
 
Table 3.5 1H (600 MHz, CDCl3) and 
13C NMR (150 MHz, CDCl3) data of 7 
Position δH m (J in 
Hz) 
δC  Position δH m (J 
in Hz) 
δC  Position δH m (J 
in Hz) 
δC 
1 1.05  37.7 11 1.52 17.3 20 29.7 - 
 1.65    1.67  21 33.6 1.09 
2 1.65  23.4 12 1.65 33.3 22 1.43 30.7 
3 4.48 dd 
(5.3, 
10.9) 
80.9  1.76   1.71  
4 - 37.4 13 - 37.3 23 0.88 s 27.9 
5 0.92 55.6 14 - 160.6 24 0.99 s 16.5 
6 1.20 18.7 15 5.52 dd 
(3.4, 7.9) 
116.7 25 0.96 s 15.6 
 1.65  16 1.95 31.4 26 0.98 s 26.1 
7 1.32 40.8  2.39  27 0.97 s 22.4 
 2.00  17 - 51.3 28 - 184.0 
8 - 39.0 18 2.29 41.5 29 0.97 s 31.9 
9 1.45 49.0 19 1.14 35.3 30 0.90 s 28.7 
10 - 37.9  1.30     
CH3CO - 170.9 OCCH3 2.06 s 21.3    
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3.3.1.2 Structure elucidation of cluytyl ferulate (149) and hexacosanoyl ferulate (150) as 
a mixture 
Compounds 149 and 150 were obtained as a mixture and as a white powder. These were 
identified as the main constituents of the n-hexane extract along with acetyl aleuritolic 
acid (7) and lupeol (8). The HR ESI-MS spectrum in negative ion mode (Figure 3.9) of 
the white powder revealed a mixture composition of two homologous substances showing 
[M-H]- peaks at m/z 557.4571 and 585.4881, with a relative abundance of 52 and 45%, 
respectively, corresponding to the formulas C36H61O4 and C38H65O4, respectively, 
calculated for [C36H61O4]
-, 557.4575 and [C38H65O4]
-, 585.4888, respectively. The 1H 
NMR spectrum (Figure 3.10, Table 3.6) exhibited signals for a methoxy group (δH 3.95, 
s), two trans olefinic protons (δH 7.63 and 6.31, J =16.0 Hz), and three aromatic 
hydrogens forming an ABX system (δH 6.93, d, J = 8.1 Hz;, 7.09, d, J = 1.8 Hz and 7.10 
, dd, J = 1.8, 8.1 Hz) that could be assigned to a ferulic acid moiety (Balde et al., 1991). 
The signals at δH 4.21 (2H, t, J = 6.7 Hz), 1.27-1.71 (2H, brs, m) and 0.90 (3H, t, J = 6.9 
Hz) could be attributed to an oxymethylene, a long saturated aliphatic chain and a terminal 
methyl functionality, respectively, suggesting the presence an aliphatic alcohol moiety in 
the molecule. The 13C NMR spectrum (Figure 3.11, Table 3.6) confirmed the presence of 
a saturated fatty alcohol moiety, an ester linkage and a ferulic moiety. Assignment of the 
1H and 13C NMR data of 149 and 150 (Table 3.6) were confirmed by the 1H-13C long-
range correlations (Figure 3.11) observed in the HMBC spectrum. All assignments of 1H 
and 13C NMR signals of these compounds are in good agreement with those published 
for cluytyl ferulate and hexacosenoyl ferulate, respectively (Wandji et al., 1990; Balde et 
al., 1991). Thus, compounds 149 and 150 were identified as cluytyl ferulate (149) and 
hexacosenoyl ferulate (150), respectively.  
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Figure 3.9 ESI-MS spectrum of 149 and 150 
 
 
 
Figure 3.10 1H NMR (600 MHz, CDCl3) of 149 and 150 
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Figure 3.11 13C NMR (150 MHz, CDCl3) and key HMBC correlations of 149 and 150 
 
 
Table 3.6 1H (600 MHz, CDCl3) and 
13C NMR (150 MHz, CDCl3) data of 149 and 150 
Position δH m (J in Hz) δC   Position δH m (J in Hz) δC  
1 - 127.1  1’ 4.20 t (6.7) 64.6 
2 7.06 d (1.8) 109.3  2’ 1.42 m 26.0 
3 - 146.7  3’ 1.71 m 28.8 
4 - 147.9  4’-23’/25’ 1.27 brs 29.3 
5 7.10 dd (1.8, 8.1) 123.0  24’/26’ 1.27 brs 31.9 
6 6.93 d (8.1) 114.7  25’/27’ 1.27 brs 22.7 
7 7.63 d (16.0) 144.6  26’/28’ 0.90 t (6.9) 14.1 
8 6.31 d (16.0) 115.7  OCH3 3.95 s 55.9 
9 - 167.4     
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3.3.1.3 Structure elucidation of crotocorylifuran (151) 
Compound 151 was obtained as a white amorphous powder. Its molecular formula 
C22H2607 was determined by ESI-MS analysis (Figure 3.12) in positive ion mode, where 
the sodiated ion peak was observed at m/z 425 [M+Na]+. Its 1H NMR spectrum (Figure 
3.13, Table 3.7) indicated the presence of a secondary methyl group at δH 1.02 (3H, d, J 
= 6.4 Hz), two methoxy singlet functions at δH 3.71 and 3.76, characteristic signals of a 
β-substituted furan ring at δH 6.41 (1H, brd, J = 0.9 Hz), 7.44 (1H, ov) and 7.45 (1H, brs) 
(Tchissambou et al., 1990), an oxymethine proton at δH 5.40 (1H, t, J = 8.5 Hz) and an 
olefinic proton belonging to a trisubstituted double bond at δH 6.84 (1H, dd, J = 4.3, 7.5 
Hz) were also observed. The l3C NMR spectrum (Figure 3.14, Table 3.8) of 151 showed 
22 carbon resonances suggesting a diterpene skeleton. The 13C NMR and HSQC DEPT 
analyses supported the observations made on the 1H NMR spectrum and also indicated 
the presence of five methylenes at δC 19.2 (C-1), 26.4 (C-2), 32.3 (C-6), 27.9 (C-7) and 
42.4 (C-11) and two methines at δC 40.2 (C-8) and 51.9 (C-10), which on the HSQC 
spectrum correlated with the proton signals appearing at δH 1.58 (m) and 1.76 (dd, J = 
2.4, 13.2 Hz), respectively. All these data together with the different correlations observed 
in the COSY and HMBC spectra suggested a neo-clerodane (ex ent-clerodane)-type 
diterpene skeleton (Li et al., 2016). The 1H and 13C NMR data (Tables 3.7-3.8) of 151 
were similar to those of crotocorylifuran (Tchissambou et al., 1990). The absolute 
configuration of the C-12 carbon was determined using the NOESY experiment.  For a 
C-12R configuration, a correlation would be seen between H-12 and 3H-17, while a 
correlation seen between H-12 and H-1α will imply C-12S configuration (Bautista et al., 
2012; Ndunda et al., 2016). For compound 151, a correlation observed in the NOESY 
spectrum between the H-12 and H-1α proton (δH 1.92) suggested a C-12S configuration. 
All the 1H and 13C NMR data of 151 supported by the 1H-13C long-range correlations 
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observed (Figure 3.14) led to its identification as crotocorylifuran, a clerodane diterpene 
first isolated from the trunk bark of Croton haumanianus (Tchissambou et al., 1990).  
 
 
Figure 3.12 ESI-MS spectrum of 151 
 
 
 
Figure 3.13 1H NMR (600 MHz, CDCl3) of compound 151 
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Figure 3.14 13C NMR (150 MHz, CDCl3) and key HMBC correlations of 151 
 
 
3.3.1.4 Structure elucidation of megalocarpoidolide D (153)  
Compound 153 was isolated as a white amorphous powder, [α]D25 -88.8 (c 0.001, MeOH). 
Its molecular formula C22H22O8 was determined from the pseudomolecular ion peak at 
m/z 437 [M+Na]+ from its ESI-MS spectrum (Figure 3.15) obtained in positive ion mode. 
The IR spectrum of 153 displayed absorption stretching bands at 1715, 1767 and 1663 
cm-1 that could be attributed to the carbonyl of ester, lactone and ketone groups, 
respectively. The 1H NMR spectrum (Figure 3.16, Table 3.7) revealed characteristic 
signals of a β-substituted furan ring at δH 6.45 (m, H-14), 7.47 (br dd, J = 1.5, 3.1 Hz, H-
15) and 7.54 (brs, H-16), two olefinic protons at δH 6.47 (d, J = 1.3 Hz) and 6.78 (d, J= 
1.3 Hz), an oxymethine at δH 5.55 (dd, J = 5.2, 11.1 Hz), as well as three methyl signals 
including two methoxy singlets at δH 3.65 and 3.84  and a doublet methyl at δH 1.17 (d, J 
= 6.4 Hz). Its 13C NMR spectrum (Figure 3.17, Table 3.8) exhibited the resonances of 22 
carbons suggesting a diterpene skeleton. The carbon signals appearing at δC 108.1 (C-14), 
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123.5 (C-13), 140.5 (C-16) and 144.6 (C-15) and correlating on the HSQC spectrum 
(Figure 3.18) with the protons at δH 6.47 (d, J = 1.3 Hz) and 6.78 (d, J = 1.3 Hz) could be 
attributed to those of the substituted furan ring. One oxymethine at δC 71.2 as well as 
seven quaternary carbons including three carbonyl ester groups at δC 165.3, 166.3 and 
172.1 and a ketone carbonyl at δC 185.7 were also observed in the 13C NMR spectrum. 
Assignment of the 1H and 13C NMR data of 153 supported by its 2D NMR correlations 
(Figures 3.18-3.21) suggested an ent-clerodane diterpene skeleton (Li et al., 2016). The 
HMBC spectrum revealed that the two carbonyls at δC 165.3 and 166.3 correlating with 
the methoxy signals at δH 3.84 and 3.65, respectively, could be at C-18 and C-19, while 
the carbonyl at δC 172.1 could be attributed to that of a lactone moiety and assigned the 
position C-20. The other carbonyl at δC 185.8 could be identified to that of a conjugated 
carbonyl and assigned to position C-2 by comparison of the NMR data of 153 with those 
published for megalocarpoidolide D (Ndunda et al., 2016). All the 1H and 13C NMR data 
of 153 and the 1H-13C long-range correlations (Figure 3.16) were in good agreement with 
those of the β-substituted furanoclerodane, megalocarpoidolide D, isolated from the roots 
of Croton megalacarpoides (Ndunda et al., 2016). Furthermore, analysis of the NOESY 
spectrum (Figure 3.20) showed a strong correlation between H-12 and H-1 confirming 
the β-orientation of H-12 (Bautista et al., 2012). Thus, compound 153 was identified as 
megalocarpoidolide D. 
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Figure 3.15 ESI-MS spectrum of 153 
 
 
 
Figure 3.16 1H NMR (300 MHz, CDCl3) of 153 
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Figure 3.17 13C NMR (75 MHz, CDCl3) and key 
1H-1H NOESY (↔) and HMBC (→) 
correlations of 153 
 
 
 
Figure 3.18 HSQC spectrum of 153 
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Figure 3.19 1H-1H COSY spectrum of 153 
 
 
 
 
Figure 3.20 HMBC spectrum of 153 
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Figure 3.21 1H-1H NOESY spectrum of 153 
 
 
3.3.1.5 Structure elucidation of 12-epi-megalocarpoloide D (154) 
Compound 154 was isolated as a white amorphous powder, [α]D25 +81.7 (c 0.0018, 
MeOH). Its molecular formula C22H22O8 was determined from the pseudomolecular ion 
peak at m/z 432.1650 calculated for C22H22O8NH4 [M+NH4]
+, 432.1653 from its HR ESI-
MS spectrum obtained in positive ion mode. The IR spectrum of 154 quite identical to 
that of 153, also displayed absorption stretching bands at 1715, 1767 and 1663 cm-1 
attributable to the carbonyl of ester, lactone and ketone groups, respectively. The 1H and 
13C NMR spectra (Figures 3.22-3.23) of compound 154 as well as its 2D NMR spectra 
including COSY, HSQC and HMBC were all similar to those of 153 with only slight 
differences in terms of chemical shifts (Tables 3.7-3.8). Analysis of its 1H, 13C, COSY, 
HSQC and HMBC spectral data concluded its core structure to be identical to that of 153. 
However, in the NOESY spectrum (Figure 3.24), a strong correlation observed between 
H-12 and H-17 suggested an α-orientation of H-12 and thus, established a 12R 
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configuration for 154 opposite to the 12S configuration found for 153 (Ndunda et al., 
2016). Therefore, the structure of compound 154 supported by its NOESY and HMBC 
key correlations (Figure 3.23) was established to be the C-12R epimer of 153 and named 
12-epi-megalocarpoidolide D, a new clerodane from natural source. 
 
 
Figure 3.22 1H NMR (300 MHz, CDCl3) of 154 
 
 
Figure 3.23 13C NMR (75 MHz, CDCl3) and key 
1H-1H NOESY (↔) and HMBC (→) 
correlations of 154 
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Figure 3.24 1H-1H NOESY spectrum of 154 
 
 
3.3.1.6 Structure elucidation of crotonolin A (156) and crotonolin B (157) as a mixture 
Compounds 156 and its 15-epimer 157 were isolated as a white amorphous powder 
mixture ([α]D25 0.0 (c 0.009, MeOH) with molecular formula of C22H22O10 as determined 
from their HR ESI-MS spectrum obtained in the negative ion mode, where the peak at 
m/z 445.1142 [M-H]- could be calculated 445.1140 for C22H21O10. Their FT-IR spectrum 
showed absorption bands at 3465, 1775, 1712 and 1661 cm-1 assignable to the stretch 
signals of hydroxyl and the carbonyls of ester, lactone and ketone groups, respectively. 
The 1H (Figure 3.25) and 13C NMR (Figure 3.26) spectra of the mixture of 156 and 157 
similar to those of compound 153, also suggested a clerodane skeleton (Li et al., 2016). 
The only difference between the 1H NMR of the mixture of 156 and 157 and that of 
compound 153 was the absence of the signals corresponding to the β-substituted furan 
ring protons in the 1H NMR spectrum of 156 and 157. Those furan ring protons were 
replaced by two methines doublets at δH 6.19 and 7.40 showing cross peak correlations 
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in the HSQC spectrum with carbon signals at δC 99.3 and 149.8, respectively. These two 
methines, in the HMBC spectrum showed a strong correlation with a deshielded carbon 
signal at δC 170.9. The above NMR data were similar to those of the unsaturated γ-
hydroxy-α,β-unsaturated-γ-lactone moiety present in salvidinin B, a clerodane diterpene 
isolated from Salvia divinorum (Shirota et al., 2006). The hemiacetal carbon C-15 was 
then attributed to the signal at δC 99.3, the olefinic carbon C-14 at δC 149.8, the carbonyl 
C-16 at δC 170.9 and C-13 at δC 135.0. These attributions were supported by the 3J 
correlation between the proton signal at δH 7.40 (H-14) and the carbon C-12, and 
correlations between protons H-12 and H-11β with C-13 observed in the HMBC 
experiment. However, the signals attributed to protons H-14 and H-15 were not broad 
singlets like in the case of similar molecular (Blas et al., 2004; Shirota et al., 2006; 
Maldonado et al., 2016). In addition, the two protons were not showing any correlation 
in the COSY experiment and the coupling constants of two doublets were different (6.5 
and 9.4 Hz). Therefore, it was clear that two broad singlets instead of doublets were 
present; this led to the conclusion that the obtained powder was a mixture of 15α-OH and 
15β-OH isomers. Furthermore, analysis of the NOESY spectrum showed a strong 
correlation between H-12 and H-1 suggesting a C-12S configuration. In addition, the 
optical inactivity of the mixture indicated that it was a racemic mixture. Based on their 
1H and 13C NMR (Table 3.7-3.8) and the 1H-13C long-range correlations observed in the 
HMBC spectrum (Figure 3.26), compounds 156 and 157 were identified as 2,16-dioxo-
15β-hydroxy-18,19-dimethoxycarbonyl-15,16-epoxy-ent-cleroda-1(10),3,13-trien-
20,12-olide and 2,16-dioxo-15α-hydroxy-18,19-dimethoxycarbonyl-15,16-epoxy-ent-
cleroda-1(10),3,13(16),14-tetraen-20,12-olide, two new clerodane diterpenes and were 
given the trivial names crotonolins A (158) and B (159), respectively.  
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Figure 3.25 1H NMR (600 MHz, CD3OD) of 156 and 157 
 
 
 
Figure 3.26 13C NMR (150 MHz, CD3OD) and key 
1H-1H NOESY (↔) and HMBC 
(→) correlations of 156 and 157 
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3.3.1.7 Structure elucidation of crotonolin C (158) and crotonolin D (159) as a mixture  
Compounds 158 and its epimer 159 were isolated as a white amorphous powder mixture 
([α]D25 -16.5 (c 0.0002, MeOH) with molecular formula of C22H22O10 as determined from 
their HR-ESI-MS spectra obtained in the positive ion mode, where the sodiated ion peak 
was observed at m/z 469.1120 [M+Na]+, calculated 469.1111 for C22H22O10Na. Their FT-
IR spectrum showed absorption bands at 3465, 1775, 1712 and 1670 cm-1 that could be 
assigned to the stretch signals of hydroxyl and the carbonyls of ester, lactone and ketone 
groups, respectively. Their 1H NMR and 13C NMR spectra (Figures 3.27-3.28) similar 
with those of compounds 156 and 157, also suggested a clerodane skeleton containing a 
γ-hydroxy-α,β-unsaturated-γ-lactone moiety (Shirota et al., 2006). However, the observed 
chemical shifts corresponding to the proton and carbon resonances of the lactones units 
in 158 and 159 were different from those observed for 156 and 157.  The lactone units 
158 and 159 were identified as 16-hydroxy-13-en-15,16-olides from their NMR data 
(Blas et al., 2004; Shirota et al., 2006; Maldonado et al., 2016). In this case, the 
combination of the different signals and correlations observed in the 1D and 2D NMR 
spectra confirmed the suggested structure elements. The resonances at δC 163.6 could be 
attributed to the β-carbon (C-13), δH 6.22 and δC 119.2 to the α-methine (C-14), δC 169.1 
to the lactone carbonyl (C-15), and δH 6.28 and δC 96.7 to the hemiacetalic methine (C-
16). The configuration of C-12 carbon in the compounds 158 and 159 were determined 
by NOESY experiment (Figure 3.28). A strong correlation observed in this spectrum 
between the H-12 protons and the H-1 protons suggested a C-12S orientation for both 
molecules. The 1H and 13C NMR data (Tables 3.7-3.8) of 158 and 159, in addition to the 
key HMBC correlations (Figure 3.28) observed led to their characterisation as 2,15-
dioxo-16β-hydroxy-18,19-dimethoxycarbonyl-15,16-epoxy-ent-cleroda-
1(10),3,13(16),14-tetraen-20,12-olide and 2,15-dioxo-16α-hydroxy-18,19-
dimethoxycarbonyl-15,16-epoxy-ent-cleroda-1(10),3,13(16),14-tetraen-20,12-olide 
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respectively, two clerodane diterpenes not previously described and were given the trivial 
names crotonolins C (158) and D (159), respectively.  
 
 
Figure 3.27 1H NMR (600 MHz, CDCl3) of 158 and 159 
 
 
Figure 3.28 13C NMR (150 MHz, CDCl3) and key 
1H-1H NOESY (↔) and HMBC (→) 
correlations of 158 and 159 
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3.3.1.8 Structure elucidation of crotonolin F (160) 
Compound 160 was isolated as a white amorphous powder, [α]D25 +58.4 (c 0.00025, 
MeOH. Its molecular formula C24H26O10 was determined from its HR ESI-MS spectra 
obtained in the positive ion mode where the peak at m/z 497.1443 [M+Na]+ was calculated 
for C24H26O10Na, 497.1418 Compound 160 could be identified as a β-substituted furan 
clerodane from its 1H, 13C NMR and HSQC spectra (Figures 3.29-3.31) which showed 
some similar features with those of previously identified clerodanes (Tchissambou et al., 
1990). The 1H NMR spectrum of 160 showed a couple of olefinic protons at δH 5.88 (H-
3) and 5.89 (H-2), which showed scalar coupling in the COSY spectrum, an oxymethine 
proton at δH 5.21 (H-1) as well as a vinyl methyl proton resonance at δH 1.84 (3H, t, J = 
1.2 Hz, H-17), which showed correlations in the HMBC spectrum (Figure 3.31) with the 
olefinic carbons at δC 126.0 (C-7) and 129.3 (C-8) and the quaternary carbon at δC 51.9 
(C-9). The 13C NMR spectrum revealed characteristic signals of ɤ-lactone (δC 175.7, C-
20; 71.8, C-12) and a β-substituted furan moiety (δC 124.8, C-13; 108.1, C-14; 144.2, C-
15; 139.6, C-16). The signals at δC 172.0, 170.1 and 170.7 were attributed to the carbonyls 
of two methyl esters (C-18 and C-19) and an acetoxy function respectively. In the HMBC 
spectrum, 3J long-range 1H-13C correlations could be observed between the oxymethine 
proton at δH 5.21 (H-1) and the carbonyl of the acetoxy at δC 170.7 suggesting an 
acetylation on that position C-1. Correlations were also observed between the carbon δC 
77.9 (C-4) and the protons at δH 5.21 (H-1), 3.14 (H-10) and 2.36 (H-6). In the NOESY 
spectrum, a strong correlation observed between H-12 and 3H-17 suggested that H-12 is 
on the same side as 3H-17. The correlation observed between H11β/H10 established the 
β-orientation of H-10. The NOESY experiment was not helpful to determine the position 
of the 1-acetoxy and 4-OH groups. The 1H and 13C NMR data of 160 (Tables 3.7-3.8), 
supported by its key HMBC correlations (Figure 3.30) led to its characterisation as 1*-
acetoxy-4*-hydroxy-18,19-dimethoxycarbonyl-15,16-epoxy-ent-cleroda-2,7,13(16),14-
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tetraen-20,12-olide, a new ent-clerodane diterpene not previously described and given the 
trivial name crotonolin F.  
 
 
Figure 3.29 1H NMR (600 MHz, CDCl3) of 160 
 
 
Figure 3.30 13C NMR (150 MHz, CDCl3) and key 
1H-1H NOESY (↔) and HMBC (→) 
correlations of 160 
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Figure 3.31 HSQC spectrum of 160 
 
 
 
Figure 3.32 HMBC spectrum of 160 
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3.3.1.9 Structure elucidation of 7-oxodehydroabietic acid (161) 
Compound 161 was obtained as a yellow powder and assigned the molecular formula of 
C20H26O3 on the basis of the pseudomolecular ion peak at m/z 315.1963 [M + H]
+ 
calculated for [C20H26O3 +H]
+, 315.1966 from the HR ESI-MS spectrum. Its 1H NMR 
spectrum (Figure 3.33; Table 3.7) indicated the presence of four methyls including two 
singlets at δH 1.38 and 1.29 and two doublets at δH 1.26 (J = 1.7 Hz) and 1.27 (J = 1.7 
Hz). Four methylenes and five methines including three aromatic methines at δH 7.32 (d, 
J = 8.2 Hz), 7.42 (dd, J = 2.0, 8.2 Hz) and 7.89 (d, J = 2.0 Hz) as well as a septuplet 
methine at δH 2.95, which coupled with the two methyl doublets in the COSY spectrum, 
were also observed. These observations were supported by the different correlations 
observed on the HSQC-DEPT. The 13C NMR spectrum (Figure 3.34; Table 3.8) also 
indicated the presence of seven quaternary carbons including two carbonyls at δC 198.7 
and 181.4, which could be attributed to ketone and carboxylic acid functions respectively. 
In the HMBC spectrum, long-range correlations could be observed between the methine 
proton at δH 2.95 (H-14) and the carbons at δC 132.6 (C-12), 125.1 (C-16), 23.8 (C-15) 
and 23.7 (C-17). The proton at δH 2.51 (H-6α) showed correlations with the carbons at δC 
198.7 (C-7) and 37.2 (C-10), while the H-6β proton at δH 2.76 showed correlations with 
the carbons on position C-4 (δC 46.3), C-5 (δC 43.6), C-7(δC 198.7), C-10 (δC 37.2) and 
C-19 (δC 16.2). The 1H and 13C NMR data (Tables 3.7-3.8), supported by the key HMBC 
correlations (Figure 3.33), were in good agreement with those published for 7-
oxodehydroabietic acid (Tanaka et al., 1997). Therefore, compound 161 was identified 
as 7-oxo-dehydroabietic acid. 
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Figure 3.33 1H NMR spectrum (600 MHz, CDCl3) of 161 
 
 
 
Figure 3.34 13C NMR (600 MHz, CDCl3) and key HMBC correlations of 161
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Table 3.7 1H NMR data of compounds 151-162 
Position δH (J in Hz) 
 151 152 153 154 155 156/157a 158 159 160 161 162 
1 1.92 m 6.00 dd 
(3.5, 9.3) 
6.47 d 
(1.3) 
6.47 d (1.0) 6.04 brt 
(1.9) 
6.91 d (1.2)  6.76 s 6.76 s 5.21 m  1.84 m 1.49 m 
 2.65 m - - - - - - - - - 2.31 m 
2 2.43 m  6.20 dd 
(3.1, 4.9) 
- -  4.87 t 
(2.4) 
- - -  5.89 ov 1.67 m 1.83 m 
 2.58 m - - - - - - - - 2.39 m - 
3 6.84 dd 
(4.3, 7.5) 
7.00 d 
(5.2)  
6.78 d 
(1.3) 
6.78 d (1.0) 6.70 dd 
(1.8, 2.3)  
6.80 d (1.2)  6.88 s 6.88 s 5.88 ov  1.84 m  1.62 m 
      - - - - - 1.83 m 
5       -  -  -  - 2.74  2.48 m 
6 1.12 ddd 
(3.6, 13.4, 
16.9) 
1.32 m 1.45 ddd 
(3.7, 13.3) 
1.44 ddd 
(13.5, 9.3, 
17.7) 
1.31 m  1.51 ddd (4.0, 
13.5 17.5)  
1.45 ddd 
(3.2, 13.1, 
16.9)  
1.45 ddd 
(3.2, 13.1, 
16.9) 
2.36 m 2.51 d 
(15.2) 
1.72 m 
 2.95 dt (3.3, 
6.4) 
2.95, dt 
(3.7, 
13.0)  
3.11 dt 
(3.0, 6.1) 
3.13 dt 
(13.3, 3.3) 
3.04 dt 
(3.3, 13.3)  
3.00 m   3.10, dt (3.1, 
13.0)  
3.10, dt (3.1, 
13.0) 
5.78 brt 
(3.4) 
2.76 d 
(15.2)  
2.12 m 
7 1.58 m 1.56 m   1.71 m 1.65 m 1.57 dd 
(3.6, 
14.2)   
1.66 m   1.74 m   1.74 m   -  -  4.79 d 
(3.4) 
 2.43 m 2.28 m 2.78 m 2.49 ddd 
(4.2, 13.9, 
17.1) 
2.40 m 2.66 m   2.77 m   2.77 m    - - - 
8 1.58 m 1.70 m  1.75 m 1.78 m 1.69 m  1.82 m  1.78 m  1.78 m  -  - - 
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Table 3.7 continued 
Position δH (J in Hz) 
 151 152 153 154 155 156/157a 158 159 160 161 162 
10 1.76 dd 
(2.4, 13.2) 
2.89 t 
(3.2) 
- -  -  -  -  - 3.14 m  - 
11 2.43 m 2.48 m  2.78 m 2.69 dd (8.2, 
14.3) 
2.62 dd 
(8.8, 14.3)  
2.80 m  2.59 dd 
(11.2, 14.6)  
2.81 m  2.43 dd 
(9.4, 
14.1)  
7.32 d 
(8.2)  
7.18 d 
(8.3) 
 - - 2.65 dd 
(11.1, 
14.5) 
2.94 dd (6.3, 
14.2) 
2.94 dd 
(6.2, 14.3)  
2.93 m  2.99 dd (5.3, 
14.6)  
 2.77 dd 
(7.9, 14.1) 
- - 
12 5.40 t (8.5) 5.48 t 
(8.7)  
5.55 dd 
(5.2, 11.1) 
5.57 t (7.0) 5.53 dd 
(6.4, 8.7)  
5.72 dd (5.5, 
11.1)  
5.34 dd (5.3, 
11.2)  
5.53 dd (6.7, 
10.7)  
5.50 m 7.42 dd 
(2.0, 8.2)  
7.12 dd 
(1.9, 8.2) 
14 6.41 brd 
(0.9) 
6.45 d 
(0.9)  
6.45 m 6.41 m 6.44 d 
(0.9)  
7.40/ 7.39, brs   6.22 s  6.22 s   6.46 brs  7.89 d 
(2.0)  
7.20 d 
(1.9) 
15 7.44 ov  7.49 brt 
(1.6)  
7.47 dd 
(1.5, 3.1) 
7.49 brd 
(1.6) 
7.49 dd 
(0.9, 1.6)  
6.18 /6.20, brs  - - 7.48 brt 
(1.6) 
2.95 m  2.86 m 
16 7.45 brs 7.51 brs  7.54 brs 7.45 m 7.48 brs    6.28 s   6.28 s 7.52 brs  1.26 d 
(6.4)  
1.23 d 
(6.4) 
17 1.02 d (6.4) 1.15 d 
(6.9)  
1.17 d 
(6.4) 
1.23 d (6.7) 1.17 d 
(6.7) 
1.15 d (5.8)  1.12 d (6.5)  1.11 d (6.3)   - 1.27 d 
(6.4) 
1.23 d 
(6.4) 
19       -  -  - -  1.38 s 1.28 s 
20       -  -  - -  1.29 s 1.16 s 
18-OCH3 3.71 s 3.74 s  3.84 s 3.84 s 3.76 s  3.71 s  3.85 s  3.85 s  3.78 s  - - 
19-OCH3 3.76 s 3.62 s  3.65 s 3.71 s 3.71 s  3.60 s  3.66 s  3.65 s  3.69 s  - - 
COCH3      - - - 2.04 s - - 
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Table 3.8 13C NMR data of compounds 151-162 
Position δC 
 151 152 153 154 155 156,157 158 159 160 161 162 
1 19.2 132.7  127.8 129.1 129.4  129.0 127.7  127.7  72.3  18.4  37.8 
2 26.4 125.9  185.8 185.7 64.4  187.2 186.1   185.8  126.8  37.0 18.6 
3 140.1 135.5  131.4 130.9 136.2  131.7 131.3  131.2 126.3  36.5  36.5 
4 136.5 136.3 150.7 151.3 156.1 152.4 150.7  151.0 77.9 46.3 47.1 
5 46.3 47.0  53.5 55.1 48.3  54.3 53.4 53.2 47.7 43.6  39.8 
6 32.3 31.9  33.1 33.2 31.4  33.9 32.9 32.9 28.0  37.7  31.1 
7 27.9 28.1  26.5 27.2 27.2  27.5 26.4  26.4  126.0  198.7  68.3 
8 40.2 43.1  39.7 43.7 41.7  40.0 39.1  39.1  129.3  130.6  135.9 
9 51.4 50.7  55.0 53.6 53.3  55.9 54.3 54.3 51.9  152.9  146.7 
10 51.9 50.0  155.4 155.7 151.9  156.2  155.2 154.7  43.2  37.2  37.5 
11 42.4 41.8  38.9 39.2 40.0  36.9 37.1  36.3 41.8  123.4  124.3 
12 71.9 72.1  71.2 72.0 71.8  72.4 71.5  71.5  71.8  132.6  126.7 
13 125.5 125.4  123.5 125.0 125.8  135.0 163.7  162.9  124.8  146.9  146.7 
14 108.2 108.3  108.1 107.8 107.9  149.8 119.5  118.7 108.1  125.1 128.3 
15 144.2 144.5 144.4 144.6 144.2  99.3 169.3 169.4  144.2 33.6  33.6 
16 139.5 139.4 140.5 139.7 139.3  170.9 96.7  97.2  139.6 23.8 23.9 
17 17.1 17.5  16.9 17.7 17.8  17.1  17.1  17.1  19.7  23.7  23.9 
18 166.9 166.9 165.3 165.5 166.2  166.7 164.9 164.9 172.0 181.4 182.2 
19 173.0 173.4 166.3 166.7 170.7  168.4 166.3 166.2  170.0  16.2  16.4 
20 176.3 176.6 172.1 173.1 174.8 174.0 171.1 171.6 175.7 23.6 24.1 
18-OCH3 51.7 51.8  53.0 52.9 52.0  53.3 53.0  53.0  53.5    
19-OCH3 51.8 51.7  53.2 53.1 52.6  53.7 53.5 53.2 51.1    
COCH3         170.7   
COCH3         20.7   
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3.3.2 Phytochemistry of Ruspolia hypocrateriformis 
Combination of CC, SPE, preparative TLC and RP-HPLC analyses of the methanol 
extract of the leaves of R. hypocrateriformis afforded ten compounds including six 
glycosylated flavonoids, a quindoline, two pyrrolidine alkaloids and a disaccharide. The 
compounds were identified as luteolin-7-O-β-D-apiofuranosyl-(1→2)-β-D-
xylopyranoside (163), chrysoeriol-7-O-β-D-apiofuranosyl-(1→2)-β-D-xylopyranoside 
(164), chrysoeriol-7-O-[4’’’-O-acetyl-β-D-apiofuranosyl-(1→2)]-β-D-xylopyranoside 
(165), luteolin-7-O-α-L-rhamnopynosyl-(1→2)-β-D-xylopyranoside (166), chrysoeriol-
7-O-α-L-rhamnopynosyl-(1→2)-β-D-xylopyranoside (167), luteolin 7-O-[β-D-
glucopyranosyl-(1→2)-α-L-rhamnosyl-(1→6)]-β-D-glucopyranoside (168), 10H-
quindoline (169), secundallerones B and C (170-171) and sucrose (60) (Figure 3.35). 
 
 
Figure 3.35 Structures of isolated compounds from the leaves of R. hypocrateriformis 
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3.3.2.1 Structure elucidation of luteolin-7-O-β-D-apiofuranosyl-(1→2)-β-D-
xylopyranoside (163) 
Compound 163 was isolated as a yellow amorphous powder. Its molecular formula 
C25H26O14 was determined by the peak at m/z 551.1392 calculated for [C25H26O14+H]
+, 
551.1395 and consistent with thirteen RDB, from its HR ESI-MS spectrum (Figure 3.36) 
in positive mode ion. The 1H NMR spectrum (Figure 3.38; Table 3.9) revealed 17 peaks 
belonging to a glycosylated molecule bearing two sugar moieties. The aglycone part of 
the compound was identified as luteolin by the presence of an ABX system resonating at 
δH 7.26 (d, J = 8.2 Hz), 7.49 (dd, J = 2.1, 8.2 Hz) and 7.87 (d, J = 2.1 Hz), characteristic 
of a 3,4-dihydroxylated B ring; an AX system appearing as two doublet signals at δH 6.92 
and 6.95 (J = 2.0 Hz), typical of a meta-dihydroxylated A ring, and one singlet at δH 6.89 
attributable to the H-3 proton of the luteolin C ring. The sugar moieties were identified 
by the presence of two anomeric proton signals at δH 5.58 (d, J = 7.4 Hz) and 6.52 (d, J = 
0.9 Hz). 2D NMR experiments, mainly COSY and HSQC (Figures 3.39-3.40), helped to 
assign the resonance signals belonging to the sugar moieties. COSY and TOCSY were 
useful to construct each sugar moiety and to identify proton signals belonging to the same 
sugar. This led to the identification of two pentose residues, one as β-D-apiofuranoside 
and the second as and β-D-xylopyranose by comparison of their NMR spectroscopic data 
with those reported in the literature (Koffi et al., 2013; Tagousop et al., 2017). Analysis 
of the HMBC spectrum (Figure 3.41) revealed that the two sugars were linked together. 
3J long-range correlations were observed between the proton H-1’’’ (δH 6.52) of the 
apiose and the carbon C-2’’ of the xylose (δC 77.0 ppm), and between the proton H-2’’ 
(δH 4.49) of the xylose and the carbon C-1’’’ (δC 110.5) of the apiose. Other long-range 
correlations observed between the proton H-1’’ (δH 5.58) of the xylose and the carbon C-
7 (δC 163.3) of the luteolin aglycone and between the proton H-8 (δH 6.95) of the aglycone 
and the anomeric carbon (δC 100.3, C-1’’) of the xylose confirmed the attachment of the 
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diglycoside unit on the carbon C-7 of the aglycone. All the 1H and 13C NMR data of 163 
(Tables 3.9-3.10), as well as the key HMBC correlations (Figure 3.37) identified 163 as 
luteolin 7-O-[β-D-apiofuranosyl-(1→2)]-β-D-xylopyranoside, a glycosylated flavone 
previously isolated from two Acanthaceae species i.e. Graptophyllum grandulosum and 
Justicia secunda (Koffi et al., 2003; Tagousop et al., 2017). 
 
 
Figure 3.36 ESI-MS spectrum of 163  
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Figure 3.37 Key HMBC correlations of 163 
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Figure 3.38 1H NMR (600 MHz, Pyr-d5) of 163 
 
  
 
Figure 3.39 1H-1H COSY spectrum of 163 
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Figure 3.40 HSQC spectrum of 163 
 
 
 
Figure 3.41 HMBC spectrum of 163 
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3.3.2.2 Structure elucidation of chrysoeriol-7-O-β-D-apiofuranosyl-(1→2)-β-D-
xylopyranoside (164) 
Compound 164 was isolated as a yellow amorphous powder. Its molecular formula 
C26H28O14 was determined from the sodiated ion peak at m/z 587 [M+Na]
+ in its ESI-MS 
spectrum in positive mode ion. Its 1D and 2D NMR spectra similar to those of 163 
suggested a luteolin diglycoside skeleton. The only difference was the presence of an 
additional signal on the 1H NMR (Figure 3.42, Table 3.9) of 164 of a singlet attributable 
to a methoxy group at δH 3.78. This was confirmed by the cross peak correlation observed 
on its HSQC spectrum between this signal and the carbon resonating at δC 55.8. In the 
HMBC spectrum, a 3J long-range correlation was observed between the signal of the 
methoxy proton and a carbon resonating at δC 148.5 corresponding to the carbon C-3’ of 
the luteolin skeleton. Therefore, the aglycone in compound 164 was identified as 3’-
methoxyluteolin or chrysoeriol. All the 1H and 13C NMR data of 164 (Tables 3.9-3.10), 
and the key long-range correlations observed in the HMBC spectrum (Figure 3.42) led to 
its identification as chrysoeriol-7-O-β-D-apiofuranosyl-(1→2)-β-D-xylopyranoside or 
granduloside A, a flavonoid previously isolated from Graptophyllum grandulosum 
(Tagousop et al., 2017). 
 
 
3.3.2.3 Structure elucidation of chrysoeriol-7-O-[4’’’-O-acetyl-β-D-apiofuranosyl-
(1→2)]-β-D-xylopyranoside (165)  
Compound 165 was also isolated as a yellow amorphous powder. Its molecular formula 
C28H30O15 was determined by the peak at m/z 629 [M+Na]
+ in its ESI-MS spectrum in 
positive mode ion. Its 1D and 2D NMR spectra similar to those of 164 also suggested a 
chrysoeriol diglycoside skeleton. The only difference was the presence of an additional 
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signal on the 1H NMR (Figure 3.43, Table 3.9) of 165 of a singlet at δH 1.93 (3H) 
attributable to the methyl protons of an acetoxy function. This was confirmed by the cross 
peak correlation observed on its HSQC spectrum between this methyl signal and the 
carbon resonating at δC 19.2. These observations were supported in the HMBC spectrum 
(Figure 3.43), by the 2J correlations observed between the methyl signal at δH 1.93 and 
the deshielded carbon signal at δC 171.1 attributable the carbonyl of the acetoxy function. 
Another correlation observed between the 2H-4’’’ protons (δH 4.08) of the apiose and the 
carbonyl carbon (δC 171.1) established an acetylation of the alcohol function on position 
C-4’’’ of the apiose moiety. Thus, all the 1H and 13C NMR data of 167 (Tables 3.9-3.10), 
in addition to the key HMBC correlations observed (Figure 3.43) led to its identification 
as chrysoeriol-7-O-[4’’’-O-acetyl-β-D-apiofuranosyl-(1→2)]-β-D-xylopyranoside or 
granduloside B, previously isolated from Graptophyllum grandulosum (Tagousop et al., 
2017). 
 
 
3.3.2.4 Structure elucidation of luteolin-7-O-α-D-rhamnopynosyl-(1→2)-β-D-
xylopyranoside (166)  
Compound 166 was isolated as a yellow amorphous powder. Its molecular formula 
C26H28O14 was confirmed from its HR ESI-MS spectrum (Figure 3.44) in positive mode 
ion, where the sodiated ion peak was observed at m/z 587.1378, calculated for 
[C26H28O14+Na]
+, 587.1377, consistent with thirteen RDB. The 1H NMR spectrum 
(Figure 3.45, Table 3.9) of 166 revealed a glycosylated flavone skeleton with the aglycone 
moiety clearly identifiable as luteolin. The only difference between the 1H NMR spectrum 
of 166 with that of 163 was the resonance signals attributable to the sugar moieties. The 
1H NMR spectrum of 166 exhibited characteristic peaks belonging to two anomeric 
protons at δH 5.62 (d, J = 7.5 Hz) and 6.38 (d, J = 1.6 Hz) and a doublet methyl at δH 1.78 
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(J = 6.1 Hz) showing a cross peak correlation in the HSQC spectrum (Figure 3.46) with 
the carbon signal resonating at δC 18.6 suggesting a rhamnose as one of the glycosylic 
unit. Complete assignment of the protons and carbons of the sugar units was achieved by 
analysis of COSY, HSQC, HMBC and TOCSY spectra of 166. The sugars were identified 
β-D-xylopyranose and α-L-rhamnose with their anomeric protons resonating at δH 5.62 
(d, J = 7.5 Hz) and 6.38 (d, J = 1.6 Hz) respectively, by comparison of their chemical 
shifts with those reported in the literature (Osterdahl, 1979; Beier and Mundy, 1980; 
Agrawal, 1992). The HMBC spectrum (Figure 3.47) showed a correlation between the 
proton H-1’’ (δH 5.62) of the xylose and the carbon C-7 (δC 163.2) of the aglycone, 
confirming its direct attachment to the luteolin skeleton. Other correlations observed 
between the proton H-1’’’ (δH 6.38) of the rhamnose and the carbon C-2’’ of the xylose 
(δC 77.4) and between the proton H-2’’ (δH 4.47) of the xylose and the carbon C-1’’’ (δC 
102.3) of the rhamnose confirmed attachment of the rhamnosyl unit on the carbon C-2’’ 
of the xylose. Thus, all the 1H and 13C NMR data of 166 (Tables 3.9-3.10), in additition 
to the keys 2D correlations observed (Figure 3.45) led to its characterisation as luteolin-
7-O-α-L-rhamnopynosyl-(1→2)-β-D-xylopyranoside, a new flavone diglycoside from 
natural source and was given the trivial name justicialoside A.  
 
Figure 3.44 ESI MS spectrum of 166  
139 
 
 
 Figure 3.42 1H NMR (600 MHz, CD3OD) and key HMBC correlations of 164  
 
 
 
Figure 3.43 1H NMR (600 MHz, CD3OD) and key HMBC correlations of 165  
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Figure 3.45 1H NMR (600 MHz, a-CD3OD, b-Pyr-d5) and key HMBC correlations of 
166 
 
 
Figure 3.46 HSQC spectrum of 166 
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Figure 3.47 HMBC spectrum of 166  
  
 
3.3.2.5 Structure elucidation of chrysoeriol-7-O-α-L-rhamnopynosyl-(1→2)-β-D-
xylopyranoside (167) 
Compound 167 was isolated as a yellow amorphous powder. Its molecular formula 
C27H30O14 was determined from its HR ESI-MS spectrum in positive mode ion by the 
peak at m/z 601.1533 calculated for [C27H30O14+Na]
+, 601.1528 consistent with thirteen 
RDB.  Its 1D and 2D NMR spectra, similar to those of 166, also suggested a luteolin 
diglycoside skeleton. The only difference was the presence of an additional signal in the 
1H NMR (Figure 3.48, Table 3.9) of 167 of a singlet attributable to a methoxy group at 
δH 3.99 (3H). This was confirmed by the cross peak correlation observed on its HSQC 
spectrum between this signal and the carbon resonating at δC 55.4. In the HMBC spectrum 
(Figure 3.48), a cross peak correlation observed between the signal of the methoxy proton 
and a carbon resonating at δC 147.7 confirmed its position on the C-3’ carbon of the 
luteolin skeleton. Thus, all the 1H and 13C NMR data (Tables 3.9-3.10), and the key 
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HMBC correlations of 167 (Figure 3.47) led to its identification as chrysoeriol-7-O-α-L-
rhamnopynosyl-(1→2)-β-D-xylopyranoside, a new flavone diglycoside from natural 
source and was given the trivial name justicialoside B. 
 
 
Figure 3.48 1H NMR (600 MHz, CD3OD) and key HMBC correlations of 167 
 
 
 
3.3.2.6 Structure elucidation of luteolin 7-O-[β-D-glucopyranosyl-(1→2)-α-L-
rhamnosyl-(1→6)]-β-D-glucopyranoside (168) 
Compound 168 was isolated as a yellow amorphous powder. Its molecular formula 
C33H40O20 was determined by the peak at m/z 779.2001 calculated for [C33H40O20+Na]
+, 
779.2005 and consistent with fourteen RDB, from its HR NSI-MS spectrum in positive 
mode ion. Its 1H NMR spectrum (Figure 3.49, Table 3.9) revealed that 168 was a 
glycosylated luteolin. There were three sugar moieties recognizable by the three anomeric 
proton signals appearing at δH 4.69 (d, J = 7.9 Hz), 4.72 (d, J = 1.1 Hz) and 5.27 (d, J = 
7.1 Hz). One of the sugar moieties could be identified as rhamnose by the presence of the 
characteristic methyl doublet at δH 1.19 (d, J = 6.1 Hz) (Osterdahl, 1979; Beier and 
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Mundy, 1980; Agrawal, 1992). TOCSY and COSY spectra of 168 were used to identify 
proton signals belonging to the same sugar moiety and for the construction of each sugar 
unit based on the direct 1H-1H coupling of their respective protons. Their corresponding 
carbon resonances was assigned using the HSQC spectrum. The two other sugar moieties 
could be identified as β-D-glucopyranoses based on their chemical shifts (Beier et al., 
1980). In the HMBC spectrum, correlations were observed between the anomeric proton 
at δH 5.27 (H-1’’) and the carbon signal at δC 163.0 attributable to the carbon C-7 of the 
luteolin aglycone. Other correlations could also be observed between the anomeric 
protons at δH 4.69 (H-1’’’) and 4.72 (H-1’’’’) with the carbons at δC 82.0 (C-2’’) and 66.1 
(C-6’’), respectively, of the glucopyranose unit attached to the aglycone. Thus, all the 1H 
and 13C NMR data of 168 (Tables 3.9-3.10), and the key HMBC correlations (Figure 
3.49) confirmed its identification as luteolin 7-O-[β-glucopyranosyl-(1→2)-β-rhamnosyl-
(1→6)]-β-glucopyranoside, a glycosylated flavone previously isolated from the leaves of 
Justicia secunda (Koffi et al., 2013). 
 
Figure 3.49 1H NMR (600 MHz, CD3OD) and key HMBC correlations of 168 
144 
 
3.3.2.7 Structure elucidation of secundallerones B and C (170-171) as a mixture  
Compounds 170 and its diastereoisomer 171 were isolated as brown amorphous powder 
mixture with molecular formula of C12H15NO6 determined from their HR ESI-MS 
spectrum (Figure 3.50) obtained in negative ion mode by the peak at m/z 268.0828 
calculated for [C12H15NO6-H]
-, 268.0827. The 1H NMR spectrum (Figure 3.51, Table 
3.11) of the mixture showed two set of signals each attributable to four methines including 
two aromatic singlets suggesting a 1,2,4,6-tetrasubstituted benzene ring and two 
oxymethines, one methylene and two methoxyls. These attributions were supported by 
the different correlations observed on the HSQC-DEPT spectrum of the mixture as well 
as the chemical shift of the corresponding carbons. The 1H and 13C NMR spectra of 170 
and 171 were quite similar to those published for secundellarones B and C, two 
diastereoisomeric pyrrolidone alkaloids isolated from the leaves of J. secunda (Theiler et 
al., 2014). In addition, their 1H and 13C NMR data (Table 3.11) were in good agreement 
with the data published for secundallerone B and C (Theiler et al., 2014). Thus, 
compounds 170 and 171 were identified as secundarellone B and C, respectively. 
 
Figure 3.50 ESI-MS spectrum of 170 and 171  
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Table 3.9 1H NMR data of compounds 163-168 
Position δH m (J in Hz) 
 163a 164a 165b 166a 167b 168b 
3 6.89 s 6.93 s 6.76 s 6.91 s 6.73 s 6.63 s 
6 6.92 d (2.0) 6.94 d (2.1) 6.43 d (2.1) 6.94 d (2.1) 6.46 d (2.1) 6.55 d (2.0) 
8 6.95 d (2.0) 7.11 d (2.1) 6.78 d (2.1) 6.96 d (2.1) 6.79 d (2.1) 6.79 d (2.0) 
2’ 7.87 d (2.1) 7.58 d (2.2) 7.56 d (2.0) 7.88 d (2.2) 7.55 d (1.9) 7.43 d (1.6) 
5’ 7.26 d (8.2) 7.25 d (8.3) 6.97 d (8.2) 7.25 d (8.3) 6.97 d (8.4) 6.94 d (8.1) 
6’ 7.49 dd (2.1, 8.2) 7.60 dd (2.2, 8.3) 7.58 dd (2.0, 8.2) 7.50 dd (2.2, 8.3) 7.58 dd (1.9, 8.4) 7.45 dd (1.6, 8.1) 
1’’ 5.58 d (7.4) 5.60 d (7.5) 5.17 d (7.3) 5.62 d (7.5) 5.21 d (7.3) 5.27 d (7.1) 
2’’ 4.49 m 4.47 dd (7.6, 9.0) 3.70 m 4.47 dd (7.6, 9.0) 3.69 m 3.76 m 
3’’ 4.30 ov 4.29 m 3.61 m 4.28 m 3.61 m 3.69 m 
4’’ 4.21 m 4.19 m 3.61 m 4.75 m 3.60 m 3.48 m 
5’’ 3.80 t (10.6) 3.78 m 3.48 m 3.80 m 3.49 m 3.72 m 
 4.30 ov 4.30 m 3.97 dd (4.0, 11.8) 4.31 m 3.98 m  
6’’      3.66 m 
      4.05 m 
1’’’ 6.52 d (1.8) 6.52 d (1.2)  5.49 d (1.4) 6.38 d (1.6) 5.28 d (1.5) 4.69 d (7.9) 
2’’’ 4.83 brs  4.84 brs 3.87 ov 4.80 m 3.96 m 3.25 m 
3’’’ - - - 4.54 dd (3.3, 9.3) 3.61 m 3.42 m 
4’’’ 4.21 s 4.21 brs 4.08 brs 4.32 m 3.41 t (9.6) 3.39 m 
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Table 3.9 continued 
Position δH m (J in Hz) 
 163a 164a 165b 166a 167b 168b 
5’’’ 4.45 d (9.6) 4.43 d (9.5) 3.87 ov 4.75 m 3.89 m 3.30 m 
 4.77 d (9.6) 4.76 d (9.5) 4.13 ov    
6’’’  -  1.78 d (6.1) 1.32 d (6.2) 3.59 m 
      3.67 m 
1’’’’      4.72 d (1.1) 
2’’’’      3.91 m 
3’’’’      3.73 m 
4’’’’      3.35 m 
5’’’’      3.65 m 
6’’’’      1.19 d (6.1) 
OCH3  3.78 s 4.00 s - 3.99 s  
a- ran in Pyr-d5; b- ran in CD3OD 
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Table 3.10 13C NMR data of compounds 165-170 
Position δC 
 163a 164a 165b 166a 167b 168b 
1 - - - - - - 
2 165.2 164.7 165.3 165.1 165.0 165.7 
3 106.5 104.0 103.5 104.0 103.2 102.9 
4 182.6 182.5 183.1 182.5 182.1 182.9 
5 162.6 157.6 161.3 162.4 160.9 161.5 
6 100.3 100.3 99.9 99.9 99.5 99.1 
7 163.3 163.0 162.6 163.2 162.5 163.0 
8 95.3 95.3 94.2 95.0 94.5 95.1 
9 157.6 157.6 157.6 157.4 156.8 157.6 
10 106.5 106.6 105.7 106.5 105.1 105.8 
1’ 122.3 122.3 122.0 122.3 121.5 122.2 
2’ 114.4 110.1 109.7 114.1 109.5 113.0 
3’ 147.5 148.5 148.0 147.6 147.7 149.9 
4’ 151.6 152.4 150.9 151.0 150.2 145.7 
5’ 116.6 116.7 115.4 116.5 115.3 115.9 
6’ 119.3 121.1 120.7 119.4 120.5 119.3 
1’’ 100.3 100.3 99.3 100.2 99.0 98.5 
2’’ 77.0 77.0 76.6 77.4 77.6 82.0 
3’’ 78.3 78.2 69.7 78.6 70.7 75.7 
4’’ 70.5 70.4 76.8 70.5 77.2 69.5 
5’’ 67.0 66.7 65.7 67.0 65.6 76.7 
6’’      66.1 
1’’’ 110.5 110.4 108.9 102.3 101.2 104.0 
2’’’ 77.6 77.7 77.2 72.1 70.7 74.6 
3’’’ 80.6 80.7 nd 72.4 69.7 76.4 
4’’’ 65.8 65.8 66.9 74.0 72.6 69.7 
5’’’ 75.6 75.4 74.1 69.9 68.6 76.7 
6’’’    18.6 16.9 60.7 
1’’’’      100.9 
2’’’’      70.7 
3’’’’      71.2 
4’’’’      72.6 
5’’’’      68.4 
6’’’’      16.4 
OCH3  55.8 55.0  55.4  
CH3CO   19.2    
COCH3   171.1    
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Table 3.11 1H and 13C NMR data of 170 and 171 
Position  170  171 
 δH m (J) δC  δH m (J) δC 
1 - -  - - 
2 - 176.0  - 177.4 
3 5.30 t (6.0) 81.8  5.42 d (6.4) 83.4 
4 1.80 ddd (5.9, 8.3, 14.3) 39.6  2.28 m  39.6 
 2.91 ddd (6.2, 8.5, 14.3)   2.42 dd (7.9, 8.4)  
5 4.36 t (8.4) 69.5  4.67 t (8.2) 69.2 
1’ - 115.9  - 116.5 
2’ - 148.8  - 148.9 
3’ 6.61 s 101.7  6.63 s 102.0 
4’ - 151.4  - 151.5 
5’ - 142.5  - 142.6 
6’ 6.86 s 116.3  6.81 s 115.0 
4’-OCH3 3.74 s 56.6  3.76 s 56.6 
5’-OCH3 3.83 s 56.7  3.81 s 57.3 
 
  
Figure 3.51 1H NMR (600 MHz, CD3OD) of 170 and 171
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Figure 3.52 Key 1H-1H NOESY (↔) and HMBC (→) correlations 170 and 171 
 
 
3.3.3 Phytochemistry of Pseudospondias microcarpa 
Chromatographic separation of the phytochemical constituents of the methanol and DCM 
extracts of the stem bark and leaves of P. microcarpa led to isolation of seven compounds 
(Figure 3.53). The compounds were characterised by spectroscopic means and by 
comparison of their spectral data with those of previously isolated compounds from our 
laboratory or with the literature. They were identified as trans-ferulic acid (148), 
chrysoeriol-7-O-β-D-apiofuranosyl-(1→2)-β-D-xylopyranoside (164), luteolin-7-O-α-L-
rhamnopynosyl-(1→2)-β-D-xylopyranoside (166), isovetexin (172), apigenin 7-O-β-D-
neohesperidoside (173), scopoletin (103) and pithecellobiumol B (174). All the isolated 
compounds belong to the class of phenolic compounds and their derivatives. To the best 
of our knowledge, this is the first report on the phytochemical studies of the genus 
Pseudospondias and the species P. microcarpa. The genus Pseudospondias derived from 
Spondioidae tribe of the Anarcadiaceae family (Mitchel and Daly, 2015), known to be a 
rich source of phenolic compounds including flavonoids, phenolic acid derivatives and 
tannins (Umadevi et al., 1988; Sameh et al., 2018).  
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Figure 3.53 Structures of isolated compounds from P. microcarpa 
 
 
3.3.3.1 Structure elucidation of scopoletin (103)  
Compound 103 was isolated as a light brown powder. Its molecular formula C10H8O4 was 
determined by the peak at m/z 215 [M+Na]+, from its ESI-MS spectrum obtained in 
positive mode ion. Its 1H NMR spectrum (Figure 3.54, Table 3.12) showed characteristic 
signal of H-3 (δH 6.20, d, J = 9.4 Hz) and H-4 (δH 7.90, d, J = 9.4 Hz) protons of the 
pyrone ring of coumarins (Kayser and Kolodziej, 1995), two aromatic singlet methines at 
δH 6.77 and 7.19 consistent with a tetrasubstituted aromatic ring and a methoxy signal at 
δH 3.80. In the HMBC spectrum (Figure 3.54), long-range correlations were observed 
between the olefinic proton at δH 7.90 (H-1’) and the carbons at δC 109.9 (C-2) and 149.8 
(C-6) and between the methoxy proton at δH 3.80 and the carbon at δC 145.7 (C-3). The 
1H and 13C NMR data (Table 3.12) of 103 were in good agreement with those published 
for scopoletin (Darmawan et al., 2012). Thus, compound 103 was characterised as 
scopoletin, a coumarin with a range of biological activities including antidiabetic, 
antimicrobial, anti-oxidant and antitumor (Zhao et al., 2015; Napiroon et al., 2018). 
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Table 3.12 1H (600 MHz, DMSO-d6) and 
13C NMR (150 MHz, DMSO-d6) data of 103 
Position  δH m (J in Hz) δC  Position  δH m (J in Hz) δC 
2 - 161.5  7 - 151.5 
3 6.20 d (9.4) 112.0  8 7.19 s 109.9 
4 7.90 d (9.4) 145.1  9 - 111.2 
5 6.77 103.1  10 - 145.7 
6 - 149.8  OCH3 3.80 s 56.4 
 
 
 
Figure 3.54 1H NMR (600 MHz, DMSO-d6) and key HMBC correlations of 103 
 
 
3.3.3.2 Structure elucidation of isovetexin (172) 
Compound 172 was isolated as a dark yellow amorphous powder. Its molecular formula 
C21H20O10 was confirmed by the peak at m/z 455 [M+Na]
+, in its ESI-MS spectrum 
obtained in positive ion mode. The 1H NMR spectrum (Figure 3.55, Table 3.13) showed 
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12 peaks belonging to a glycosylated molecule bearing one sugar moiety. The aglycone 
part of the compound was identified as apigenin by the presence of an A2B2 system 
resonating at δH 7.87 (2H, d, J = 8.8 Hz) and 6.95 (2H, d, J = 8.8 Hz) characteristic of the 
1,4-disubstituted B ring; a singlet at δH 6.63 attributable to the H-3 proton of the C ring 
and another singlet at δH 6.54 ppm attributable to the H-6 or H-8 proton of the A ring 
suggesting an additional substituent on that ring at one of those positions. The sugar 
moiety was characterised by the presence of the methylene protons at δH 3.75 (dd, J = 
5.3, 12.1 Hz) and 3.90 (dd, J = 2.3, 12.1 Hz) and four methines including the anomeric 
proton at δH 4.92 (d, J = 9.9 Hz), which on the HSQC spectrum (Figure 3.56) correlated 
with the carbon at δC 75.3 suggesting the direct C-C attachment of the sugar moiety to the 
aglycone ring. The observed 1H and 13C NMR data (Table 3.13) associated with the sugar 
moiety were in agreement with those published for β-D-glucose (Agrawal, 1992). In the 
HMBC spectrum (Figure 3.57), the singlet at δH 6.54 showed long-range correlations with 
the carbons at δC 105.2 (C-10), 158.7 (C-9) and 164.9 (C-7) and was therefore assigned 
to the proton at C-8 of the A ring. A 3J long-range correlations were observed between 
the anomeric proton of the glucosyl moiety (δH 4.92, H-1’’) and the carbon at δC 109.3 
(C-6), 162.0 (C-5) and 164.9 (C-7) confirming the direct attachment of the sugar carbon 
C-1’’at C-6 by a C–C linkage. All the observed NMR data (Table 3.13) were consistent 
with those published for apigenin-6-C-β-D-glucoside or isovitexin (Krafczyk et al., 2008; 
Ganbaatar et al., 2015). Thus, compound 172 was identified as isovitexin. Isovitexin has 
been identified and isolated from several genus of Anarcadiaceae and possesses a range 
of biological properties including anti-inflammatory, antispasmodic, antimicrobial and 
antinociceptive (Picerno et al., 2006; Correa et al., 2012; Abu-Reidah et al., 2015). 
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Figure 3.55 1H NMR (600 MHz, CD3OD) and key HMBC correlations of 172 
 
 
 
Figure 3.56 HSQC spectrum of 172 
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Figure 3.57 HMBC (600 MHz, CD3OD) of 172  
 
 
3.3.3.3 Structure elucidation of apigenin 7-O-β-D-neohesperidoside (173) 
Compound 173 was isolated as a dark brown amorphous powder. Its molecular formula 
C27H30O14 was determined from the peak at m/z 601 [M+Na]
+, in its ESI-MS spectrum in 
positive mode ion. Its 1H NMR spectrum (Figure 3.58, Table 3.13) suggested a 
glycosylated apigenin bearing two sugar moieties payable to the presence of two 
anomeric protons at δH 5.30 (d, J = 1.7 Hz) and 5.22 (d, J = 7.6 Hz) and the proton signals 
at δH 7.91 (2H, d, J = 8.8 Hz), 6.95 (2H, d, J = 8.8 Hz), 6.82 (1H, d, J = 2.2 Hz), 6.68 
(1H, s) and 6.48 (1H, d, J = 2.2 Hz) attributable to the apigenin aglycone. The two sugar 
moieties were identified as α-L-rhamnose and β-D-glucose by comparison of the 
observed data with those published for the respective molecules (Osterdahl, 1979; Beier 
and Mundy, 1980). In the HMBC spectrum (Figure 3.58), a correlation observed between 
the anomeric proton of the glucosyl unit (δH 5.22, H-1’’) and the carbon at δC 162.5 (C-
7) confirmed its direct attachment to the aglycone. While, the correlation of the rhamnosyl 
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anomeric proton (δH 5.30, H-1’’’) with the carbon C-2’’ of the glycosyl at δC 77.6 led to 
the fixation of the rhamnosyl unit on the carbon C-2’’ of the glycoside. The 1H and 13C 
NMR data (Table 3.13) of 173 and the key HMBC correlations (Figure 3.58) were in 
good agreement with those published for apigenin 7-O-β-D-neohesperidoside (Osterdahl, 
1979; Zhang et al., 2016). Thus, compounds 173 was identified as apigenin 7-O-β-D-
neohesperidoside, a flavone glycoside with antioxidant properties (Zhang et al., 2016).  
 
 
Figure 3.58 1H NMR (600 MHz, CD3OD) and key HMBC correlations of 173 
 
 
3.3.3.4 Structure elucidation of pithecellobiumol B (174) 
Compound 174 was isolated as a brown amorphous powder. Its molecular formula 
C10H10O4 was determined from the pseudomolecular peak at m/z 217 [M+Na]
+, in its ESI-
MS spectrum. Its 1H NMR spectrum (Figure 3.59, Table 3.14) depicted seven peaks 
which could be attributed to five methines including three aromatic methine at δH 7.58 
(dd, J = 7.3, 8.3 Hz), 6.97 (dd, J = 0.9, 8.3 Hz) and 6.96 (dd, J = 0.9, 7.3 Hz) and two 
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oxymethines at δH 4.75 (dq, J = 2.1, 6.6 Hz) and 4.50 (dd, J = 2.1, 6.3 Hz); a doublet 
methyl at δH 1.40 (J = 6.6 Hz) and a doublet proton at δH 5.71 (d, J = 6.3 Hz) which was 
attributed to the proton of a hydroxyl group as no cross peak correlation was observed for 
this signal in the HSQC-DEPT spectrum. In the HMBC (Figure 3.59), long-range 
correlations were observed between the methine at δH 4.50 (H-3) and the carbon at δC 
107.7 (C-10) and 142.8 (C-9) and between the methine at δH 7.58 (H-7) and the carbons 
at δC 142.8 (C-8a) and 160.6 (C-5). The 1H and 13C NMR data (Table 3.14) of compound 
174 were similar to those published for pithecellobiumol B (Wang et al., 2017). In 
addition, pithecellobiumol B and 174 were found to have quite identical 1H NMR spectra 
when ran in DMSO. Thus, 174 was recognised as pithecellobiumol B, a chromanone 
previously isolated from the leaves and twigs of Pithecellobium clypearia (Fabaceae) 
(Wang et al., 2017). 
 
 
Figure 3.59 1H NMR (600 MHz, DMSO-d6) and key HMBC correlations of 174 
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Table 3.13 1H (600 MHz, CD3OD) and 
13C NMR (75 MHz, CD3OD) data of 172 and 173 
Position δH m (J in Hz) δC 
 172 173 172 173 
1 - - - - 
2 - - 166.3 164.8 
3 6.63 s 6.68 s 103.9 102.7 
4 - - 183.9 182.1 
5 - - 162.0 nd 
6 - 6.48 d (2.2) 109.3 99.5 
7 - - 164.9 162.5 
8 6.54 s 6.82 d (2.2) 95.4 94.7 
9 - - 158.7 157.0 
10 - - 105.2 105.5 
1’ - - 123.1 121.4 
2’ 7.87 d (8.8) 7.91d (8.8) 129.4 128.6 
3’ 6.95 d (8.8) 6.95 d (8.8) 117.0 115.9 
4’ - - 162.8 161.3 
5’ 6.95 d (8.8) 6.95 d (8.8) 117.0 115.9 
6’ 7.87 d (8.8) 7.91d (8.8) 129.4 128.6 
1’’ 4.92 d (9.9) 5.22 d (7.6) 75.3 98.4 
2’’ 4.17 brt (9.3) 3.71 ov 72.6 77.6 
3’’ 3.49 ov 3.65 ov 80.1 77.6 
4’’ 3.47 ov 3.42 m  71.8 72.6 
5’’ 3.44 m 3.55 m 82.8 76.9 
6’’ 3.75 dd (5.3, 12.1) 3.73 m 62.8 61.1 
 3.90 dd (2.3,12.1) 3.94 m   
1’’’  5.30 d (1.7)  101.3 
2’’’  3.97 m  70.7 
3’’’  3.62 m  70.7 
4’’’  3.43 m  70.1 
5’’’  3.96 m  68.4 
6’’’  1.34 d (6.2)  16.8 
nd not determined 
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Table 3.14 1H (600 MHz, DMSO-d6) and 
13C NMR (150 MHz, DMSO-d6) data of 174 
Position δH m (J in Hz) δC  Position δH m (J in Hz) δC 
1 - -  8 6.97 dd (0.9, 8.3) 117.6 
2 4.75 dq (1.9, 6.6) 79.2  9 - 142.8 
3 4.50 dd (2.1, 6.3) 65.8  10 - 107.7 
4 - nd  2-CH3 1.40 d (6.6) 16.1 
5 - 160.6  3-OH 5.71 d (6.3) - 
6 6.96 dd (0.9, 7.3) 119.6  5-OH 10.9 brs - 
7 7.58 dd (7.3, 8.3) 137.3     
nd not determined  
 
3.3.4 Phytochemistry of Zanthoxylum leprieurii  
Silica gel CC and RP-HPLC analyses of the n-hexane and DCM extracts of the fruits of 
Z. leprieurii afforded nine compounds including five kaurane diterpenes i.e., kaurenoic 
acid  (175), xylopic acid (176), ent-kauran-16β-ol-19-oic acid (177), ent-kauran-16β-ol-
19-al (178) and ent-kauran-16β-ol (179); two flavanes i.e., dulcisflavane (180) and 
epicatechin (181); caffeic acid (114) and icariside D2 (182) (Figure 3.60)  along with a 
mixture of sterols. All the above listed compounds are here reported from the first time 
from Z. leprieurii. Compounds 114 and 180-182 have previously been reported from 
other Zanthoxylum species including Z. piperitum, Z. schinifolium (Kusuda et al., 2006; 
Fang et al., 2010). This is the first report on the occurrence kaurane diterpenoids (175-
179) in the genus Zanthoxylum. Kaurane diterpenes are mainly found in the Asteraceae, 
Annonaceae and Euphorbiaceae families among others (Garcia et al., 2007). First 
occurrence of kaurane diterpenes in the Rutaceae was the isolation of kaurenoic acid and 
its 15β-hydroxylated derivative from the genus Phebalium (Cannon et al., 1966). Several 
kauranes were later isolated from the genus Fortunella (El-Shafae and Ibrahim, 2003). 
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Diterpenes are rather rare in the Rutaceae and only a few have been reported from the 
genus Citrus, Evodia, Glycosmis and Pamburus (Dreyer and Park, 1975; Seger et al., 
1998; Garcia et al., 2007). 
 
  
Figure 3.60 Isolated compounds from the fruits of Z. leprieurii 
 
 
3.3.4.1 Structure elucidation of kaurenoic acid (175) 
Compound 175 was isolated as white crystalline powder from the hexane extract of Z. 
leprieurii. Its molecular formula C20H30O2 was determined from its HR ESI-MS spectrum 
(Figure 3.61) obtained in negative ion mode where the peak at m/z 301.2170 [M-H]- 
calculated for C20H29O2, 301.2173 was observed. The 
1H NMR spectrum (Figure 3.62, 
Table 3.15) of 175 showed characteristic signals of two tertiary methyls at δH 0.92 (s, H-
20) and 1.25 (s, H-18), two singlets at δH 4.67 and 4.72 (1H each) typical of the methylene 
protons (H-17) of an exocyclic double bond and one methine proton at δH 2.56 (brs, H-
13). The 13C NMR spectrum (Figure 3.62, Table 3.15) depicted 20 peaks which could be 
attributed to two methyls at δC 15.6 (C-20) and 28.9 (C-18); ten methylenes at δ 103.0 
(C-17), 48.9 (C-15), 41.3 (C-7), 40.7 (C-1), 39.7 (C-14), 37.8 (C-3), 33.1 (C-12), 21.8 
(C-6), 19.1 (C-2) and 18.4 (C-11); three methines at δC 57.0 (C-5), 55.1 (C-9) and 43.7 
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(C-13) and five quaternary carbons including a carboxylic acid function at δC 184.6 (C-
19) and an olefinic carbon at δC 155.9 (C-16) suggesting 175 was a diterpene (Pacheco et 
al., 2009). In the HMBC spectrum (Figure 3.64), long-range correlations could be 
observed between the olefinic protons H-17 and the carbons C-13, C-15 and C-16 and 
between the methine proton H-13 and the carbons C-8, C-12, C-15, C-16 and C-17. The 
1H and 13C NMR data (Table 3.15) of 175 and the key correlations observed (Figure 3.64) 
were in good agreement with those published for ent-kaurenoic acid (Mitscher et al., 
1983; Viera et al., 2002). Thus, compound 175 was identified as ent-kaurenoic acid, a 
kaurene diterpene with a range of biological activities including analgesic, antidiabetic, 
anti-inflammatory, antioxidant and neurological activities (Villa-Ruano et al., 2016). 
 
 
Figure 3.61 ESI-MS spectrum of 175 
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Figure 3.62 1H NMR (300 MHz, CDCl3) of 175 
 
 
 
Figure 3.63 13C NMR (75 MHz, CDCl3) and key HMBC correlations of 175 
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Figure 3.64 HMBC spectrum of 175 
 
 
3.3.4.2 Structure elucidation of xylopic acid (176)  
Compound 176 was also isolated as white crystalline powder. Its molecular formula 
C22H32O4 was determined from its HR ESI-MS spectrum by the peak at m/z 361.2375 
[M+H]+ calculated for C22H33O4, 361.2379. Its 
1H NMR spectrum (Figure 3.65, Table 
3.15) was similar to that of 175. The only difference was the presence in the 1H NMR 
spectrum of 176 of an additional methyl singlet at δH 2.26 suggesting the presence of an 
acetoxy function in the molecule, and an oxymethine at δH 5.16 (t, J = 2.5, 4.9 Hz). This 
was supported in the 13C NMR spectrum (Figure 3.66, Table 3.15) by the peaks at δC 
171.4 and 21.3 corresponding to the carbonyl and methyl of the acetoxy respectively and 
the oxymethine carbon at δC 81.6. In the HMBC spectrum (Figure 3.66), correlations 
observed between the olefinic methylene protons (H-17) and the carbons at δC 40.6 (C-
13), 81.6 (C-15) and 153.7 (C-16) and between the oxymethine H-15 and the carbons at 
δC 45.9 (C-8), 106.1 (C-17), 153.7 (C-16) and 171.4 led to the fixation of the acetoxy 
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function on the carbon C-15 at δC 81.6. The orientation of the acetoxy function on C-15 
was determined to be β-oriented using the NOESY experiment. All the 1H and 13C NMR 
data (Table 3.15) of 176 supported by the key HMBC correlations observed were in 
agreement with those published for ent-15β-acetoxy-kaur-16-en-19-oic acid or xylopic 
acid (Takahashi et al., 2001). This was further confirmed in the MS spectrum of 176 by 
the peak at m/z 301.2245 which correspond to the loss of the acetoxy function [M-
OAc+H]+. Thus, compound 176 was identified as xylopic acid, a kaurene diterpene 
widespread in the Xylopia genus of the Annonaceae family (Takahashi et al., 2001; Silva 
et al., 2015). 
 
 
 
Figure 3.65 1H NMR (300 MHz, CDCl3) of 176 
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Figure 3.66 13C NMR (75 MHz, CDCl3) and key HMBC correlations of 176 
 
 
3.3.4.3 Structure elucidation of ent-kauran-16β-ol-19-oic acid (177) 
Compound 177 was isolated as a white granular powder. Its molecular formula C20H32O3 
was confirmed from its HR ESIMS spectrum obtained in negative ion mode by the peak 
at m/z 319.2273 [M-H]- calculated for C20H31O3, 319.2279. Its 
1H NMR spectrum (Figure 
3.67, Table 3.15) was similar to that of 175. The only difference was the absence in the 
1H NMR spectrum of 177 of the olefinic methylene protons suggesting an oxidation, and 
the presence of an additional tertiary methyl singlet at δH 1.46. This was supported in its 
13C NMR spectrum (Figure 3.68, Table 3.15) by the absence of the olefinic carbons and 
the presence of a quaternary oxygenated carbon at δC 78.5 and a methyl at δC 23.2 which 
show in the HSQC spectrum cross peak correlation with the proton at δH 1.46. In the 
HMBC spectrum (Figure 3.68), long-range correlations could be observed between the 
methyl signal at δH 1.46 (H-17) and the carbons at δC 48.8 (C-13), 58.0 (C-15) and 78.5 
(C-16) and between the methine proton at δH 1.76 (H-13) and the carbons δC 78.5 (C-16), 
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58.0 (C-15), 45.4 (C-8), 26.2 (C-12) and 23.2 (C-17). The orientation of the hydroxy 
function on C-16 was determined to be β-oriented using the NOESY experiment. All the 
1H and 13C NMR data (Table 3.15) of 177 supported by the key HMBC correlations 
observed were in good agreement with those published for ent-16β-hydroxykauran-19-
oic acid (Takahashi et al., 1995). Thus, compound 177 was identified as ent-16β-
hydroxykauran-19-oic acid, previously isolated from Xylopia frutescens (Takahashi et 
al., 1995). 
 
 
3.3.4.4 Structure elucidation of ent-kauran-16β-ol (179) 
Compound 179 was isolated as white powder. Its molecular formula C20H35O was 
determined from its HR ESI-MS spectrum obtained in positive ion mode by the peak at 
m/z 290.2843 [M-H2O+NH4]
+ calculated for C20H32NH4, 290.2848. Its 
1H NMR spectrum 
(Figure 3.69, Table 3.15) was similar to that of 177. The only difference was the presence 
of an additional tertiary methyl singlet at δH 0.78 in the 1H NMR spectrum of 179. In its 
13C NMR spectrum (Figure 3.70, Table 3.15), the presence of an additional methyl signal 
at δC 21.5 and the absence of the carboxylic acid carbon were clearly visible. In the 
HMBC spectrum (Figure 3.70), long-range correlations could be observed between the 
methyl signal at δH 0.78 (H-19) and the carbons at δC 18.6 (C-2), 33.2 (C-4), 33.6 (C-18), 
42.0 (C-3) and 56.2 (C-5). All the 1H and 13C NMR data (Table 3.15) of 179, supported 
by its key HMBC correlations, were in agreement with those published for ent-kauran-
16β-ol (Morris et al., 2005). This was further confirmed in the MS spectrum of 179 by 
the peak at m/z 273.2578 [M-H2O+H]
+ arising from the loss of a water molecule due to 
the dehydration of the tertiary alcohol function. Thus, compound 179 was identified as 
ent-kauran-16β-ol, a kaurane diterpene previously isolated from sunflowers (Morris et 
al., 2005). 
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Figure 3.67 1H NMR (300 MHz, CDCl3+ drops MeOH) of 177 
 
 
 
Figure 3.68 13C NMR (75 MHz, CDCl3+ drops MeOH) and key HMBC correlations of 
177 
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Figure 3.69 1H NMR (300 MHz, CDCl3) of 179 
 
 
 
Figure 3.70 13C NMR (75 MHz, CDCl3) and key HMBC correlations of 179 
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Table 3.15 1H NMR (CDCl3, 300 MHz) and 
13C NMR (CDCl3, 75 MHz) data of 175-179 
Position δH m (J in Hz) δC 
 175 176 177a 178b 179 175 176 177a 178b 179 
1 0.75 ddd (13.0, 
12.9, 5.5) 
0.91 ddd (13.1, 
8.8, 6.2) 
0.69 ddd (15.0, 
12.0, 3.0) 
0.84 ddd (17.0, 
13.6, 4.1) 
0.67 m 40.7 40.7 40.5 39.7 40.3 
 1.76  m 1.97  m 1.76 m 1.86 m 1.76  m      
2 1.32  m 1.49  m 1.35 m 1.48 m 1.40  m 19.1 19.0 18.9 18.3 18.6 
 1.79  m 1.93  m 1.83 m 1.66 m 1.63  m      
3 0.94  m 1.08  m 0.96 m 1.05 m 1.08  m 37.8 38.8 37.3 34.2 42.0 
 2.06 dm 2.18  m 2.08 dm 2.16 dm 1.46  m      
4      43.8 43.6 48.3 48.4 33.2 
5 1.03 m 1.04  m 0.96 m 1.17 dd (2.5, 2.1) 0.97  m 57.0 56.4 56.6 56.6 56.2 
6 1.71 m 1.87  m 1.76 m 1.72 m 1.28  m 21.8 21.3 21.8 20.0 20.4 
  2.26  m  1.91 m 1.59  m      
7 1.40 m 1.50  m 1.39 m 1.52 d (3.8) 1.31  m 41.3 39.9 43.4 41.9 42.0 
   1.46 m 1.72 m 1.65  m      
8      44.2 45.9 45.0 45.1 45.3 
9 0.97 m 1.35 m 0.93 m 1.05 m 0.75 m 55.1 46.9 55.7 55.4 56.8 
10      39.6 36.3 39.4 39.3 39.3 
11 1.43 m 1.55 m 1.46 m 1.60 m 1.57 m 18.4 18.0 18.0 18.0 17.9 
  1.66 m         
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Table 3.15 continued 
Position δH m (J in Hz) δC 
 175 176 177a 178b 179 175 176 177a 178b 179 
12 1.38  m 1.61 m 1.46 m 1.53 m 1.61 m 33.1 33.2 26.6 26.6 26.9 
 1.47  m 1.73 m  1.62 m       
13 2.56 bs 2.68 bm 1.76 m 1.88 m 1.84 m 43.7 40.6 48.3 48.8 49.0 
14 1.09 m 1.29 m 1.46 m 1.64 m 1.61 m 39.7 37.7 37.9 37.7 37.6 
 1.90 d (3.7) 2.16 d (3.5) 1.83 m 1.94 m 1.93 m      
15 1.98 bs 5.16 t (2.5, 4.9) 1.46 bs 1.60 bs 1.55 bs 48.9 81.6 57.3 57.6 58.0 
16      155.9 153.7 79.3 79.3 79.3 
17 4.67 s 4.88 bs 1.12 s 1.39 s  1.38 s 103.0 106.1 23.9 24.5 24.4 
 4.72 s 4.94 d (2.6)         
18 1.25 s 1.33 s 0.93 s 1.05 s 0.83 s 28.9 28.8 28.7 24.2 33.6 
19 - - - 9.75 d (1.4) 0.78 s 184.6 184.2 180.7 205.9 21.5 
20 0.93 s 1.01 s 0.69 s 0.89 s 1.03 s 15.6 15.8 15.2 16.4 17.7 
CH3CO  2.26 s     21.3    
CH3CO       171.4    
a recorded in CDCl3+drops of MeOH;
 b recorded at 600 MHz for 1H and 150 MHz for 13C 
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3.3.4.5 Structure elucidation of dulcisflavan (180)  
Compound 180 was isolated as a brown amorphous powder. Its molecular formula 
C15H14O8 was determined from its ESI-MS spectrum obtained in positive ion mode, 
where the sodiated ion peak was observedat m/z 345 [M+Na]+. Its 1H NMR spectrum 
(Figure 3.71, Table 3.16) revealed the presence of three aromatic protons at δH 6.77 (d, J 
= 8.1 Hz), 6.81 (dd, J = 1.6, 8.1 Hz) and 6.99 (d, J = 1.6 Hz) members of a 1,3,4-
trisubstituted benzene as well as two oxygenated methines at δH 4.19 and 4.83 and a set 
of methylene protons at δH 2.75 (dd, J = 2.8, 16.5 Hz) and 2.88 (dd, J = 4.5, 16.5 Hz). 
The 13C NMR spectrum (Figure 3.72, Table 3.16) of 180 depicted thirteen peaks which 
could be assigned based on the correlation observed in the HSQC and HMBC spectra 
(Figures 3.73-3.74) to one methylene, five methines and nine quaternary carbons. In the 
HMBC spectrum (Figure 3.72), correlations could be observed between the methylene 
protons (H-4) and the carbons at δC 67.5 (C-3), 79.8 (C-2), 100.2 (C-10) and 157.6 (C-5) 
and between the oxymethine at δH 4.83 (H-2) and the carbons at δC 29.3 (C-4), 67.5 (C-
3), 115.3 (C-2’), 119.5 (C-6’), 132.5 (C-1’) and 157.3 (C-9). The 1H and 13C NMR data 
(Table 16) of 180 were in good agreement with those published for dulcisflavan 
(Deachathai et al., 2005). Thus, compound 180 was identified as dulcisflavan, a flavan 
with antioxidant activity previously isolated from the fruit of Garcinia dulcis (Deachathai 
et al., 2005).  
 
 
3.3.4.6 Structure elucidation of icariside D2 (182)  
Compound 182 was isolated as a dark brown amorphous powder. Its molecular formula 
C15H14O8 was determined from its pseudomolecular ion peak at m/z 345 [M+Na]
+ in the 
ESI-MS spectrum obtained in positive ion mode Its 1H NMR spectrum (Figure 3.75, 
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Table 3.17) suggested a glycosylated compound bearing a sugar moiety by the presence 
of an anomeric proton at δH 4.90 (d, J = 7.5 Hz). Four aromatic protons forming an A2B2 
system at δH 7.18 (d, J = 8.7 Hz) and 7.06 (d, J = 8.7 Hz) suggesting a 1,4-disubstituted 
benzene, five oxygenated methines as well as three methylenes including two oxygenated 
ones at δH 4.69 (t, J = 7.0 Hz) and 3.90 (dd, J = 2.2, 12.1 Hz) and 3.71 (dd, J = 5.5, 12.1 
Hz) were also observed. In the COSY spectrum, a chain of correlation from the anomeric 
proton at δH 4.90 to the methylenes at δH 3.90 and 3.71 led to the identification of the 
sugar moiety as β-D-glucoside. Their corresponding carbons were determined by analysis 
of the 13C (Figure 3.76, Table 3.17) and HSQC-DEPT spectra. The obtained NMR data 
of the sugar moiety (Table 3.17) were consistent with those published for β-D-
glucopyranoside (Agrawal, 1992). In the HMBC spectrum (Figure 3.76), correlations 
could be observed between the anomeric proton at δH 4.90 (H-1’) and the carbon at δC 
158.3 (C-4), 78.1 (C-5’), 78.0 (C-3’) and 71.4 (C-10) and between the methylene at δH 
3.24 (t, J=7.0 Hz) and the carbons at δC 131.7 (C-1), 130.7 (C-2, C-6) and 77.5 (C-β). All 
the 1H and 13C NMR data (Table 3.17) of 182 supported by the observed key HMBC 
correlations, were comparable with those published for 4-(2-hydroxyethyl)phenyl-β-D-
glucopyranoside or icariside D2 (Miyase et al., 1989). Thus, compound 182 was 
identified as icariside D2, a lignan glycoside with cytotoxic properties first isolated from 
Epimedium diphyllum (Berberidaceae) (Miyase et al., 1989; Hien et al., 2015).  
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Figure 3.71 1H NMR (300 MHz, CD3OD) of 180 
 
 
 
Figure 3.72 13C NMR (75 MHz, CD3OD) and key HMBC correlations of 180 
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Figure 3.73 HSQC spectrum of 180 
 
 
 
Figure 3.74 HMBC spectrum of 180 
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Table 3.16 1H (600 MHz, CD3OD) and 
13C NMR (75 MHz, CD3OD) data of 180 
Position  δH m (J in Hz) δC Position  δH m (J in Hz) δC 
1 - - 9 - 157.3 
2 4.86 ov 79.8 10 - 100.2 
3 4.19 m 67.5 1’ - 132.4 
4 2.75 dd (2.8, 16.5)  29.3 2’ 6.99 d (1.6) 115.3 
 2.88 dd (4.5, 16.5)  3’ - 145.8 
5 - 157.3 4’  145.9 
6 - 132.4 5’ 6.77 d (8.1) 115.9 
7 - 157.6 6’ 6.81 dd (1.6, 8.1) 119.5 
8 - 157.9    
 
 
 
 
Figure 3.75 1H NMR (600 MHz, CD3OD) of 182 
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Figure 3.76 13C NMR (75 MHz, CD3OD) and key HMBC correlations of 182 
 
 
Table 3.17 1H (600 MHz, CD3OD) and 
13C NMR (75 MHz, CD3OD) data of 182 
Position  δH m (J in Hz)  δC  Position  δH m (J in Hz) δC 
1   131.7  3’ 3.47 ov 78.0 
2 7.18 d (8.7)  130.7  4’ 3.40 ov 71.4 
3 7.06 d (8.7)  118.0  5’ 3.44 ov 78.1 
4   158.3  6’ 3.71 dd (2.2, 12.1) 62.5 
5 7.06 d (8.7)  118.0   3.90 dd (5.5, 12.1)  
6 7.18 d (8.7)  130.7  C-α 3.24 t (7.0) 33.5 
1’ 4.90 d (7.5)  102.4  C-β 4.69 t (7.0) 77.5 
2’ 3.46 ov  74.9     
 
 
 
176 
 
3.3.5 Phytochemistry of Zanthoxylum zanthoxyloides 
Preparative RP-HPLC and TLC analyses of the DCM and MeOH extracts of the fruits Z. 
xanthoxyloides afforded fourteen compounds including eight quinoline alkaloids, 
skimmianine (55), atanine (128), N-methylplatydesminium cation (183), isoplatydesmine 
(184), myrtopsine (185), ribalinine (186) and N-methylatanine (187); five alkamides, 
trans-fagaramide (79), zanthoamides G-I (188-190) and; a lignan, sesamin (54); and two 
flavanones, hesperidin (59) and hesperetin (191) (Figure 3.77). Compounds 188-190 are 
new alkamides, whilst compounds 183-187 are here reported for the first time from Z. 
zanthoxyloides.  
 
Figure 3.77 Structures of isolated compounds from the fruits of Z. zanthoxyloides 
 
 
3.3.5.1 Structure elucidation of skimmianine (55) 
Compound 55 was isolated as white needles. Its molecular formula C14H13NO4 was 
determined from its HR ESI-MS spectrum (Figure 3.78) obtained in positive ion mode, 
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where the pseudomolecular ion peak was observed at m/z 260.0919 [M+H]+ calculated 
for C14H13NO4H, 260.0917. Its 
1H NMR spectrum (Figure 3.79, Table 3.18) showed 
characteristic signals of three methoxy groups at δH 3.89 (OCH3-8), 4.02 (OCH3-7) and 
4.49 (OCH3-4) and four aromatic methines at δH 7.28 (d, J = 2.6 Hz, H-1’), 7.36 (d, J = 
9.4 Hz, H-6), 7.75 (d, J = 2.6 Hz, H-2’) and 8.05 (d, J = 9.4 Hz, H-5). Its 13C NMR (Figure 
3.80, Table 3.18) revealed 14 signals attributable to three methoxy, four methines and 
seven quaternary carbons including the deshielded signal at δC 164.6 suggesting the 
presence of an amide in the molecule. Analysis of the different correlations present in the 
HMBC spectrum (Figure 3.80) revealed the core structure of the molecule to be quinoline 
alkaloid. The 1H and 13C NMR data (Table 3.18) of 55 were in good agreement with those 
published for skimmianine (Chakravarty et al., 1999). Thus, compound 55 was identified 
as skimmianine, a common quinoline alkaloids in the Rutaceae family (Adamska-
Szewczyk et al., 2016). 
 
 
Figure 3.78 ESI-MS spectrum of 55 
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Figure 3.79 1H NMR (300 MHz, CD3OD) of 55 
 
 
 
Figure 3.80 13C NMR (75 MHz, CD3OD) and key HMBC correlations of 55 
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3.3.5.2 Structure elucidation of N-methylplatydesminium cation (183) 
Compound 183 was isolated as a dark yellow amorphous powder. Its molecular formula 
C16H20NO3 was determined from its HR ESI-MS spectrum by the peak at m/z 274.1440 
[M]+ calculated for C16H20NO3, 274.1438. Its 
1H NMR spectrum (Figure 3.81, Table 
3.18) showed characteristic signals of an ortho-disubstituted benzene ring at δH 8.32 (d, 
J = 9.0 Hz), 8.03 (ov), 7.96 (ov) and 7.71 (td, J = 6.0, 9.0 Hz). Four methyl singlets 
including two deshielded methyls at δH 4.11 and 4.53; a methylene at δH 3.97 (dd, J = 6.0, 
15.0 Hz) and an oxymethine at δH (dd, J = 6.0, 15.0 Hz) were also observed. Analysis of 
its 13C NMR (Figure 3.82, Table 3.18) led to the identification of 16 signals which could 
be attributed to four methyls including an N-methyl at δC 33.0 (δH 4.11); a methylene at 
δC 28.6; five methines including an oxymethine at δC 94.3 and six quaternary carbons 
including the deshielded signal at δC 166.1 suggesting the presence of an amide in the 
molecule. In the HMBC spectrum, correlations observed between the methyl signals at 
δH 1.25 (3H-4’) and 1.42 (H-5’) with the carbons at δC 23.4 or 24.6 (C-4’ or C-5’), 70.5 
(C-3’) and 94.3 (C-2’) suggested they were in geminal position on the carbon C-3’ and 
the entire group fixed on C-2’. Correlations observed between the methyl at δH 4.11 (N-
CH3) and the carbons at δC 136.7 (C-10) and 166.1 (C-2) confirmed its position on the 
nitrogen atom. The proton H-2’was determined to be β-oriented due to the observed 
coupling constants (J = 6.0, 15.0 Hz) with the adjacent methylene 2H-1’.  All the 1H and 
13C NMR data (Table 3.18) of 183 were in good agreement with those published for N-
methylplatydesminium cation (Boyd and Grundon, 1967; Boyd et al., 2007). Thus, 
compound 183 was identified as N-methylplatydesminium cation, a quaternary quinoline 
alkaloid first isolated from Skimmia Japonica (Rutaceae) (Boyd and Grundon, 1967). 
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Figure 3.81 1H NMR (300 MHz, CD3OD) of 183 
 
 
 
Figure 3.82 13C NMR (75 MHz, CD3OD) and key HMBC correlations of 183 
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3.3.5.3 Structure elucidation of isoplatydesmine (184) 
Compound 184 was isolated as yellow amorphous powder. Its molecular formula 
C15H17NO3 was determined from its HR ESI-MS spectrum obtained in positive ion mode 
by the peak at m/z 260.1284 [M+H]+ calculated for C15H17NO3H, 260.1281. Its 1D and 
2D NMR spectra were similar to those of 183. The only difference was the absence in the 
1H NMR spectrum (Figure 3.83, Table 3.18) of 184 of the methoxy proton signal present 
in that of 183 suggesting a demethylation on position C-4. This was further confirmed by 
the different 13C chemical shifts in the 13C NMR (Figure 3.84) especially the carbon C-4 
which appeared at δC 172.6 as well as the key correlations observed in its HMBC spectra 
(Figure 3.84). Therefore, compound 184 was identified as isoplatydesmine and all its 1H 
and 13C NMR data (Table 3.18) were in good agreement with the published data (Boyd 
and Grundon, 1967; Boyd et al., 2007). 
 
 
Figure 3.83 1H NMR (600 MHz, acetone-d6) of 184 
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Figure 3.84 13C NMR (150 MHz, acetone-d6) and key HMBC correlations of 184 
 
 
3.3.5.4 Structure elucidation of ribalinine (186) 
Compound 186 was isolated as yellow amorphous powder. Its molecular formula 
C15H17NO3 was determined from its HR ESI-MS spectrum obtained in positive ion mode 
by the peak at m/z 260.1284 [M+H]+ calculated for C15H17NO3H, 260.1281. Its 1D and 
2D NMR spectra were very similar to those of 184. The only difference was the chemical 
shifts observed for the C-3 side chain. In the 1H NMR spectrum (Figure 3.85, Table 3.18) 
of 186, the H-2’ proton (δH 3.91, dd, J = 5.0, 5.6 Hz) was found to be shielded compared 
to the corresponding proton in 184. In the 13C NMR spectrum (Figure 3.86, Table 3.18), 
the signal of carbon C-3’ (δC 84.3) bearing the two gem-methyls was deshielded while 
that of C-2’ (δC 69.0) was shielded compared to the values observed for the same carbons 
in 184. This observation suggested a six membered side ring. The 2’-OH was determined 
to be β-oriented due to the small coupling constants (J = 5.0, 5.6 Hz) for its coupling with 
the 2H-1’ protons. Therefore, compound 186 was identified as ribalinine (Corral and 
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Orazi, 1967). Its 1H and 13C NMR data (Tables 3.21-3.22) were in good agreement with 
the published data (Corral and Orazi, 1967; Boyd et al., 2007). 
 
 
Figure 3.85 1H NMR (300 MHz, CD3OD) of 186 
 
 
 
Figure 3.86 13C NMR (75 MHz, CD3OD) and key HMBC correlations of 186 
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3.3.5.5 Structure elucidation of atanine (128) 
Compound 128 was isolated as yellow amorphous powder. Its molecular formula 
C15H17NO2 was determined from its HR ESI-MS spectrum obtained in positive ion mode 
by the peak at m/z 244.1337 [M+H]+ calculated for C15H17NO2H, 244.1338. Its 1D and 
2D NMR spectra similar to those of 183 also suggested a quinoline skeleton. The 
chemical shifts observed for the C-3 side chain in 128 suggested an open cycle compared 
to the previous isolated quinolones. In addition, the absence of the N-methyl signal in the 
1H NMR spectrum (Figure 3.87, Table 3.18) of 128 was clearly visible. The methine 
signal appearing at δH 5.25 showing cross peak correlation in the HSQC-DEPT spectrum 
with the carbon at δC 122.7 was attributed to H-2’. In the HMBC spectrum (Figure 3.87), 
correlations observed between the two gem-methyls (δC 25.8, C-4’; 18.0, C-5’; δH 1.71, 
H-4’; 1.82, H-5’) with the carbons at δC 18.0 or 25.8 (C-5’ or C-4’), 122.7 (C-2’) and 
133.3 (C-3’) suggested the C-3 side chain to be a dimethylallyl moiety. The 1H and 13C 
NMR data (Table 3.18) of 128 were in good agreement with those published for atanine 
(Brown, 1980). Thus, compound 128 was identified as atanine, a quinolone alkaloid first 
isolated from Z. zanthoxyloides by Eshiett and Taylor (1968). 
 
Figure 3.87 1H NMR (600 MHz, CD3OD) and key HMBC correlations of 128 
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3.3.5.6 Structure elucidation of N-methylatanine (187) 
Compound 187 was isolated as yellow amorphous powder. Its molecular formula 
C16H19NO2 was determined from its HR ESI-MS spectrum obtained in positive ion mode 
by the peak at m/z 258.1494 [M+H]+ calculated for C16H19NO2H, 258.1494. Its 1D and 
2D NMR spectra were very similar to those of 128. The only difference was the presence 
in the 1H NMR spectrum (Figure 3.88, Table 3.18) of 187 of a singlet methyl at δH 3.74 
attributable to N-methyl. This attribution was confirmed in the HMBC spectrum (Figure 
3.88) by the correlation between the N-methyl protons and the carbons at δC 139.0 (C-10) 
and 164.5 (C-2). Thus, 187 was identified as N-methylatanine and all its 1H and 13C NMR 
data (Table 3.18) were in good agreement with the published data (Brown, 1980). 
 
 
Figure 3.88 1H NMR (600 MHz, CDCl3) and key HMBC correlations of 187 
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Table 3.18 1H and 13C NMR data of 55, 128, 183-184 and 186-187 
Position δH m (J in Hz) δC 
 55 128 183 184 186 187 55 128 183 184 186 187 
1       - - - - - - 
2       164.6 164.3 166.1* 161.2 156.8 164.5 
3       101.9 122.7 103.4 98.0 98.4 122.6 
4       157.8 162.1 163.1 172.6 nd  159.8 
5 8.05 d 
(9.4) 
7.82 dd (1.0, 
8.1) 
8.32 d (9.0) 8.31 dd (1.4, 
7.9) 
8.32 dd (1.4, 
7.9) 
7.84 dd (1.4, 
7.9) 
118.3 124.0 124.2 125.8 124.1 123.4 
6 7.36 d 
(9.4) 
7.29 ddd (1.2, 
7.1, 8.1) 
7.71 td (6.0, 
9.0) 
7.34 ddd (1.0, 
7.0, 7.9) 
7.40 m 7.27 m 111.9 123.5 126.5 122.0 126.5 121.8 
7  7.53 ddd (1.3, 
7.1, 8.3) 
7.96 ov 7.65 ddd (1.5, 
6.4, 8.4) 
7.75 ov 7.56 td (1.4, 
7.2, 8.4) 
152.4 131.4 133.5 130.7 133.2 130.0 
8  7.36 d (8.2) 8.03 ov 7.63 brd (8.4) 7.75 ov 7.39 d (8.4) 104.9 116.6 116.3 114.8 116.6 114.1 
9       114.6 117.0 119.5 118.0 124.4 117.8 
10       104.4 142.1 136.7 139.1 140.7 139.0 
1’ 7.28 d 
(2.6) 
3.37 ov 3.97 dd (6.0, 
15.0) 
3.13 dd (7.4, 
16.6) 
2.74 dd (5.6, 
16.5)  
3.43 d (6.8) 104.9 24.2 28.6 27.3 26.7 24.3 
    3.17 dd (9.6, 
16.6) 
2.96 dd (5.0, 
16.5) 
       
2’ 7.75 d 
(2.6) 
5.25 m  5.25 dd (6.0, 
15.0) 
4.98 dd (9.6, 
7.4)  
3.91 dd (5.0, 
5.6) 
5.28 m  143.9 122.7 94.3 91.5 69.0 121.5 
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Table 3.18 continued 
Position δH m (J in Hz) δC 
 55 128 183 184 186 187 55 128 183 184 186 187 
3’  - - - - - - 133.3 70.5 70.1 84.3 132.5 
4’  1.71 1.25 s 1.29 s 1.48 s 1.71 s - 25.8 23.4 24.2 25.3 25.7 
5’  1.82 s 1.42 s 1.38 s 1.50 s 1.83 s - 18.0 24.6 24.9 22.1 18.0 
N-CH3  - 4.11 s 3.78 s 3.82 s 3.74 s  - - 33.0 30.7 31.1 29.7 
4-OCH3 4.49 s 3.96 s 4.53 s -   58.7 62.4 59.0 - - 61.7 
7-OCH3 4.02 s - - -   55.8      
8-OCH3 3.89 s - - -   60.4      
*Values determined from the HMBC spectrum 
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3.3.5.7 Structure elucidation of zanthoamides G (188) 
Compound 188 was obtained as white viscous liquid. Its molecular formula was 
determined as C18H29NO4 from its HR ESI-MS spectrum (Figure 3.89) by the 
pseudomolecular ion at m/z 346.1984 calculated 346,1989 for its sodium adduct [M + 
Na]+ (C18H29NO4Na). The 
1H NMR spectrum of 188 (Figure 3.90, Table 3.19) exhibited 
14 signals corresponding to 24 protons including the signals of the proton of a secondary 
amine at δH 8.56 (1H, brs), six olefinic protons at δH 7.12 (1H, dd, J = 10.4, 15.1 Hz), 
6.60 (1H, dd, J = 11.1, 15.1 Hz), 6.27 (1H, dd, J = 10.8, 15.1 Hz), δ5.99 (1H, d, J = 15.0 
Hz), 5.70 (1H, dd, J = 6.4, 15.0 Hz) and 5.44 (1H, m, J = 7.4 Hz), signals at δH 1.18 (6H, 
brs) and 1.11 (3H, d, J = 6.3 Hz) for three methyls, two oxygenated methines at δH 3.58 
(1H, m, J = 6.3 Hz) and 3.91 (1H, m, J = 6.4 Hz) and three methylene signals including 
a broad singlet at δH 3.27 and two double doublets at δH 2.29 (J = 7.0, 13.2 Hz) and 2.35 
(J = 7.3, 14.8 Hz). Overlapping signals occurring between δH 6.0-6.15 ppm resulting from 
two olefinic protons resonances were also observed. The 13C NMR spectrum (Figure 3.91, 
Table 3.19) revealed signals for 18 carbons attributable to three methyls (δC 27.2 x 2, δC 
18.8), three methylenes with one appearing relatively downfield at δC 51.1, ten methines 
including two oxymethines at δC 77.8 and 71.7, eight olefinic methines at δC 143.0, 142.3, 
134.0, 131.7, 130.2, 129.9, 128.2 and 123.2, and two quaternary carbons including an 
amide at δC 169.4 and an oxygenated quaternary carbon at δC 71.6. The assignment of the 
carbon signals was consistent with the resonances observed in the 1H NMR experiment 
as well as the 1J 1H-13C correlations observed in the HSQC-DEPTQ spectrum (Figure 
3.92). In the 1H-1H COSY spectrum (Figure 3.93), a chain of vicinal correlations observed 
from H-2 to H-14, helped to construct one part of the compound structure as CH3-
CH=CH-CH=CH-CH2-CH2-CH=CH-CH=CH-. In the HMBC spectrum (Figure 3.94), 
correlations from δC 1.18 (H-3’ and H-4’) to carbon signals at δC 51.1 (C-1’), 71.6 (C-2’) 
and 27.2 (C3’ or C-4’), and from δC 3.27 (s, H-1’) to C-2’, C-3’ and C-4’ identified the 
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other part of the molecule as 2-hydroxy-isobutyl moiety. Further correlations in the 
HMBC spectrum from H-1’ (δH 3.27), H-2 (δH 5.99) and H-3 (δH 7.12) to C-1 (δC 169.4), 
in addition to the appearance of the methylene of the isobutyl moiety at δC 55.1, 
established that the 2-hydroxy-isobutyl moiety was linked to the nitrogen of the amide 
group and the aliphatic moiety to the carbonyl of the amide. The geometry of the double 
bond C2-C3 was deduced as trans (JH2/H3 = 15.0 Hz) like those of C4-C5, C8-C9 and C10-
C11. Compound 188 did not show any optical activity suggesting that it was obtained as 
a racemic mixture. Thus compound 188 was identified as (12RS, 13RS)-(2E, 4E, 8E, 
10E)-N-(2-hydroxy-2-methylpropyl)-12,13-dihydroxy-2,4,8,10-tetradecatetraenamide, a 
new alkamide from natural source and given the trivial name zanthoamide G. The 1H and 
13C NMR data (Table 3.19) were similar to those published for zanthoamide C isolated 
from Zanthoxylum bungeanum (Wang et al., 2016) with the only difference being the 
additional olefinic bond between C3 and C6 present in 188. 
 
Figure 3.89 ESI-MS spectrum of 188 
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Figure 3.90 1H NMR (600 MHz, CD3OD) of 188 
 
 
 
Figure 3.91 13C NMR (150 MHz, CD3OD), COSY (−) and Key HMBC (→) correlation 
of 188 
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Figure 3.92 HSQC spectrum of 188 
 
 
 
Figure 3.93 1H-1H COSY spectrum of 188 
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Figure 3.94 HMBC spectrum of 188 
 
 
3.3.5.8 Structure elucidation of zanthoamides H (189) 
Compound 189 was also obtained as white viscous liquid. Its molecular formula was 
determined as C18H29NO4 from its HR ESI-MS spectrum, where a pseudomolecular ion 
was observed as at m/z 346.1992 [M + Na]+ (calculated 346.1989 for C18H29NO4Na). The 
1H and 13C NMR spectra (Figures 3.95-3.96, Table 3.19) of 189 established it as an 
aliphatic amide, similar to 188, with the only difference being the placement of the two 
oxymethines, which were not adjacent to each other like in 188. The COSY spectrum 
(Figure 3.96) revealed scaler couplings between oxymethine at δH 4.28 (H-13) and the 
methyl at δH 1.20 (H-14) and with the olefinic proton at δH 5.73 (H-12), and the 
correlations from the other oxymethine at δH 4.10 (H-8) to the methylene at δH 1.60 (H-
7) and the olefinic proton at δH 5.68 (H-9). These correlations could be further confirmed 
from the HMBC spectrum (Figure 3.96), where correlations from H-8 to C-6 (δC 29.9), 
C-7 (δC 37.4) and C-9 (δC 137.0), and from H-13 to C-12 (δC 138.6) and C-14 (δC 23.5) 
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were observed. The geometry of the olefinic bonds were confirmed as trans from relevant 
coupling constants (JH2/H3 = 15.1, JH4/H5 = 15.2, JH9/H10 = 14.6 and JH11/H12 = 14.5). 
Compound 189 was optically inactive suggesting that it was a racemic mixture. 
Therefore, compound 189 was identified as (8RS, 13RS)-(2E, 4E, 9E, 11E)-N-(2-
hydroxy-2-methylpropyl)-8,13-dihydroxy-2,4,9,11-tetradecatetraenamide, and given the 
trivial name, zanthoamide H.  
 
 
3.3.5.9 Structure elucidation of zanthoamides I (190) 
Compound 190 had a molecular formula C18H27NO4 determined at m/z 322.2017 by HR 
ESI-MS [M+H]+ (calculated for [C18H27NO4+H]
+, 322.2013) corresponding to six double 
bonds and rings equivalent. The comparison of 1H NMR spectrum (Figure 3.97, Table 
3.19) of 190 to those of 189 clearly disclosed that 190 was also an aliphatic amide. The 
obvious difference between the two compounds was that the hydroxyl group at C-8 on 
189 was replaced by a ketone group in 190, which was confirmed by the signal at δC 202.0 
in the 13C NMR spectrum (Figure 3.98, Table 3.19) of 190. The position of the ketone 
group was confirmed using HMBC spectrum (Figure 3.98) by the correlation observed 
between this later and the protons at δH 2.48 (H-6), 6.21 (H-9), 2.79 (H-7) and 7.29 (H-
10). This was also supported by the downfield shifts of C-10 and C-12 from δC 129.8 and 
138.6 in 189 to δC 144.5 and 149.3 respectively in 190 confirming the presence of a ketone 
group nearby. The geometry of the double bonds C2-C3, C4-C5, C9-C10 and C11-C12 was 
determined as trans-configured (J = 15.0, 15.0, 15.6 and 15.1 Hz, respectively). 
Compound 190 was found to be optically active, [α]D25 = -25.6. However, the absolute 
configuration could not be determined because of paucity of this sample. Thus, compound 
190 was identified as (13*)-(2E, 4E, 9E, 11E)-N-(2-hydroxy-2-methylpropyl)-13-
hydroxy-2,4,9,11-tetradecatetraenamide and given the trivial name, zanthoamide I.  
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Figure 3.95 1H NMR (600 MHz, CD3OD) of 189 
 
 
 
Figure 3.96 13C NMR (150 MHz, CD3OD), COSY (−) and Key HMBC (→) correlation 
of 189 
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Figure 3.97 1H NMR (600 MHz, CD3OD) of 190 
 
 
 
 
 
Figure 3.98 13C NMR (150 MHz, CD3OD), COSY (−) and Key HMBC (→) correlation 
of 190 
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Table 3.19 1H (600 MHz) and 13C (150 MHz) NMR Data of zanthoamide G-I (188-190) 
1 δH m (J in Hz) δC 
 
188 189 190 188 189 190 
1 - - - 169.4 169.5 169.4 
2 5.99 d (15.0) 6.01 d (15.1) 6.01 d (15.0) 123.2 123.1 123.5 
3 7.12 dd (10.4, 
15.1) 
7.15 dd (10.7, 
15.0) 
7.13 dd (10.7, 
15.1) 
142.3 142.4 142.1 
4 6.27 dd (10.8, 
15.1) 
6.25 dd (10.7, 
15.2) 
6.26 m 130.2 130.1 130.4 
5 6.11 m 6.14 m 6.13 dt (7.0, 
15.0) 
143.0 143.4 142.2 
6 2.29 dd (7.0, 
13.2) 
2.20 m 2.48 dd (7.2, 
14.1) 
33.9 29.9 28.4 
7 2.35 dd (7.3, 
14.8) 
1.60 m 2.79 dd (7.2, 
14.5) 
28.0 37.4 39.9 
8 5.44 dd (7.2, 
15.1) 
4.10 q (6.5, 13.0) - 131.7 72.4 202.0 
9 6.07 m 5.68 dd (6.7, 
14.6) 
6.21 d (15.6) 129.9 137.0 130.2 
10 6.60 dd (11.1, 
15.1) 
6.20 m 7.29 dd (10.8, 
15.6) 
128.2 129.8 144.5 
11 5.70 dd (6.4, 
15.0) 
6.20 m 6.42 dd (10.3, 
15.1) 
134.0 131.0 128.0 
12 3.91 dd (6.4, 
12.9) 
5.73 m 6.31 m 77.8 138.6 149.3 
13 3.58 m 4.28 q (6.3, 12.5) 4.38 m 71.7 68.8 68.4 
14 1.11 d (6.3) 1.20 d (6.4) 1.22 d (6.5) 18.8 23.5 23.1 
1’ 3.27 s 3.28 s 3.27 s 51.1 51.1 51.1 
2’ - - - 71.6 71.6 71.5 
3’ 1.18 s 1.19 s 1.18 s 27.2 27.2 27.2 
4’ 1.18 s 1.19 s 1.18 s 27.2 27.2 27.2 
NH 8.56 br s 8.56 br s 8.56 br s - - - 
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3.3.5.10 Structure elucidation of hesperetin (191)  
Compound 191 was isolated as yellow amorphous powder. Its molecular formula 
C20H30O2 was determined from its HR ESI-MS spectrum (Figure 3.99) obtained in 
negative ion mode by the peak at m/z 301.2170 [M-H]- calculated for C20H29O2, 301.2173. 
Its 1H NMR spectrum (Figure 3.100, Table 3.20) revealed the presence of a methoxy at 
δH 3.88 (s); a 1,3,4-trisubstituted benzene ring formed by the protons at δH 7.06 (d, J = 
1.7 Hz), 7.00 and 6.99; two meta coupling protons at δH 5.97 (dd, J = 3.0, 16.8 Hz) and 
an oxymethine at δH 5.45 (dd, J = 3.0, 12.6 Hz) which were found to couple in the COSY 
spectrum with the methylene protons appearing at δH 2.76 (dd, J = 3.0, 16.8 Hz) and 3.16 
(dd, J = 12.6, 16.8 Hz). The 13C NMR spectrum (Figure 3.101, Table 3.20) of 191 
depicted sixteen peaks which could be assigned based on the correlation observed in the 
HSQC spectrum to one methoxy at δC 55.2; one methylene at δC 42.9, six methines 
including an oxymethine at δC 79.0 and eight quaternary carbons including the highly 
deshielded carbon at δC 196.2 suggesting a conjugated carbonyl. The 1H and 13C NMR 
data (Table 3.20) of 191 and its key HMBC correlations (Figure 301) were in good 
agreement with those described for hesperetin (EI-Shafae et al., 2002). The C-2 proton at 
δH 5.97 (d, J = 3.0, 16.8 Hz) was determined to be β-oriented due to the coupling constant 
observed from its coupling with the C-3 methylene. Thus, compound 191 was identified 
as hesperetin, a flavone commonly isolated from Citrus species (Rutaceae) (EI-Shafae et 
al., 2002; Gattuso et al., 2007).  
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Figure 3.99 ESI-MS spectrum of 191 
 
 
 
Figure 3.100 1H NMR (600 MHz, acetone-d6) of 191 
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Figure 3.101 13C NMR (150 MHz, acetone-d6) of compound 191 
 
 
 
Table 3.20 1H (600 MHz, acetone-d6) and 
13C NMR data (150 MHz, acetone-d6) of 191 
Position  δH m (J in Hz) δc  Position  δH m (J in Hz) δc 
1 - -  9 - 163.3 
2 5.45 dd (3.0, 12.6) 79.0  10 - 102.5 
3 2.76 dd (3.0, 16.8)  42.8  1’ - 132.0 
 3.16 dd (12.6, 16.8)   2’ 7.00 ov 111.6 
4 - 196.2  3’ - 147.9 
5 - 166.6  4’ - 146.7 
6 5.97 d (2.1) 95.7  5’ 7.06 d (1.7) 113.7 
7 - 164.4  6’ 6.99 ov 117.9 
8 6.00 d (2.1) 95.0  OCH3 3.88 s 55.4 
 
 
200 
 
3.4 Biogenesis and chemotaxonomic significance of isolated compounds 
Three main classes of secondary metabolites including alkaloids, diterpenes and 
flavonoids were isolated in the course of this study. 
 
3.4.1 Alkaloids 
Quinoline alkaloids (55, 128, 183-187) and alkamides (188-190) were isolated from Z. 
zanthoxyloides (Rutaceae). Zanthoxyllum is a rich source of alkaloids including acridone, 
aliphatic and aromatic amides, aporphine and benzophenantridine (Adesina, 2005; Patino 
et al., 2012).  
This is the first report on the occurrence of compounds 183-187, in addition to three new 
alkamides (189-191), in Z. zanthoxyloides. Several alkamides with structures similar to 
zanthoamides G-I (189-191) were previously reported in several Zanthoxylum species 
including Z. zanthoxyloides, Z. bungeanum, Z. syncarpum, Z. piperitum, Z. ailanthoides, 
Z. integrifoliolum, Z. schinifolium, Z. armatum, Z. tessmannii, Z. achtoum, and Z. heitzii 
(Ross et al., 2005; Wang et al., 2016; Chruma et al., 2018). N-methylplatydesminium 
catium (183) was previously isolated from Z. usambarense and Z. chalybeum (Kato et al., 
1996), isoplatydesmine (184) from Z. nididum (Ishikawa et al., 1995), myrtopsine (185) 
from Z. integrifoliolum (Ishii et al., 1982), ribalinine (186) from Z. mayu (Torres and 
Cassels, 1978), and N-methylatanine (187) from Z. beecheyanum (Cheng et al., 2004) and 
Z. rigidum (Moccelini et al., 2009). 
Quinoline alkaloids are biosynthesized from anthranilic acid, which is formed from 
chorismate and L-glutamine, while alkamides derived from the condensation of amino 
acid and/or cinnamic acid unit (Waterman, 1975). For quinoline synthesis, anthranilic 
acid is acetylated followed by cyclisation to form the basic 2,4-dihydroxyquinoline ring, 
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which may then undergo a nucleophilic addition of an isoprenyl unit on the highly 
reactive C-3 carbon to give rise to 3-(3’,3’-dimethylallyl)-4-hydroxy-2-quinolone 
(Waterman, 1975; Grundon, 1988). Subsequent modifications on the obtained quinolone 
including alkylation, cyclisation (e.g. C-2 and C-2’ or C-3’) and oxidation may lead to 
the formation of the known quinoline alkaloids such as those isolated from Z. 
zanthoxyloides in the course of this study (Figure 3.102) (Fish and Waterman, 1973; 
Waterman, 1978; Boyd et al., 2000). 
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Figure 3.102 Possible biosynthesis pattern of the quinolines isolated from Z. 
zanthoxyloides 
 
 
3.4.2 Diterpenes 
Abietane and clerodane were isolated from C. oligandrus, and kaurane from Z. leprieurii, 
respectively.  
202 
 
The genus Croton is a great natural source of diterpenes. Its phytochemical studies have 
led to the isolation of several diterpenes including clerodanes and abietanes, which 
represent about 27% and 4%, respectively, of all the diterpenes isolated (Xu et al., 2018). 
A previous study of C. oligandrus has led to the isolation and identification of clerodane, 
trachylobane and labdane type diterpenes (Abega et al., 2014).  
Regarding Z. leprieurii, this is the first report on the occurrence of kaurane diterpenes in 
Z. leprieurii, and in the genus Zanthoxylum in general. Diterpenes are rare in the 
Rutaceae, and only a few including abietane, clerodane, kaurane and labdane have been 
reported from the genera Citrus, Evodia, Fortunella, Glycosmis, Pamburus and 
Phebalium (Cannon et al., 1966; Dreyer and Park, 1975; Billet et al., 1976; Seger et al., 
1998; Luis et al., 2000; El-Shafae and Ibrahim, 2003). In addition to alkaloids, 
Zanthoxylum is known to be rich in coumarins and lignans, and contains few flavonoids 
(Adesina, 2005; Patino et al., 2012; Li et al., 2014). Alkaloids including acridone, 
alkamide, aporphine and benzophenanthridine, coumarins and lignans have been reported 
from Z. leprieurii (Adesina, 2005; Tchinda et al., 2009). In the present study, in addition 
to kauranes, two flavonoids and a lignan previously reported from other Zanthoxylum 
species, have also been identified. 
The biogenesis of diterpenes have extensively been studied. Diterpenes are now 
recognized to derive from geranylgeranyl diphosphate (GGPP) (Peters, 2010), though 
some few have been found to arise from carotene degradation (Seger et al., 1998). Acid 
catalyzed cyclisation of GGPP can give rise to a fused decalin bicylic intermediate, 
copalyl diphosphate (CPP), from which subsequent modifications including internal 
additions, rearrangements and elimination may lead to bicyclic, tricyclic and tetracyclic 
diterpenes e.g. clerodane, abietane and kaurane, respectively (Figure 3.103) (Wilson et 
al., 1976; Gershenzon and Croteau, 1993; Brunetton, 1999; Peters, 2010). Secondary 
modifications including oxidization and addition of different oxygen containing groups 
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may give rise to the range of diverse structural diterpenes occurring in nature (Gershenzon 
and Croteau, 1993) such as those isolated in the present study. 
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Figure 3.103 Summarised biosynthetic pathway toward abietane, clerodane and kaurane 
diterpenoids basic skeletons 
 
 
3.4.3 Flavonoids  
Flavonoids were isolated from J. hypocrateriformis and P. microcarpa. This is the first 
phytochemical study of P. microcarpa and the third of J. hypocrateriformis.  
Previous phytochemistry of J. hypocrateriformis have reavealed the presence of 
pyrrolidine alkaloids (Roessler et al., 1978; Neukomm et al., 1983). In the current study, 
in addition to pyrrolidine alkaloids, we have also isolated flavones. A similitude in terms 
of phytochemical constituents were found between J. hypocrateriformis and two other 
Acanthaceae species, Justicia secunda and Graphtophyllum grandulosum as all the 
compounds isolated, excluding the two new reported flavonoids 166 and 167, have also 
been reported earlier in those two species.  
Regarding P. microcarpa, two of the flavonoids isolated, 164 and 166, have also been 
identified in J. hypocrateriformis. The genus Pseudospondias is constituted of two 
species, P. microcarpa and P. longifolia, and this study constitutes the first phytochemical 
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study of the genus. Species known today within Pseudospondias genus, were once 
members of the Spondias genus (Burkill, 1985). Spondias is a rich source of phenolic 
compounds including, tannins, flavonoids and phenolic acid derivatives (Sameh et al., 
2018). Flavonoids have been reported from Spondias as well as other Anarcadiaceae 
genus e.g. Rhus from which isovitexin and several glycosylated flavones and flavonols 
have been identified and isolated (Shrestha et al., 2012; Abu-Reidah et al., 2015). 
Flavonoids are a large group of natural products. They usually occur in plants as 
glycosides (Ikan, 1991). Flavonoid subclasses are all related by a common biosynthetic 
pathway, which incorporates precursors from both the shikimate and acetate-malonate 
pathways. Condensation between p-coumarylCoA and three acetylCoA units results in 
the formation of a chalcone, the biogenetic intermediate to other structural subclasses of 
flavonoids (Figure 3.104) (Markham, 1982; Ikan, 1991; Schijlen et al., 2004). Further 
modification of the flavonoids skeleton including addition (or reduction) of hydroxyl 
groups, arylation, dimerization and glycosylation may occur at various stages resulting in 
the diverse structural known flavonoids (Markham, 1982). 
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Figure 3.104 Summarised biosynthetic pathway toward basic flavonoid skeletons isolated 
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3.5 Bio-activity of the isolated compounds 
3.5.1 Cytotoxicity of isolated compounds 
The cytotoxicity of the isolated compounds (except 114, 155, 169, 181 and sucrose) were 
evaluated against A549 (adenocarcinomic human alveolar basal epithelial), MCF7 
(human breast adenocarcinoma), PC3 (human prostate cancer) and PNT2 (human normal 
prostate epithelium) cells using the MTT assay. The obtained LC50 values are shown in 
Table 3.21. Doxorubicin was used as positive control.  
 
Table 3.21 Cell viability effect (LC50 in µM) of isolated compounds against cancer and 
non-cancer (PNT2) cells 
 Plant Cpds LC50 in µM 
 COB    A549  MCF-7  PC-3  PNT2  
7 136.8 ± 18.9 >200 172.3 ± 39.7 167.5 ± 25.3 
8 >200 >200 135.6 ± 21.1 >200 
147  >200 >200  >200  >200 
148 >200 >200 >200 106.6 ± 6.0 
149/150  >200 >200  160.9±36.2  >200 
151  106.6 ± 27.2 >200  >200  >200 
152 >200 >200 131.1 ± 10.8 >200 
153  63.8 ± 13.8 136.2 ± 22.7   >200  >200 
154   138.6 ± 22.1 171.3 ± 51.4   >200  >200 
156/157  128.6 ± 31.0 >200  111.2 ± 2.9  >200 
158/159 >200 >200 >200 >200 
160 >200 >200 153.0 ± 9.1 97.6 ± 8.9 
161 >200 >200 68.9 ± 6.6 >200 
162 >200 >200 >200 197.7 ± 14.9 
JHL 163 >200 >200 >200 >200 
164 >200 >200 146.6 ± 20.4 >200 
165 >200 >200 128.1 ± 8.5 >200 
166 >200 >200 87.1 ± 10.6 >200 
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Table 3.21 continued 
 Plant Cpds LC50 in µM 
JHC  A549  MCF-7  PC-3  PNT2  
167 >200 >200 117.4 ± 12.3 >200 
168 >200 >200 >200 >200 
170/171 >200 >200 >200 >200 
PMB and 
PML 
103 >200 >200 125.7 ± 11.8 >200 
172 >200 >200 >200 >200 
173 >200 >200 112.5 ± 9.4 >200 
174 >200 >200 180.5 ± 23.4 >200 
ZLF 175 >200 132.1 ± 14.9 33.3 ± 9.1 >200 
176 >200 >200 138.9 ± 16.0 >200 
177 82.0 ± 7.2 62.0 ± 1.8 94.4 ± 6.9 10.6 ± 3.6 
178 >200 >200 147.9 ± 14.1 >200 
179 116.8 ± 13.7 167.9 ± 10.1 >200 >200 
180 >200 >200 112.7 ± 7.5 >200 
182 >200 >200 149.5±21.9 >200 
ZZF 54 108.5 ± 22.1 >200 33.4 ± 9.8 >200 
55 113.4±0.15.8 53.7±09.5 164.7±0.21.3 104.4 ± 16.2 
59 29.5 ± 7.5 74.2 ± 17.8 51.7 ± 8.7 129.0 ± 20.3 
79 >200 >200 >200 >200 
128 112.0 ± 17.4 >200 195.3 ± 22.6 >200 
183 >200 152.2 ± 33.6 >200 >200 
184 >200 172.2 ± 31.4 >200 >200 
185 >200 >200 >200 >200 
186 >200 >200 >200 >200 
187 114.7 ± 18.3 142.5 ± 17.0 >200 >200 
188 >200 153.6 ± 32.7 >200 >200 
189 >200 >200 >200 181.6 ± 35.7 
190 >200 >200 >200 >200 
191 151.4 ± 25.4 >200 159.7 ± 28.5 >200 
 Doxy 1.3 ± 0.3 0.7 ± 0.1  16.4 ± 2.9  1.5 ± 0.3  
Data are represented as mean ± SEM (n = 3); LC50 = sample concentration that caused 
50% of cells death 
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The LC50 values of the screened compounds ranged from 29.5 to 138.6 μM (A549), 53.7 
to 172.2 μM towards MCF-7 cells, 33.3 to 195.3 μM (PC-3), and 10.6 to 197.7 μM 
(PNT2). The isolated flavonoids from JHL, PMB and PML were found to have selective 
effect on PC-3 cells. None of the isolated compounds has shown a significant cytotoxic 
effect. They have showed moderate or low cytotoxic effect at the tested concentrations. 
A pure compound to be consider as promising candidate for drug development should 
have its LC50 value below 25 μM (Choudhary and Thomsen, 2003). Among the tested 
compounds, kaurenoic acid (175) and sesamin (54) were found to exert reasonable 
cytotoxicity against PC3 with IC50 both about 33 µM. Hesperidin (59) and ent-kauran-
16β-ol-19-oic acid (177) were the only compounds with wide active spectrum, having 
effect against all the cell lines tested even on the normal prostate cells PNT2 with IC50 
129.0 ± 20.3 and 10.6 ± 3.6 μM, respectively. Hesperidin was the most active compound 
with IC50 29.5 ± 7.5, 74.2 ± 17.8 and 51.7 ± 8.7 μM against A549, MCF-7 and PC3, 
respectively.  
 
 
3.5.2 Chemopreventive activity of isolated compounds 
3.5.2.1 Cytotoxicity of the compounds against AREc32 cells 
Compounds isolated from plants extracts, which have shown potent chemopreventive 
properties, were screened to assess their chemopreventive property by evaluating their 
effect on the activation of the level of luciferase in AREc32 cells. This include compounds 
isolated from C. oligandrus and Z. zanthoxyloides. The toxicity of the compounds on the 
viability of AREc32 cells was first determined by the MTT assay to find a suitable 
concentration at which to conduct the following luciferase assay which would not cause 
significant cell death (concentrations causing more than 10% cell death, relative to control 
were not used, Table 3.22).  
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Table 3.22 Least toxic concentration (no more than 10% cells death) of isolated 
compounds against AREc32 cells 
C. oligandrus Z. zanthoxyloides 
Cpds LC10 
(µM) 
Cpds LC10 
(µM) 
Cpds LC10 
(µM) 
Cpds LC10 
(µM) 
7 6.0 153 12.5 54 6.0 185 12.5 
8 12.5 154  12.5 55 6.0 186 12.5 
147 25.0 156/157 6.0 59 6.0 187 6.0 
148 25.0 158/159 6.0 79 25.0 188 6.0 
149/150 25.0 160 25 128 25.0 189 6.0 
151 6.0 161 6.0 183 12.5 190 25.0 
152 6.0 162 6.0 184 12.5 191 12.5 
 
 
 
3.5.2.2 Luciferase activity 
The luciferase activity was measured using the Steady-Glo luciferase kit provided by 
Promega Corp. After the exposure of AREc32 cells for 24 h to tBHQ 6 and 12 μM, the 
activity of luciferase increased by 2.51 and 7.37-fold compared to the control (Figure 
3.105). Among the tested compounds, the mixtures of epimeric clerodanes 156/157 and 
158/159 (crotonolins A-D), skimmianine (55), hesperidin (79) and myrtopsine (185) were 
found to produce 2.7, 2.4, 2.4, 1.8 and 2.0-fold induction, respectively. Other tested 
compounds had slight or negligible effects on the luciferase activity at the dosage tested. 
The results suggested the above active compounds might be potential activators of the 
NrF2 pathway, meaning potent chemopreventive compounds at non cytotoxic dosages. 
The diterpenes 156-159 were the most activitors of the Nrf2 activity. Their activities were 
comparable to that tBHQ when tested at the same concentration. Several diterpenes 
including clerodanes have been reported to possess cytoprotective and cytotoxic 
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properties (Thoppil and Bishayee, 2011; Islam, 2017). For example, the clerodane 
columbin has been revealed to have chemoproventive activity against colorectal cancer 
when administered as a diet to male rats in the early phase of azoxymethane-induced 
colon carcinogenesis (Kohno et al., 2002). Therefore, clerodanes, represent an interesting 
group of compounds to explore for the discovery of cancer chemopreventive agents. 
 
Figure 3.105 Luciferase activity of isolated compounds 
AREc32 cells were seeded in 96-well plates at 1.2 x 104 cells/well. After 24 h, tBHQ (6 
and 12 μM) and the compounds were added to the medium. The cells were then incubated 
for another 24 h and assayed for luciferase activity as detailed in Chapter 2, 2.4.4. The 
value of luciferase activity of untreated cells (CT) was set at 1. Values shown are mean ± 
SEM of three experiments. *p < 0.01; **p < 0.001, ***p < 0.0001, significantly increased 
versus control. DMSO 0.1%: (cells treated with 0.1% DMSO medium). 
 
 
 
3.5.3 Haem polymerisation assay of the isolated compounds 
The isolated compounds from extracts, which have shown antimalarial activity, were 
screened to evaluate their antimalarial potential using haem polymerisation assay. 
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Quinoline antimalarials in use today, such as chloroquine, mefloquine and quinine, have 
been reported to act in the erythrocytic stage of the parasite life cycle by blocking the 
polymerisation of free haem generated during haemoglobin digestion to its polymer 
haemozoin, a step which is essential for the parasite survival (Foley and Tilley, 1998). 
None of the isolated compounds have demonstrated an effect at the tested concentration 
(0-250 µM). These compounds included the diterpenes isolated from C. oligandrus and 
Z. leprieurii, and flavonoids from J. hypocrateriformis and P. microcarpa. These results 
were not consistent with our early finding regarding the activity associated with the 
extracts from which the compounds have been isolated. However, as previously noted, 
the activity of an extract is the result of different interactions occurring between the 
chemical constituents within the extract. In addition, the isolated compounds might not 
be iron chelators making it difficult to bind with haem via the ion present at its center 
(Sarker et al., 2016), hence their inactivity.  
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Chapter 4 Conclusion and Future 
Prospects 
  
212 
 
4. Conclusion and future prospects 
Bioassay-guided isolation of active compounds was carried out with five Cameroonian 
medicinal plants, including Croton oligandrus Pierre ex Hutch (Euphorbiaceae), Justicia 
hypocrateriformis (Vahl) Milne-Redh (Acanthanceae), Pseudospondias microcarpa (A. 
Rich.) Engl. (Anacardiaceae), Zanthoxylum lepreurii Guill. and Perr. and Zanthoxylum 
zanthoxyloides (Lam.) Zepern. and Timler (Rutaceae).   
The n-hexane and the DCM extracts of Croton oligandrus bark, and the DCM and MeOH 
extracts of Z. zanthoxyloides fruits were active in the luciferase assay causing 18, 21, 34 
and 36-fold induction of the level of luciferase in AREc32 cells, respectively. The 
diterpenes crotonolins A-D, isolated from the DCM extract of C. oligandrus were 
identified as the most active principle of the plant with 2-fold or greater. From Z. 
zanthoxyloides, skimmianine isolated from both the DCM and MeOH extracts, and 
hesperidin and myrtopsine isolated from the MeOH extract, increased the level of 
luciferase by 2.4, 1.8 and 2.0-fold, respectively. 
The antimalarial activity of the selected plants was evaluated using the haem 
polymerisation assay. Pseudospondias microcarpa was the most active plant with IC50 
73.9 ± 25.8, 2.5 ± 1.5 and 4.0 ± 1.7 µM for the stem bark n-hexane, DCM and MeOH 
extracts, respectively, and 13.0 ± 9.0 µM for the leaves MeOH extract. No inhibition of 
haem polymerisation was observed for the isolated compounds at the assayed 
concentrations. 
Three major classes of phytochemicals including alkaloids, diterpenes and flavonoids 
were isolated from the five plants studied. Some of the compounds, 12-epi-
megalocarpoloide D (154), crotonolins A-F (155-160), justicialosides A and B (166-167) 
and zanthoamides G-I (188-190) were being reported for the first time from natural 
sources. Kaurane diterpenes were reported for the first time from the genus Zanthoxylum 
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and the quinoline alkaloids N-methylplatydesminium cation (183), isoplatydesmine 
(184), myrtopsine (185), ribalinine (186) and N-methylatanine (187) from the species Z. 
zanthoxyloides for the first time. Other isolated compounds included two triterpenes, 
acetyl aleuritolic acid (7) and lupeol (8); two lignans, sesamine (54) and icariside D2 
(183); ferulic acid derivatives (114, 147-150); a quindoline, 10H-quindoline (169); a 
coumarin, scopoletin (103); and a chromanone, pithecellobiumol B (174). The 
cytotoxicity of all the isolated compounds were evaluated against three cancer cell lines 
(A549, MCF7 and PC3) and a non cancer cell line (PNT2). Hesperidin (59) was the most 
cytotoxic compound with LC50 29.5 ± 7.5, 74.2 ± 17.8, 51.7 ± 8.7 and 129.0 ± 20.3 µM 
against A549, MCF7, PC3 and PNT2, respectively. 
This study generated the first, second and third phytochemical report of P. microcarpa, 
C. oligandrus and J. hypocrateriformis, respectively. The chemotaxonomy of the isolated 
compounds has also been discussed. J. hypocrateriformis and J. secunda were observed 
to have similar compounds and should be investigated further to establish whether the 
two names refer to the same species, and kaurane diterpenes were identified as new 
markers of Z. leprieurii.  
This study also supports the use of C. oligandrus and Z. zanthoxylum as alternative and 
complementary medicine for the treatment and prevention of cancer, and P. microcarpa 
for the treatment of malaria. However, further studies need to be carried out to define 
standardised dosage as those plants were found to contain moderate cytotoxic compounds 
against the human normal prostate epithelium cells (PNT2).   
Future studies may involve: 
• chemical modification of active compounds as well as the novel compounds and 
evaluation of the activity of obtained analogues; 
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• investigation of the mechanism of action of chemopreventive extracts and 
compounds identified; 
• investigation of the antimalarial activity of isolated compounds using a different 
assay e.g. in vitro against parasites; 
• investigation of synergism, antagonism and additive interactions as a contributor 
to activity of crude plant extracts specially those active in the antimalarial assay. 
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Appendix I MS, 1H and 13C NMR spectra of crotonolin E (155) 
White amorphous powder, [α]D25 -70.0 (c 0.00005, MeOH).  
Molecular formula C22H24O8 determined from the peak at m/z 417.1557 calculated for 
C22H25O8 [M+H]
+, 417.1543 
 
 
1H NMR spectrum (CDCl3, 600 MHz) of 155 
 
 
13C NMR spectrum (150 MHz, CDCl3) and Keys 
1H-1H NOESY (↔) and HMBC (→) 
correlations of 155 
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ESI-MS spectrum of 155 
 
 
Appendix II ESI-MS spectrum of justivialoside B (167) 
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Appendix III ESI-MS spectrum of scopoletin (103) 
 
 
 
Appendix IV 1H NMR (600 MHz, CD3OD) spectrum of myrtopsine 
(185) 
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